{ "version": "2.2", "instance": { "abvx-20251231.htm": { "nsprefix": "abvx", "nsuri": "http://www.abivax.com/20251231", "dts": { "inline": { "local": [ "abvx-20251231.htm" ] }, "schema": { "local": [ "abvx-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "abvx-20251231_cal.xml" ] }, "definitionLink": { "local": [ "abvx-20251231_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "abvx-20251231_lab.xml" ] }, "presentationLink": { "local": [ "abvx-20251231_pre.xml" ] } }, "keyStandard": 334, "keyCustom": 274, "axisStandard": 39, "axisCustom": 8, "memberStandard": 53, "memberCustom": 194, "hidden": { "total": 23, "http://www.abivax.com/20251231": 18, "http://xbrl.sec.gov/dei/2025": 5 }, "contextCount": 1319, "entityCount": 1, "segmentCount": 288, "elementCount": 1172, "unitCount": 20, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 2140, "http://xbrl.sec.gov/dei/2025": 46, "http://xbrl.sec.gov/cyd/2025": 15, "http://xbrl.sec.gov/ecd/2025": 1 }, "report": { "R1": { "role": "http://www.abivax.com/role/Coverpage", "longName": "0000001 - Document - Cover page", "shortName": "Cover page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.abivax.com/role/Auditorinformation", "longName": "0000002 - Document - Auditor information", "shortName": "Auditor information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "longName": "9952151 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:Goodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:NoncurrentAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R4": { "role": "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "longName": "9952152 - Statement - CONSOLIDATED STATEMENTS OF INCOME (LOSS)", "shortName": "CONSOLIDATED STATEMENTS OF INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueAndOperatingIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R5": { "role": "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R6": { "role": "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-10", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R7": { "role": "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R8": { "role": "http://www.abivax.com/role/TheGroup", "longName": "9952156 - Disclosure - The Group", "shortName": "The Group", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.abivax.com/role/Basisofpreparation", "longName": "9952157 - Disclosure - Basis of preparation", "shortName": "Basis of preparation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequentevents", "longName": "9952158 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events", "shortName": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.abivax.com/role/Accountingprinciples", "longName": "9952159 - Disclosure - Accounting principles", "shortName": "Accounting principles", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.abivax.com/role/Segmentinformation", "longName": "9952160 - Disclosure - Segment information", "shortName": "Segment information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.abivax.com/role/Goodwillandimpairmenttest", "longName": "9952161 - Disclosure - Goodwill and impairment test", "shortName": "Goodwill and impairment test", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.abivax.com/role/Intangibleassets", "longName": "9952162 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.abivax.com/role/Propertyplantandequipment", "longName": "9952163 - Disclosure - Property, plant and equipment", "shortName": "Property, plant and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.abivax.com/role/Otherfinancialassets", "longName": "9952164 - Disclosure - Other financial assets", "shortName": "Other financial assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.abivax.com/role/Otherreceivablesandotherassets", "longName": "9952165 - Disclosure - Other receivables and other assets", "shortName": "Other receivables and other assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.abivax.com/role/Cashandcashequivalents", "longName": "9952166 - Disclosure - Cash and cash equivalents", "shortName": "Cash and cash equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.abivax.com/role/Financialassetsandliabilities", "longName": "9952167 - Disclosure - Financial assets and liabilities", "shortName": "Financial assets and liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.abivax.com/role/Shareholdersequity", "longName": "9952168 - Disclosure - Shareholders\u2019 equity", "shortName": "Shareholders\u2019 equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.abivax.com/role/Sharebasedpayments", "longName": "9952169 - Disclosure - Share-based payments", "shortName": "Share-based payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.abivax.com/role/Financialliabilities", "longName": "9952170 - Disclosure - Financial liabilities", "shortName": "Financial liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.abivax.com/role/Retirementbenefitobligations", "longName": "9952171 - Disclosure - Retirement benefit obligations", "shortName": "Retirement benefit obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.abivax.com/role/Payablesandothercurrentliabilities", "longName": "9952172 - Disclosure - Payables and other current liabilities", "shortName": "Payables and other current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.abivax.com/role/Otheroperatingincome", "longName": "9952173 - Disclosure - Other operating income", "shortName": "Other operating income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.abivax.com/role/Operatingexpenses", "longName": "9952174 - Disclosure - Operating expenses", "shortName": "Operating expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.abivax.com/role/Employees", "longName": "9952175 - Disclosure - Employees", "shortName": "Employees", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.abivax.com/role/Financialgainloss", "longName": "9952176 - Disclosure - Financial gain (loss)", "shortName": "Financial gain (loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.abivax.com/role/Incometax", "longName": "9952177 - Disclosure - Income tax", "shortName": "Income tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.abivax.com/role/Incomelosspershare", "longName": "9952178 - Disclosure - Income (loss) per share", "shortName": "Income (loss) per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.abivax.com/role/Relatedparties", "longName": "9952179 - Disclosure - Related parties", "shortName": "Related parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.abivax.com/role/Offbalancesheetcommitmentsgiven", "longName": "9952180 - Disclosure - Off-balance sheet commitments given", "shortName": "Off-balance sheet commitments given", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.abivax.com/role/Offbalancesheetcommitmentsreceivedandcontingentassets", "longName": "9952181 - Disclosure - Off-balance sheet commitments received and contingent assets", "shortName": "Off-balance sheet commitments received and contingent assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.abivax.com/role/Managementandassessmentoffinancialrisks", "longName": "9952182 - Disclosure - Management and assessment of financial risks", "shortName": "Management and assessment of financial risks", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R35": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R36": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.abivax.com/role/AccountingprinciplesPolicies", "longName": "9955511 - Disclosure - Accounting principles (Policies)", "shortName": "Accounting principles (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.abivax.com/role/AccountingprinciplesTables", "longName": "9955512 - Disclosure - Accounting principles (Tables)", "shortName": "Accounting principles (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.abivax.com/role/IntangibleassetsTables", "longName": "9955513 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.abivax.com/role/PropertyplantandequipmentTables", "longName": "9955514 - Disclosure - Property, plant and equipment (Tables)", "shortName": "Property, plant and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.abivax.com/role/OtherfinancialassetsTables", "longName": "9955515 - Disclosure - Other financial assets (Tables)", "shortName": "Other financial assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.abivax.com/role/OtherreceivablesandotherassetsTables", "longName": "9955516 - Disclosure - Other receivables and other assets (Tables)", "shortName": "Other receivables and other assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.abivax.com/role/CashandcashequivalentsTables", "longName": "9955517 - Disclosure - Cash and cash equivalents (Tables)", "shortName": "Cash and cash equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.abivax.com/role/FinancialassetsandliabilitiesTables", "longName": "9955518 - Disclosure - Financial assets and liabilities (Tables)", "shortName": "Financial assets and liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.abivax.com/role/SharebasedpaymentsTables", "longName": "9955519 - Disclosure - Share-based payments (Tables)", "shortName": "Share-based payments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.abivax.com/role/FinancialliabilitiesTables", "longName": "9955520 - Disclosure - Financial liabilities (Tables)", "shortName": "Financial liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.abivax.com/role/RetirementbenefitobligationsTables", "longName": "9955521 - Disclosure - Retirement benefit obligations (Tables)", "shortName": "Retirement benefit obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables", "longName": "9955522 - Disclosure - Payables and other current liabilities (Tables)", "shortName": "Payables and other current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.abivax.com/role/OtheroperatingincomeTables", "longName": "9955523 - Disclosure - Other operating income (Tables)", "shortName": "Other operating income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.abivax.com/role/OperatingexpensesTables", "longName": "9955524 - Disclosure - Operating expenses (Tables)", "shortName": "Operating expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.abivax.com/role/EmployeesTables", "longName": "9955525 - Disclosure - Employees (Tables)", "shortName": "Employees (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfAverageNumberOfEmployeesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfAverageNumberOfEmployeesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.abivax.com/role/FinancialgainlossTables", "longName": "9955526 - Disclosure - Financial gain (loss) (Tables)", "shortName": "Financial gain (loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.abivax.com/role/IncometaxTables", "longName": "9955527 - Disclosure - Income tax (Tables)", "shortName": "Income tax (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.abivax.com/role/IncomelosspershareTables", "longName": "9955528 - Disclosure - Income (loss) per share (Tables)", "shortName": "Income (loss) per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.abivax.com/role/RelatedpartiesTables", "longName": "9955529 - Disclosure - Related parties (Tables)", "shortName": "Related parties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.abivax.com/role/TheGroupDetails", "longName": "9955530 - Disclosure - The Group (Details)", "shortName": "The Group (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://www.abivax.com/role/BasisofpreparationDetails", "longName": "9955531 - Disclosure - Basis of preparation (Details)", "shortName": "Basis of preparation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-67", "name": "ifrs-full:ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R58": { "role": "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "longName": "9955532 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2023 (Details)", "shortName": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2023 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-451", "name": "ifrs-full:IssueOfEquity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-88", "name": "abvx:ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R59": { "role": "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "longName": "9955533 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2024 (Details)", "shortName": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2024 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-93", "name": "abvx:NumberOfFreeSharesPlansIssued", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-108", "name": "abvx:NumberOfADSPerOrdinaryShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R60": { "role": "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "longName": "9955534 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2025 (Details)", "shortName": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - For the year ended 2025 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-93", "name": "abvx:NumberOfFreeSharesPlansIssued", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-123", "name": "abvx:SharePrice1", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R61": { "role": "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails", "longName": "9955535 - Disclosure - Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - Subsequent events (Details)", "shortName": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent events - Subsequent events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-74", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-137", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R62": { "role": "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails", "longName": "9955536 - Disclosure - Accounting principles - Intangible assets (Details)", "shortName": "Accounting principles - Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "abvx:ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias", "unitRef": "criteria", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias", "unitRef": "criteria", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails", "longName": "9955537 - Disclosure - Accounting principles - Disclosure of depreciation period of property, plant and equipment (Details)", "shortName": "Accounting principles - Disclosure of depreciation period of property, plant and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-146", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-146", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.abivax.com/role/SegmentinformationDetails", "longName": "9955538 - Disclosure - Segment information (Details)", "shortName": "Segment information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-157", "name": "abvx:ContributionToGroupsAssetsPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-157", "name": "abvx:ContributionToGroupsAssetsPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.abivax.com/role/GoodwillandimpairmenttestDetails", "longName": "9955539 - Disclosure - Goodwill and impairment test (Details)", "shortName": "Goodwill and impairment test (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill", "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill", "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.abivax.com/role/IntangibleassetsNarrativeDetails", "longName": "9955540 - Disclosure - Intangible assets - Narrative (Details)", "shortName": "Intangible assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-165", "name": "abvx:TechnologyBasedIntangibleAssetsAssetsAcquisitions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-165", "name": "abvx:TechnologyBasedIntangibleAssetsAssetsAcquisitions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "longName": "9955541 - Disclosure - Intangible assets - Disclosure of reconciliation of intangible assets (Details)", "shortName": "Intangible assets - Disclosure of reconciliation of intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R68": { "role": "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails", "longName": "9955542 - Disclosure - Property, plant and equipment - Disclosure of reconciliation of property, plant and equipment (Details)", "shortName": "Property, plant and equipment - Disclosure of reconciliation of property, plant and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-302", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R69": { "role": "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails", "longName": "9955543 - Disclosure - Property, plant and equipment - Narrative (Details)", "shortName": "Property, plant and equipment - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-319", "name": "ifrs-full:RightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-319", "name": "ifrs-full:RightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails", "longName": "9955544 - Disclosure - Other financial assets - Disclosure of other financial assets (Details)", "shortName": "Other financial assets - Disclosure of other financial assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-5", "name": "abvx:NonCurrentAdvancesToCROContractsUndiscountedAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:LongtermDeposits", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R71": { "role": "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails", "longName": "9955545 - Disclosure - Other financial assets - Narrative (Details)", "shortName": "Other financial assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-5", "name": "abvx:NonCurrentAdvancesToCROContractsUndiscountedAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-329", "name": "abvx:DiscountRateAppliedToLongTermAdvances", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R72": { "role": "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails", "longName": "9955546 - Disclosure - Other receivables and other assets - Disclosure of other receivables and other assets (Details)", "shortName": "Other receivables and other assets - Disclosure of other receivables and other assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-5", "name": "abvx:NonCurrentPrepaidExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "abvx:NonCurrentPrepaidExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails", "longName": "9955547 - Disclosure - Other receivables and other assets - Narrative (Details)", "shortName": "Other receivables and other assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "abvx:ProceedsFromResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "abvx:CurrentPrepaidExpensesRelatedToCRO", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R74": { "role": "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails", "longName": "9955548 - Disclosure - Cash and cash equivalents - Disclosure of composition of cash and cash equivalents (Details)", "shortName": "Cash and cash equivalents - Disclosure of composition of cash and cash equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:CashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:CashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails", "longName": "9955549 - Disclosure - Cash and cash equivalents - Narrative (Details)", "shortName": "Cash and cash equivalents - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:OtherCashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:OtherCashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "longName": "9955550 - Disclosure - Financial assets and liabilities (Details)", "shortName": "Financial assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:Assets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R77": { "role": "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails", "longName": "9955551 - Disclosure - Shareholders\u2019 equity - Share capital issued (Details)", "shortName": "Shareholders\u2019 equity - Share capital issued (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:IssuedCapital", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "abvx:NumberOfTreasurySharesHeld", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "abvx:NumberOfTreasurySharesHeld", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R78": { "role": "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "longName": "9955552 - Disclosure - Shareholders\u2019 equity - Change in share capital (Details)", "shortName": "Shareholders\u2019 equity - Change in share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-451", "name": "ifrs-full:IssueOfEquity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-461", "name": "abvx:ShareWarrantsSubscriptionPricePerShare", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R79": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "longName": "9955553 - Disclosure - Share-based payments - Disclosure of reconciliation of BCEs (Details)", "shortName": "Share-based payments - Disclosure of reconciliation of BCEs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-500", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-500", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "longName": "9955554 - Disclosure - Share-based payments - Narrative (Details)", "shortName": "Share-based payments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:OtherShorttermProvisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-501", "name": "abvx:VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R81": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "longName": "9955555 - Disclosure - Share-based payments - Disclosure of reconciliation of BSAs (Details)", "shortName": "Share-based payments - Disclosure of reconciliation of BSAs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-543", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-544", "name": "ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R82": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "longName": "9955556 - Disclosure - Share-based payments - Disclosure of assumptions used for the measurement of BSAs (Details)", "shortName": "Share-based payments - Disclosure of assumptions used for the measurement of BSAs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-522", "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-522", "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "longName": "9955557 - Disclosure - Share-based payments - Disclosure of reconciliation of AGAs (Details)", "shortName": "Share-based payments - Disclosure of reconciliation of AGAs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-641", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-641", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "longName": "9955558 - Disclosure - Share-based payments - Disclosure of assumptions used for the measurement of AGAs (Details)", "shortName": "Share-based payments - Disclosure of assumptions used for the measurement of AGAs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-644", "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ix:continuation", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-644", "name": "abvx:UnderlyingShareFairValueOtherEquityInstrumentsGranted", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ix:continuation", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "longName": "9955559 - Disclosure - Share-based payments - Disclosure of breakdown of the compensation expenses (Details)", "shortName": "Share-based payments - Disclosure of breakdown of the compensation expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "longName": "9955560 - Disclosure - Financial liabilities - Disclosure of financial liabilities breakdown (Details)", "shortName": "Financial liabilities - Disclosure of financial liabilities breakdown (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:NoncurrentFinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:NoncurrentFinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "longName": "9955561 - Disclosure - Financial liabilities - Kreos / Claret Financing (Details)", "shortName": "Financial liabilities - Kreos / Claret Financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-63", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-753", "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R88": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "longName": "9955562 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret minimum return indemnifications (Details)", "shortName": "Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret minimum return indemnifications (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-774", "name": "abvx:AggregateFairValueOtherEquityInstrumentsOutstanding", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-774", "name": "abvx:AggregateFairValueOtherEquityInstrumentsOutstanding", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "longName": "9955563 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret BSA (Details)", "shortName": "Financial liabilities - Disclosure of the main data and assumptions, Kreos / Claret BSA (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-841", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-841", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "longName": "9955564 - Disclosure - Financial liabilities - Heights convertible notes (Details)", "shortName": "Financial liabilities - Heights convertible notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-8", "name": "abvx:NetProceedsFromConvertibleLoansNotes", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-978", "name": "ifrs-full:IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R91": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "longName": "9955565 - Disclosure - Financial liabilities - Disclosure of the main data and assumptions, Heights convertible loan notes (Details)", "shortName": "Financial liabilities - Disclosure of the main data and assumptions, Heights convertible loan notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-933", "name": "abvx:NumberOfConvertibleNotesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-933", "name": "abvx:NumberOfConvertibleNotesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "longName": "9955566 - Disclosure - Financial liabilities - Kreos 1 (Details)", "shortName": "Financial liabilities - Kreos 1 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-986", "name": "abvx:IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-992", "name": "abvx:NumberOfSharesPerShareWarrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R93": { "role": "http://www.abivax.com/role/FinancialliabilitiesKreos2Details", "longName": "9955568 - Disclosure - Financial liabilities - Kreos 2 (Details)", "shortName": "Financial liabilities - Kreos 2 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-83", "name": "abvx:RepaymentsOfConvertibleLoansNotes", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-993", "name": "ifrs-full:NotionalAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R94": { "role": "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "longName": "9955569 - Disclosure - Financial liabilities - OCEANE (Details)", "shortName": "Financial liabilities - OCEANE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-88", "name": "abvx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1004", "name": "abvx:AggregateFairValueConvertibleNotes", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R95": { "role": "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails", "longName": "9955570 - Disclosure - Financial liabilities - State guaranteed loan \u2013 \u201cPGE\u201d (Details)", "shortName": "Financial liabilities - State guaranteed loan \u2013 \u201cPGE\u201d (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromGovernmentGrants", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1013", "name": "abvx:BorrowingsMaturityTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R96": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails", "longName": "9955571 - Disclosure - Financial liabilities - Disclosure of conditional advances (Details)", "shortName": "Financial liabilities - Disclosure of conditional advances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-5", "name": "abvx:ConditionalAdvances", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": null }, "R97": { "role": "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "longName": "9955572 - Disclosure - Financial liabilities - Conditional advances (Details)", "shortName": "Financial liabilities - Conditional advances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-5", "name": "abvx:ConditionalAdvances", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-104", "name": "abvx:RepaymentOfExcessConditionalAdvancesClaimed", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R98": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails", "longName": "9955573 - Disclosure - Financial liabilities - Disclosure of variation in lease liabilities (Details)", "shortName": "Financial liabilities - Disclosure of variation in lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:LeaseLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:IncreaseInLeaseLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R99": { "role": "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails", "longName": "9955574 - Disclosure - Financial liabilities - Lease liabilities (Details)", "shortName": "Financial liabilities - Lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-1", "name": "abvx:ExpenseOnLeaseLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:ExpenseOnLeaseLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "longName": "9955575 - Disclosure - Financial liabilities - Royalty certificates (Details)", "shortName": "Financial liabilities - Royalty certificates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-451", "name": "ifrs-full:IssueOfEquity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "abvx:InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R101": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "longName": "9955576 - Disclosure - Financial liabilities - Disclosure of reconciliation of liabilities arising from financing activities (Details)", "shortName": "Financial liabilities - Disclosure of reconciliation of liabilities arising from financing activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R102": { "role": "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "longName": "9955577 - Disclosure - Financial liabilities - Change in financial liabilities (Details)", "shortName": "Financial liabilities - Change in financial liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-8", "name": "abvx:NetProceedsFromConvertibleLoansNotes", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "abvx:GrossProceedsFromNonConvertibleLoansNotes", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R103": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "longName": "9955578 - Disclosure - Financial liabilities - Disclosure of changes in derivative instruments (Details)", "shortName": "Financial liabilities - Disclosure of changes in derivative instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-7", "name": "ifrs-full:DerivativeFinancialLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "abvx:IssuanceOfDerivativeInstruments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R104": { "role": "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "longName": "9955579 - Disclosure - Financial liabilities - Disclosure of remaining contractual maturities of financial liabilities (Details)", "shortName": "Financial liabilities - Disclosure of remaining contractual maturities of financial liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-5", "name": "abvx:ConditionalAdvances", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "abvx:ConditionalAdvancesUndiscountedCashFlows", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R105": { "role": "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails", "longName": "9955580 - Disclosure - Financial liabilities - Breakdown of financial liabilities by maturity (Details)", "shortName": "Financial liabilities - Breakdown of financial liabilities by maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-1055", "name": "abvx:RoyaltyCertificatePercentageOfFutureSales", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1053", "name": "abvx:RoyaltyCertificateExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R106": { "role": "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails", "longName": "9955581 - Disclosure - Retirement benefit obligations - Disclosure of main actuarial assumptions used to measure the retirement benefit obligations (Details)", "shortName": "Retirement benefit obligations - Disclosure of main actuarial assumptions used to measure the retirement benefit obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R107": { "role": "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails", "longName": "9955582 - Disclosure - Retirement benefit obligations - Disclosure of changes in projected benefit obligation (Details)", "shortName": "Retirement benefit obligations - Disclosure of changes in projected benefit obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-1238", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1234", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R108": { "role": "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails", "longName": "9955583 - Disclosure - Payables and other current liabilities - Disclosure of breakdown of trade and other payables (Details)", "shortName": "Payables and other current liabilities - Disclosure of breakdown of trade and other payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R109": { "role": "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails", "longName": "9955584 - Disclosure - Payables and other current liabilities - Disclosure of tax and employee-related payables (Details)", "shortName": "Payables and other current liabilities - Disclosure of tax and employee-related payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R110": { "role": "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails", "longName": "9955585 - Disclosure - Other operating income - Disclosure of breakdown of operating income (Details)", "shortName": "Other operating income - Disclosure of breakdown of operating income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-1", "name": "abvx:IncomeFromResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:IncomeFromDepositaryServiceFees", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R111": { "role": "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails", "longName": "9955586 - Disclosure - Other operating income - Narrative (Details)", "shortName": "Other operating income - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-1", "name": "abvx:IncomeFromResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1244", "name": "abvx:IncomeFromResearchTaxCredit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R112": { "role": "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails", "longName": "9955587 - Disclosure - Operating expenses - Disclosure of sales and marketing expenses (Details)", "shortName": "Operating expenses - Disclosure of sales and marketing expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1247", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R113": { "role": "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "longName": "9955588 - Disclosure - Operating expenses - Disclosure of research and development expenses (Details)", "shortName": "Operating expenses - Disclosure of research and development expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1250", "name": "abvx:SubContractingStudiesAndResearchExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R114": { "role": "http://www.abivax.com/role/OperatingexpensesNarrativeDetails", "longName": "9955589 - Disclosure - Operating expenses - Narrative (Details)", "shortName": "Operating expenses - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "c-1250", "name": "abvx:IncreaseDecreaseInUlcerativeColitisExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1250", "name": "abvx:IncreaseDecreaseInUlcerativeColitisExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R115": { "role": "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "longName": "9955590 - Disclosure - Operating expenses - Disclosure of general and administrative expenses (Details)", "shortName": "Operating expenses - Disclosure of general and administrative expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OperatingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1253", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R116": { "role": "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails", "longName": "9955591 - Disclosure - Operating expenses - Disclosure of principal audit fees and services (Details)", "shortName": "Operating expenses - Disclosure of principal audit fees and services (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AuditorsRemunerationForAuditServices", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AuditorsRemunerationForAuditServices", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R117": { "role": "http://www.abivax.com/role/EmployeesDetails", "longName": "9955592 - Disclosure - Employees (Details)", "shortName": "Employees (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AverageNumberOfEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AverageNumberOfEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R118": { "role": "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "longName": "9955593 - Disclosure - Financial gain (loss) - Disclosure of net financial income (loss) (Details)", "shortName": "Financial gain (loss) - Disclosure of net financial income (loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestExpenseOnBonds", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestExpenseOnBonds", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R119": { "role": "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "longName": "9955594 - Disclosure - Financial gain (loss) - Narrative (Details)", "shortName": "Financial gain (loss) - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:LossesOnChangeInFairValueOfDerivatives", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1260", "name": "ifrs-full:LossesOnChangeInFairValueOfDerivatives", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R120": { "role": "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails", "longName": "9955595 - Disclosure - Income tax - Disclosure of reconciliation of effective income tax (loss) (Details)", "shortName": "Income tax - Disclosure of reconciliation of effective income tax (loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AccountingProfit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "abvx:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AccountingProfit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "abvx:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R121": { "role": "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails", "longName": "9955596 - Disclosure - Income tax - Disclosure of deferred tax assets and liabilities by nature (Details)", "shortName": "Income tax - Disclosure of deferred tax assets and liabilities by nature (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:DeferredTaxLiabilityAsset", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R122": { "role": "http://www.abivax.com/role/IncometaxNarrativeDetails", "longName": "9955597 - Disclosure - Income tax - Narrative (Details)", "shortName": "Income tax - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:DeferredTaxLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R123": { "role": "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails", "longName": "9955598 - Disclosure - Income (loss) per share - Schedule of earnings per share (Details)", "shortName": "Income (loss) per share - Schedule of earnings per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:WeightedAverageShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "ifrs-full:AdjustedWeightedAverageShares", "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:EarningsPerShareExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": null }, "R124": { "role": "http://www.abivax.com/role/IncomelosspershareNarrativeDetails", "longName": "9955599 - Disclosure - Income (loss) per share - Narrative (Details)", "shortName": "Income (loss) per share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R125": { "role": "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails", "longName": "9955600 - Disclosure - Related parties - Disclosure of aggregate compensation of the members of the Group\u2019s Board of Directors and CEO (Details)", "shortName": "Related parties - Disclosure of aggregate compensation of the members of the Group\u2019s Board of Directors and CEO (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "c-1", "name": "abvx:KeyManagementPersonnelCompensationFixedCompensation", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "abvx:KeyManagementPersonnelCompensationFixedCompensation", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R126": { "role": "http://www.abivax.com/role/RelatedpartiesNarrativeDetails", "longName": "9955601 - Disclosure - Related parties - Narrative (Details)", "shortName": "Related parties - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "c-1290", "name": "ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1290", "name": "ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R127": { "role": "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails", "longName": "9955602 - Disclosure - Off-balance sheet commitments given (Details)", "shortName": "Off-balance sheet commitments given (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "127", "firstAnchor": { "contextRef": "c-1", "name": "abvx:RepaymentsOfConditionalAdvances", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:CapitalCommitments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } }, "R128": { "role": "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails", "longName": "9955603 - Disclosure - Off-balance sheet commitments received and contingent assets (Details)", "shortName": "Off-balance sheet commitments received and contingent assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "128", "firstAnchor": { "contextRef": "c-1310", "name": "abvx:NumberOfProjectsTerminated", "unitRef": "project", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1310", "name": "abvx:NumberOfProjectsTerminated", "unitRef": "project", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true, "unique": true } }, "R129": { "role": "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails", "longName": "9955604 - Disclosure - Management and assessment of financial risks (Details)", "shortName": "Management and assessment of financial risks (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:Assets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1313", "name": "abvx:InterestRateCollarRange", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "abvx-20251231.htm", "unique": true } } }, "tag": { "abvx_A130.0MillionCrossOverFinancingFebruary2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "A130.0MillionCrossOverFinancingFebruary2023Member", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "\u20ac130.0\u00a0million cross-over financing, february 2023", "label": "\u20ac130.0\u00a0Million Cross-Over Financing, February 2023 [Member]", "documentation": "\u20ac130.0\u00a0Million Cross-Over Financing, February 2023" } } }, "auth_ref": [] }, "abvx_A150.0MillionFinancingAugust2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "A150.0MillionFinancingAugust2023Member", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "\u20ac150.0\u00a0million financing, august 2023", "label": "\u20ac150.0\u00a0Million Financing, August 2023 [Member]", "documentation": "\u20ac150.0\u00a0Million Financing, August 2023" } } }, "auth_ref": [] }, "abvx_A2021TaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "A2021TaxYearMember", "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Year 2021", "label": "2021, Tax Year [Member]", "documentation": "Tax Year 2021" } } }, "auth_ref": [] }, "abvx_A2022TaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "A2022TaxYearMember", "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Year 2022", "label": "2022, Tax Year [Member]", "documentation": "Tax Year 2022" } } }, "auth_ref": [] }, "abvx_A2023TaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "A2023TaxYearMember", "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Year 2023", "label": "2023, Tax Year [Member]", "documentation": "Tax Year 2023" } } }, "auth_ref": [] }, "abvx_A2024TaxYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "A2024TaxYearMember", "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Year 2024", "label": "2024, Tax Year [Member]", "documentation": "2024, Tax Year" } } }, "auth_ref": [] }, "abvx_A49.2MillionCrossOverFinancingSeptember2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "A49.2MillionCrossOverFinancingSeptember2022Member", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "\u20ac49.2 million cross-over financing, september 2022", "label": "\u20ac49.2\u00a0Million Cross-Over Financing, September 2022 [Member]", "documentation": "\u20ac49.2\u00a0Million Cross-Over Financing, September 2022" } } }, "auth_ref": [] }, "abvx_AGA20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20231Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2023-1", "label": "AGA-2023-1 [Member]", "documentation": "AGA-2023-1" } } }, "auth_ref": [] }, "abvx_AGA20232Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20232Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2023-2", "label": "AGA-2023-2 [Member]", "documentation": "AGA-2023-2" } } }, "auth_ref": [] }, "abvx_AGA20233AGA20234AndAGA20235Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20233AGA20234AndAGA20235Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2023-3 , AGA-2023-4 and AGA-2023-5", "label": "AGA-2023-3 , AGA-2023-4 And AGA-2023-5 [Member]", "documentation": "AGA-2023-3 , AGA-2023-4 And AGA-2023-5" } } }, "auth_ref": [] }, "abvx_AGA20233AndAGA20234Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20233AndAGA20234Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2023-3 and AGA-2023-4", "label": "AGA-2023-3 And AGA-2023-4 [Member]", "documentation": "AGA-2023-3 And AGA-2023-4" } } }, "auth_ref": [] }, "abvx_AGA20233Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20233Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2023-3", "label": "AGA-2023-3 [Member]", "documentation": "AGA-2023-3" } } }, "auth_ref": [] }, "abvx_AGA20234Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20234Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2023-4", "label": "AGA-2023-4 [Member]", "documentation": "AGA-2023-4" } } }, "auth_ref": [] }, "abvx_AGA20235Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20235Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2023-5", "label": "AGA-2023-5 [Member]", "documentation": "AGA-2023-5" } } }, "auth_ref": [] }, "abvx_AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20241AGE20242AGA20243AGA20244AGA20245AndAGA20247Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7", "label": "AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7 [Member]", "documentation": "AGA-2024-1, AGE-2024-2, AGA-2024-3, AGA-2024-4, AGA-2024-5 and AGA-2024-7" } } }, "auth_ref": [] }, "abvx_AGA20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20241Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024-1", "label": "AGA-2024-1 [Member]", "documentation": "AGA-2024-1" } } }, "auth_ref": [] }, "abvx_AGA20242Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20242Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024-2", "label": "AGA-2024-2 [Member]", "documentation": "AGA-2024-2" } } }, "auth_ref": [] }, "abvx_AGA20243Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20243Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024-3", "label": "AGA-2024-3 [Member]", "documentation": "AGA-2024-3" } } }, "auth_ref": [] }, "abvx_AGA20244AGA20245AndAGA20246Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20244AGA20245AndAGA20246Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024-4, AGA-2024-5 and AGA-2024-6", "label": "AGA-2024-4, AGA-2024-5 and AGA-2024-6 [Member]", "documentation": "AGA-2024-4, AGA-2024-5 and AGA-2024-6" } } }, "auth_ref": [] }, "abvx_AGA20244Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20244Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024-4", "label": "AGA-2024-4 [Member]", "documentation": "AGA-2024-4" } } }, "auth_ref": [] }, "abvx_AGA20245Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20245Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024-5", "label": "AGA-2024-5 [Member]", "documentation": "AGA-2024-5" } } }, "auth_ref": [] }, "abvx_AGA20246Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20246Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024-6", "label": "AGA-2024-6 [Member]", "documentation": "AGA-2024-6" } } }, "auth_ref": [] }, "abvx_AGA20247Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20247Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024-7", "label": "AGA-2024-7 [Member]", "documentation": "AGA-2024-7" } } }, "auth_ref": [] }, "abvx_AGA2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA2024Member", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2024", "label": "AGA-2024 [Member]", "documentation": "AGA-2024" } } }, "auth_ref": [] }, "abvx_AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20251AGA20253AGA20254AGA20256AGA20257AndAGA20258Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8", "label": "AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8 [Member]", "documentation": "AGA-2025-1, AGA-2025-3, AGA-2025-4, AGA-2025-6, AGA-2025-7 and AGA-2025-8" } } }, "auth_ref": [] }, "abvx_AGA20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20251Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-1", "label": "AGA-2025-1 [Member]", "documentation": "AGA-2025-1" } } }, "auth_ref": [] }, "abvx_AGA20252Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20252Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-2", "label": "AGA-2025-2 [Member]", "documentation": "AGA-2025-2" } } }, "auth_ref": [] }, "abvx_AGA20253Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20253Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-3", "label": "AGA-2025-3 [Member]", "documentation": "AGA-2025-3" } } }, "auth_ref": [] }, "abvx_AGA20254Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20254Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-4", "label": "AGA-2025-4 [Member]", "documentation": "AGA-2025-4" } } }, "auth_ref": [] }, "abvx_AGA20255Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20255Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-5", "label": "AGA-2025-5 [Member]", "documentation": "AGA-2025-5" } } }, "auth_ref": [] }, "abvx_AGA20256Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20256Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-6", "label": "AGA-2025-6 [Member]", "documentation": "AGA-2025-6" } } }, "auth_ref": [] }, "abvx_AGA20257Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20257Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-7", "label": "AGA-2025-7 [Member]", "documentation": "AGA-2025-7" } } }, "auth_ref": [] }, "abvx_AGA20258Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA20258Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025-8", "label": "AGA-2025-8 [Member]", "documentation": "AGA-2025-8" } } }, "auth_ref": [] }, "abvx_AGA2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AGA2025Member", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "AGA-2025", "label": "AGA-2025 [Member]", "documentation": "AGA-2025" } } }, "auth_ref": [] }, "abvx_AbivaxLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AbivaxLLCMember", "presentation": [ "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Abivax LLC", "label": "Abivax LLC [Member]", "documentation": "Abivax LLC" } } }, "auth_ref": [] }, "abvx_AccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Principles [Abstract]", "label": "Accounting Principles [Abstract]", "documentation": "Accounting Principles [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_AccountingProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccountingProfit", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss before tax", "label": "Accounting profit" } }, "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r2", "r3", "r201", "r202" ] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued invoices", "label": "Accruals classified as current" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r525" ] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AMORTIZATION", "label": "Accumulated depreciation, amortisation and impairment [member]" } } }, "auth_ref": [ "r9", "r12", "r57", "r68", "r71", "r207", "r238", "r247", "r250" ] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DEPRECIATION", "label": "Accumulated depreciation and amortisation [member]" } } }, "auth_ref": [ "r12", "r493", "r499", "r502", "r503" ] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate (IBoxx Corporates AA)", "label": "Actuarial assumption of discount rates" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r496" ] }, "abvx_ActuarialAssumptionOfEmployeeContributionRate": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ActuarialAssumptionOfEmployeeContributionRate", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee contribution rate", "label": "Actuarial Assumption Of Employee Contribution Rate", "documentation": "Actuarial Assumption Of Employee Contribution Rate" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salary increase rate", "label": "Actuarial assumption of expected rates of salary increases" } }, "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [domain]; Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r496" ] }, "abvx_ActuarialAssumptionOfExpectedRatesOfTurnover": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ActuarialAssumptionOfExpectedRatesOfTurnover", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Turnover rate", "label": "Actuarial Assumption Of Expected Rates Of Turnover", "documentation": "Actuarial Assumption Of Expected Rates Of Turnover" } } }, "auth_ref": [] }, "abvx_ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ActuarialAssumptionOfExpectedRatesOfTurnoverAverageExitRate", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Turnover rate, average exit rate", "label": "Actuarial Assumption Of Expected Rates Of Turnover, Average Exit Rate", "documentation": "Actuarial Assumption Of Expected Rates Of Turnover, Average Exit Rate" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfRetirementAge2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfRetirementAge2019", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement age", "label": "Actuarial assumption of retirement age" } }, "en": { "role": { "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r496" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r427" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition", "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r58", "r239" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition", "label": "Additions other than through business combinations, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment including right-of-use assets other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r494" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r440" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r440" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r440" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r440" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average number of outstanding shares used for computing diluted loss per share (in shares)", "terseLabel": "Weighted average number of outstanding shares, diluted loss per share (in shares)", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r42" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease / (increase) in other receivables and related accounts", "label": "Adjustments for decrease (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r507" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangibles and depreciation of property, plant and equipment", "label": "Adjustments for depreciation and amortisation expense" } } }, "auth_ref": [ "r506" ] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase/(decrease) in derivatives and liabilities measured at fair value", "label": "Adjustments for fair value losses (gains)" } } }, "auth_ref": [ "r506" ] }, "abvx_AdjustmentsForForgivenessOfConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AdjustmentsForForgivenessOfConditionalAdvances", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Forgiveness of conditional advances", "label": "Adjustments For Forgiveness Of Conditional Advances", "documentation": "Adjustments For Forgiveness Of Conditional Advances" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Current and deferred taxes expenses", "label": "Adjustments for income tax expense" } } }, "auth_ref": [ "r77" ] }, "abvx_AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeAndOtherLiabilities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in deferred income and other liabilities", "label": "Adjustments For Increase (Decrease) In Deferred Income And Other Liabilities", "documentation": "Adjustments For Increase (Decrease) In Deferred Income And Other Liabilities" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement benefit obligations", "label": "Adjustments for increase (decrease) in employee benefit liabilities" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r507" ] }, "abvx_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase / (decrease) in tax and social security liabilities", "label": "Adjustments For Increase (Decrease) In Tax And Social Security Liabilities", "documentation": "Adjustments For Increase (Decrease) In Tax And Social Security Liabilities" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase / (decrease) in trade payables", "label": "Adjustments for increase (decrease) in trade accounts payable" } } }, "auth_ref": [ "r505" ] }, "abvx_AdjustmentsForNetGainOnSaleOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AdjustmentsForNetGainOnSaleOfTreasuryShares", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain on sale of treasury shares", "label": "Adjustments For Net Gain On Sale Of Treasury Shares", "documentation": "Adjustments For Net Gain On Sale Of Treasury Shares" } } }, "auth_ref": [] }, "abvx_AdjustmentsForOtherFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AdjustmentsForOtherFinanceCosts", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expenses and other financial expenses", "label": "Adjustments For Other Finance Costs", "documentation": "Adjustments For Other Finance Costs" } } }, "auth_ref": [] }, "abvx_AdjustmentsForOtherFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AdjustmentsForOtherFinanceIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial income", "label": "Adjustments For Other Finance Income", "documentation": "Adjustments For Other Finance Income" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForProvisions", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in provisions", "label": "Adjustments for provisions" } } }, "auth_ref": [ "r506" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for:", "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expenses", "label": "Adjustments for share-based payments" } } }, "auth_ref": [ "r506" ] }, "abvx_AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AdjustmentsForUnwindingOfDiscountRelatedToConditionalAdvances", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of unwinding the discount related to advances", "label": "Adjustments For Unwinding Of Discount Related To Conditional Advances", "documentation": "Adjustments For Unwinding Of Discount Related To Conditional Advances" } } }, "auth_ref": [] }, "abvx_AdvisorToTheChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AdvisorToTheChiefExecutiveOfficerMember", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advisor to the Chief Executive Officer", "label": "Advisor To The Chief Executive Officer [Member]", "documentation": "Advisor To The Chief Executive Officer" } } }, "auth_ref": [] }, "abvx_After18MonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "After18MonthsMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After 18 months", "label": "After 18 Months [Member]", "documentation": "After 18 Months" } } }, "auth_ref": [] }, "abvx_After24MonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "After24MonthsMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After 24 months", "label": "After 24 Months [Member]", "documentation": "After 24 Months" } } }, "auth_ref": [] }, "abvx_After36MonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "After36MonthsMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After 36 months", "label": "After 36 Months [Member]", "documentation": "After 36 Months" } } }, "auth_ref": [] }, "abvx_AggregateExercisePriceOtherEquityInstrumentsGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AggregateExercisePriceOtherEquityInstrumentsGranted", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate exercise price", "label": "Aggregate Exercise Price, Other Equity Instruments Granted", "documentation": "Aggregate Exercise Price, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_AggregateFairValueConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AggregateFairValueConvertibleNotes", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of convertible notes", "label": "Aggregate Fair Value, Convertible Notes", "documentation": "Aggregate Fair Value, Convertible Notes" } } }, "auth_ref": [] }, "abvx_AggregateFairValueOtherEquityInstrumentsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AggregateFairValueOtherEquityInstrumentsOutstanding", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of other equity instruments", "label": "Aggregate Fair Value, Other Equity Instruments Outstanding", "documentation": "Aggregate Fair Value, Other Equity Instruments Outstanding" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r485" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r398", "r409", "r419", "r452" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r401", "r412", "r422", "r455" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r486" ] }, "abvx_AgreementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AgreementPeriod", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement, period", "label": "Agreement, Period", "documentation": "Agreement, Period" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r440" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r447" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r402", "r413", "r423", "r447", "r456", "r460", "r468" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r466" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "abvx_AmericanDepositorySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AmericanDepositorySharesMember", "presentation": [ "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "ADS", "label": "American Depository Shares [Member]", "documentation": "American Depository Shares" } } }, "auth_ref": [] }, "abvx_AmericanDepositorySharesNASDAQGlobalMarketMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AmericanDepositorySharesNASDAQGlobalMarketMember", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "American Depositary Shares, each representing one ordinary share, nominal value \u20ac0.01 per share", "label": "American Depository Shares, NASDAQ Global Market [Member]", "documentation": "American Depository Shares, NASDAQ Global Select Market [Member]" } } }, "auth_ref": [] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase", "label": "Amortisation, intangible assets other than goodwill" } } }, "auth_ref": [ "r60", "r241" ] }, "abvx_AmortizedCostEIRMethodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AmortizedCostEIRMethodMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized cost (EIR method)", "label": "Amortized Cost (EIR Method) [Member]", "documentation": "Amortized Cost (EIR Method)" } } }, "auth_ref": [] }, "abvx_AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AmountOfReasonablyPossibleDecreaseInUnobservableInputLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amount of reasonably possible decrease in unobservable input, liabilities (in euro per share)", "label": "Amount Of Reasonably Possible Decrease In Unobservable Input, Liabilities", "documentation": "Amount Of Reasonably Possible Decrease In Unobservable Input, Liabilities" } } }, "auth_ref": [] }, "abvx_AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AmountOfReasonablyPossibleIncreaseInUnobservableInputLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of reasonably possible increase in unobservable input, liabilities (in euro per share)", "label": "Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities", "documentation": "Amount Of Reasonably Possible Increase In Unobservable Input, Liabilities" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statutory French tax rate", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r3", "r202" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "terseLabel": "Financial assets", "verboseLabel": "Assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r103", "r104", "r106", "r165", "r167", "r270", "r271", "r296" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "abvx_AssetsAcquisitionsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AssetsAcquisitionsAxis", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets Acquisitions [Axis]", "label": "Assets Acquisitions [Axis]", "documentation": "Assets Acquisitions" } } }, "auth_ref": [] }, "abvx_AssetsAcquisitionsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AssetsAcquisitionsDomain", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets Acquisitions [Domain]", "label": "Assets Acquisitions [Domain]", "documentation": "Assets Acquisitions [Domain]" } } }, "auth_ref": [] }, "abvx_AtTheMarketATMProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AtTheMarketATMProgramMember", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "At-The-Market (ATM) Program", "label": "At-The-Market (ATM) Program [Member]", "documentation": "At-The-Market (ATM) Program" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [axis]", "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r516", "r519" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [domain]", "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r516", "r519" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://www.abivax.com/role/Auditorinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r381", "r382", "r405" ] }, "abvx_AuditorInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AuditorInformationAbstract", "lang": { "en-us": { "role": { "label": "Auditor Information [Abstract]", "documentation": "Auditor Information" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://www.abivax.com/role/Auditorinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r381", "r382", "r405" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://www.abivax.com/role/Auditorinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r381", "r382", "r405" ] }, "ifrs-full_AuditorsRemuneration": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemuneration", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total auditor's remuneration", "label": "Auditor's remuneration" } } }, "auth_ref": [ "r519" ] }, "abvx_AuditorsRemunerationForAuditRelatedFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "AuditorsRemunerationForAuditRelatedFees", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails": { "parentTag": "ifrs-full_AuditorsRemuneration", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Audit-related fees", "label": "Auditor's Remuneration For Audit-Related Fees", "documentation": "Auditor's Remuneration For Audit-Related Fees" } } }, "auth_ref": [] }, "ifrs-full_AuditorsRemunerationForAuditServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemunerationForAuditServices", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails": { "parentTag": "ifrs-full_AuditorsRemuneration", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Audit fees", "label": "Auditor's remuneration for audit services" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_AuditorsRemunerationForOtherServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemunerationForOtherServices", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails": { "parentTag": "ifrs-full_AuditorsRemuneration", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All other fees", "label": "Auditor's remuneration for other services" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_AuditorsRemunerationForTaxServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemunerationForTaxServices", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails": { "parentTag": "ifrs-full_AuditorsRemuneration", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofprincipalauditfeesandservicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax fees", "label": "Auditor's remuneration for tax services" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_AverageNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageNumberOfEmployees", "presentation": [ "http://www.abivax.com/role/EmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average number of employees", "label": "Average number of employees" } }, "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } } }, "auth_ref": [ "r519" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r463" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r464" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r459" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r459" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r459" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r459" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r459" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r459" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r462" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r461" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r460" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r460" ] }, "abvx_BCE20161Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BCE20161Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BCE-2016-1", "label": "BCE-2016-1 [Member]", "documentation": "BCE-2016-1" } } }, "auth_ref": [] }, "abvx_BCE20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BCE20171Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BCE-2017-1", "label": "BCE-2017-1 [Member]", "documentation": "BCE-2017-1" } } }, "auth_ref": [] }, "abvx_BCE20172Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BCE20172Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BCE-2017-2", "label": "BCE-2017-2 [Member]", "documentation": "BCE-2017-2" } } }, "auth_ref": [] }, "abvx_BCE20174Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BCE20174Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BCE-2017-4", "label": "BCE-2017-4 [Member]", "documentation": "BCE-2017-4" } } }, "auth_ref": [] }, "abvx_BCE20175Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BCE20175Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BCE-2017-5", "label": "BCE-2017-5 [Member]", "documentation": "BCE-2017-5" } } }, "auth_ref": [] }, "abvx_BCE20181Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BCE20181Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BCE-2018-1", "label": "BCE-2018-1 [Member]", "documentation": "BCE-2018-1" } } }, "auth_ref": [] }, "abvx_BCE20184Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BCE20184Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BCE-2018-4", "label": "BCE-2018-4 [Member]", "documentation": "BCE-2018-4" } } }, "auth_ref": [] }, "abvx_BCE20185Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BCE20185Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BCE-2018-5", "label": "BCE-2018-5 [Member]", "documentation": "BCE-2018-5" } } }, "auth_ref": [] }, "abvx_BCEExceptBCE20142Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BCEExceptBCE20142Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BCE except BCE 2014-2", "label": "BCE Except BCE 2014-2 [Member]", "documentation": "BCE Except BCE 2014-2" } } }, "auth_ref": [] }, "abvx_BSA201511Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BSA201511Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2015-11", "label": "BSA-2015-11 [Member]", "documentation": "BSA-2015-11" } } }, "auth_ref": [] }, "abvx_BSA201512Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BSA201512Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2015-12", "label": "BSA-2015-12 [Member]", "documentation": "BSA-2015-12" } } }, "auth_ref": [] }, "abvx_BSA20171Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BSA20171Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2017-1", "label": "BSA-2017-1 [Member]", "documentation": "BSA-2017-1" } } }, "auth_ref": [] }, "abvx_BSA20181Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BSA20181Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2018-1", "label": "BSA-2018-1 [Member]", "documentation": "BSA-2018-1" } } }, "auth_ref": [] }, "abvx_BSA20241AndBSA20242Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BSA20241AndBSA20242Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2024-1 and BSA-2024-2", "label": "BSA-2024-1 And BSA-2024-2 [Member]", "documentation": "BSA-2024-1 And BSA-2024-2" } } }, "auth_ref": [] }, "abvx_BSA20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BSA20241Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2024-1", "label": "BSA-2024-1 [Member]", "documentation": "BSA-2024-1" } } }, "auth_ref": [] }, "abvx_BSA20242Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BSA20242Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2024-2", "label": "BSA-2024-2 [Member]", "documentation": "BSA-2024-2" } } }, "auth_ref": [] }, "abvx_BSA20251AndBSA20252Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BSA20251AndBSA20252Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2025-1 and BSA-2025-2", "label": "BSA-2025-1 And BSA-2025-2 [Member]", "documentation": "BSA-2025-1 And BSA-2025-2" } } }, "auth_ref": [] }, "abvx_BSA20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BSA20251Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2025-1", "label": "BSA-2025-1 [Member]", "documentation": "BSA-2025-1" } } }, "auth_ref": [] }, "abvx_BSA20252Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BSA20252Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2025-2", "label": "BSA-2025-2 [Member]", "documentation": "BSA-2025-2" } } }, "auth_ref": [] }, "abvx_BSA20253Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BSA20253Member", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BSA-2025-3", "label": "BSA-2025-3 [Member]", "documentation": "BSA-2025-3" } } }, "auth_ref": [] }, "abvx_BalancesWithBanksInExcessOfLegallyInsuredLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BalancesWithBanksInExcessOfLegallyInsuredLimit", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balances with banks in excess of legally insured limit", "label": "Balances With Banks In Excess Of Legally Insured Limit", "documentation": "Balances With Banks In Excess Of Legally Insured Limit" } } }, "auth_ref": [] }, "ifrs-full_BankBorrowingsUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BankBorrowingsUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, undiscounted cash flows", "label": "Bank borrowings, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r356", "r359" ] }, "abvx_BanquePubliqueDInvestissementBPIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BanquePubliqueDInvestissementBPIMember", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional advances Bpifrance", "label": "Banque Publique d\u2019Investissement (BPI) [Member]", "documentation": "Banque Publique d\u2019Investissement (BPI)" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic loss per share (in euro per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r40", "r41" ] }, "abvx_BlackScholesModelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BlackScholesModelMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Black Scholes Model", "label": "Black Scholes Model [Member]", "documentation": "Black Scholes Model" } } }, "auth_ref": [] }, "abvx_BoardMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BoardMemberMember", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board member", "label": "Board Member [Member]", "documentation": "Board Member" } } }, "auth_ref": [] }, "abvx_BoardOfDirectorsAndChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BoardOfDirectorsAndChiefExecutiveOfficerMember", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board of Directors and Chief Executive Officer", "label": "Board Of Directors And Chief Executive Officer [Member]", "documentation": "Board Of Directors And Chief Executive Officer" } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Borrowings", "terseLabel": "Borrowings", "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r522" ] }, "abvx_Borrowings1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Borrowings1Member", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Borrowings1 [Member]", "documentation": "Borrowings by name" } } }, "auth_ref": [] }, "abvx_BorrowingsAdditionalTrancheAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsAdditionalTrancheAmount", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos2Details" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, additional tranche mount", "label": "Borrowings, Additional Tranche Amount", "documentation": "Borrowings, Additional Tranche Amount" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsAdjustmentToInterestRateBasis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, adjustment to interest rate basis", "label": "Borrowings, adjustment to interest rate basis" } }, "en": { "role": { "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r514" ] }, "abvx_BorrowingsBasisInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsBasisInterestRate", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, interest rate basis", "label": "Borrowings, Basis Interest Rate", "documentation": "Borrowings, Basis Interest Rate" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreos2Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails", "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [axis]", "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r514" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreos2Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails", "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [domain]", "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r514" ] }, "abvx_BorrowingsDebtToMarketCapitalizationRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsDebtToMarketCapitalizationRatio", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, debt-to-market capitalization ratio", "label": "Borrowings, Debt-To-Market Capitalization Ratio", "documentation": "Borrowings, Debt-To-Market Capitalization Ratio" } } }, "auth_ref": [] }, "abvx_BorrowingsDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsDeposit", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposit paid, borrowing", "label": "Borrowings, Deposit", "documentation": "Borrowings, Deposit" } } }, "auth_ref": [] }, "abvx_BorrowingsDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsDiscountRate", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, discount rate", "label": "Borrowings, Discount Rate", "documentation": "Borrowings, Discount Rate" } } }, "auth_ref": [] }, "abvx_BorrowingsEarlyRepaymentDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsEarlyRepaymentDiscountRate", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, early repayment, discount rate", "label": "Borrowings, Early Repayment, Discount Rate", "documentation": "Borrowings, Early Repayment, Discount Rate" } } }, "auth_ref": [] }, "abvx_BorrowingsExitFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsExitFeeAmount", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, exit fee amount", "label": "Borrowings, Exit Fee Amount", "documentation": "Borrowings, Exit Fee Amount" } } }, "auth_ref": [] }, "abvx_BorrowingsExitFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsExitFeePercentage", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, exit fee percentage", "label": "Borrowings, Exit Fee Percentage", "documentation": "Borrowings, Exit Fee Percentage" } } }, "auth_ref": [] }, "abvx_BorrowingsFixedConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsFixedConversionPrice", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, fixed conversion price (in euro per share)", "label": "Borrowings, Fixed Conversion Price", "documentation": "Borrowings, Fixed Conversion Price" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, interest rate", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r514" ] }, "abvx_BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsMarketPriceNumberOfDaysWithLowestDailyVWAP", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, market price, number of days with lowest daily VWAP", "label": "Borrowings, Market Price, Number Of Days With Lowest Daily VWAP", "documentation": "Borrowings, Market Price, Number Of Days With Lowest Daily VWAP" } } }, "auth_ref": [] }, "abvx_BorrowingsMarketPriceNumberOfTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsMarketPriceNumberOfTradingDays", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, market price, number of trading days", "label": "Borrowings, Market Price, Number Of Trading Days", "documentation": "Borrowings, Market Price, Number Of Trading Days" } } }, "auth_ref": [] }, "abvx_BorrowingsMaturityDeferralPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsMaturityDeferralPeriod", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings maturity, deferral period", "label": "Borrowings Maturity, Deferral Period", "documentation": "Borrowings Maturity, Deferral Period" } } }, "auth_ref": [] }, "abvx_BorrowingsMaturityExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsMaturityExtensionTerm", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings maturity, extension term", "label": "Borrowings Maturity, Extension Term", "documentation": "Borrowings Maturity, Extension Term" } } }, "auth_ref": [] }, "abvx_BorrowingsMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsMaturityTerm", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, maturity term", "label": "Borrowings Maturity, Term", "documentation": "Borrowings Maturity, Term" } } }, "auth_ref": [] }, "abvx_BorrowingsMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, maximum borrowing capacity", "label": "Borrowings, Maximum Borrowing Capacity", "documentation": "Borrowings, Maximum Borrowing Capacity" } } }, "auth_ref": [] }, "abvx_BorrowingsMaximumBorrowingCapacityPerTranche": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsMaximumBorrowingCapacityPerTranche", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, maximum borrowing capacity per tranche", "label": "Borrowings, Maximum Borrowing Capacity Per Tranche", "documentation": "Borrowings, Maximum Borrowing Capacity Per Tranche" } } }, "auth_ref": [] }, "abvx_BorrowingsNumberOfQuarterlyInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsNumberOfQuarterlyInstallments", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, number of quarterly installments", "label": "Borrowings, Number Of Quarterly Installments", "documentation": "Borrowings, Number Of Quarterly Installments" } } }, "auth_ref": [] }, "abvx_BorrowingsNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsNumberOfTranches", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreos2Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, number of tranches", "label": "Borrowings, Number Of Tranches", "documentation": "Borrowings, Number Of Tranches" } } }, "auth_ref": [] }, "abvx_BorrowingsPercentageOfMarketPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsPercentageOfMarketPrice", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, percentage of market price", "label": "Borrowings, Percentage Of Market Price", "documentation": "Borrowings, Percentage Of Market Price" } } }, "auth_ref": [] }, "abvx_BorrowingsPerformanceConditionsMinimumFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsPerformanceConditionsMinimumFinancing", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance conditions, minimum financing", "label": "Borrowings, Performance Conditions, Minimum Financing", "documentation": "Borrowings, Performance Conditions, Minimum Financing" } } }, "auth_ref": [] }, "abvx_BorrowingsStateGuaranteedPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "BorrowingsStateGuaranteedPremium", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, state guaranteed premium", "label": "Borrowings, State Guaranteed Premium", "documentation": "Borrowings, State Guaranteed Premium" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails", "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails", "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails", "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of range", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r81", "r109", "r122", "r130", "r195", "r342", "r344", "r514" ] }, "ifrs-full_BuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BuildingsMember", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails", "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BUILDINGS", "verboseLabel": "Buildings", "label": "Buildings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r492" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r382", "r405" ] }, "abvx_CARENAConditionalAdvanceBPIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CARENAConditionalAdvanceBPIMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails", "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "CARENA conditional advance", "verboseLabel": "CARENA \u2013 Bpifrance", "label": "CARENA Conditional Advance, BPI [Member]", "documentation": "CARENA Conditional Advance, BPI" } } }, "auth_ref": [] }, "abvx_CIRTaxYearAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CIRTaxYearAxis", "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CIR Tax Year [Axis]", "label": "CIR Tax Year [Axis]", "documentation": "CIR Tax Year" } } }, "auth_ref": [] }, "abvx_CIRTaxYearDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CIRTaxYearDomain", "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CIR Tax Year [Domain]", "label": "CIR Tax Year [Domain]", "documentation": "CIR Tax Year [Domain]" } } }, "auth_ref": [] }, "abvx_CSOSettlementAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CSOSettlementAgreementMember", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CSO, settlement agreement", "label": "CSO, Settlement Agreement [Member]", "documentation": "CSO, Settlement Agreement" } } }, "auth_ref": [] }, "ifrs-full_CapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalCommitments", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital commitments", "label": "Capital commitments" } }, "en": { "role": { "documentation": "The amount of future capital expenditures that the entity is committed to make." } } }, "auth_ref": [ "r519" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r9", "r10", "r57", "r61", "r67", "r68", "r69", "r70", "r71", "r137", "r145", "r146", "r207", "r208", "r238", "r242", "r246", "r247", "r248", "r249", "r250", "r256", "r264", "r265" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount [member]", "label": "Carrying amount [member]" } } }, "auth_ref": [ "r10", "r61", "r67", "r69", "r70", "r137", "r145", "r146", "r208", "r242", "r246", "r248", "r249", "r256", "r264", "r265" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r508" ] }, "abvx_CashAndCashEquivalentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CashAndCashEquivalentMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash And Cash Equivalent [Member]", "documentation": "Cash And Cash Equivalent" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 }, "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at the beginning of the year", "periodEndLabel": "Cash and cash equivalents at the end of the year", "totalLabel": "Cash and cash equivalents", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r82", "r97", "r196", "r292" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]" } } }, "auth_ref": [] }, "abvx_CashAndCashEquivalentsAndOtherShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CashAndCashEquivalentsAndOtherShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents and other short-term investments", "label": "Cash And Cash Equivalents And Other Short-Term Investments", "documentation": "Cash And Cash Equivalents And Other Short-Term Investments" } } }, "auth_ref": [] }, "ifrs-full_CashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashEquivalents", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsDisclosureofcompositionofcashandcashequivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash equivalents" } }, "en": { "role": { "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value." } } }, "auth_ref": [ "r508" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows provided by (used in) financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r72", "r84" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows provided by (used in) financing activities", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows provided by (used in) investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r72", "r84" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows provided by (used in) investing activities", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows provided by (used in) operating activities", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r72", "r84" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows provided by (used in) operating activities", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows provided by (used in) operating activities before change in working capital requirements", "label": "Cash flows from (used in) operations before changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r333", "r507" ] }, "abvx_CashPaymentsForDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CashPaymentsForDeposits", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in deposits", "label": "Cash Payments For Deposits", "documentation": "Cash Payments For Deposits" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [axis]", "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r160", "r262" ] }, "ifrs-full_CategoriesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [domain]", "label": "Categories of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r160", "r262" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities [axis]", "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r160", "r262" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities [domain]", "label": "Categories of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r160", "r262" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of related parties [axis]", "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r34", "r225" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of related parties [domain]", "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r34", "r225" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r438" ] }, "ifrs-full_ChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInEquityAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in equity [abstract]", "label": "Changes in equity [abstract]" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r435" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r433" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of assets [axis]", "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r45", "r46", "r108", "r116", "r178", "r228", "r272" ] }, "ifrs-full_ClassesOfAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of assets [domain]", "label": "Classes of assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r45", "r108", "r116", "r178", "r228", "r272" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial instruments [axis]", "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r145", "r147", "r148", "r149", "r264", "r266" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial instruments [domain]", "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r145", "r147", "r148", "r149", "r264", "r266" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails", "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails", "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [axis]", "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r153", "r154", "r172", "r173" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails", "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails", "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [domain]", "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r153", "r154", "r172", "r173" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails", "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [axis]", "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r62", "r243" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails", "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [domain]", "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r62", "r243" ] }, "ifrs-full_ClassesOfLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of liabilities [axis]", "label": "Classes of liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r108", "r272" ] }, "ifrs-full_ClassesOfLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of liabilities [domain]", "label": "Classes of liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } } }, "auth_ref": [ "r108", "r272" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [axis]", "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r11", "r209" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [domain]", "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r11", "r209" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [axis]", "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r189", "r274", "r306" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [domain]", "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r189", "r274", "r306" ] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Closing foreign exchange rate", "label": "Closing foreign exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r519" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r439" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r439" ] }, "abvx_CollaborationAgreementsDevelopmentMilestonePaymentINDApproval": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CollaborationAgreementsDevelopmentMilestonePaymentINDApproval", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreements, development milestone payment, IND approval", "label": "Collaboration Agreements, Development Milestone Payment, IND Approval", "documentation": "Collaboration Agreements, Development Milestone Payment, IND Approval" } } }, "auth_ref": [] }, "abvx_CollaborationAgreementsDevelopmentMilestonePaymentPhase2": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CollaborationAgreementsDevelopmentMilestonePaymentPhase2", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration agreements, development milestone payment, Phase 2", "label": "Collaboration Agreements, Development Milestone Payment, Phase 2", "documentation": "Collaboration Agreements, Development Milestone Payment, Phase 2" } } }, "auth_ref": [] }, "abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDApproval", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential development milestone payment, IND approval", "label": "Collaboration Agreements, Potential Development Milestone Payment, IND Approval", "documentation": "Collaboration Agreements, Potential Development Milestone Payment, IND Approval" } } }, "auth_ref": [] }, "abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CollaborationAgreementsPotentialDevelopmentMilestonePaymentINDFiling", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential development milestone payment, IND filing", "label": "Collaboration Agreements, Potential Development Milestone Payment, IND Filing", "documentation": "Collaboration Agreements, Potential Development Milestone Payment, IND Filing" } } }, "auth_ref": [] }, "abvx_CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CollaborationAgreementsPotentialDevelopmentMilestonePaymentPhase3", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential development milestone payment, phase 3", "label": "Collaboration Agreements, Potential Development Milestone Payment, Phase 3", "documentation": "Collaboration Agreements, Potential Development Milestone Payment, Phase 3" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r444" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r443" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r445" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r442" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r285" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [domain]", "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r285" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income (loss) for the period", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r87", "r89", "r95", "r227", "r252", "r280", "r310", "r335" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "IT equipment", "label": "Computer equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r492" ] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFTWARE", "label": "Computer software [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r321" ] }, "abvx_ConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConditionalAdvances", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional advances", "label": "Conditional Advances", "documentation": "Conditional Advances" } } }, "auth_ref": [] }, "abvx_ConditionalAdvancesAndPGELoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConditionalAdvancesAndPGELoanMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional advances and PGE loan", "label": "Conditional Advances And PGE Loan [Member]", "documentation": "Conditional Advances And PGE Loan" } } }, "auth_ref": [] }, "abvx_ConditionalAdvancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConditionalAdvancesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional advances Bpifrance", "label": "Conditional Advances [Member]", "documentation": "Conditional Advances" } } }, "auth_ref": [] }, "abvx_ConditionalAdvancesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConditionalAdvancesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional advances, undiscounted cash flows", "label": "Conditional Advances, Undiscounted Cash Flows", "documentation": "Conditional Advances, Undiscounted Cash Flows" } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Name", "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "abvx_ContributionToGroupsAssetsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ContributionToGroupsAssetsPercentage", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contribution to Group's assets, percentage", "label": "Contribution To Group's Assets, Percentage", "documentation": "Contribution To Group's Assets, Percentage" } } }, "auth_ref": [] }, "abvx_ContributionToGroupsLiabilitiesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ContributionToGroupsLiabilitiesPercentage", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contribution to Group's liabilities, percentage", "label": "Contribution To Group's Liabilities, Percentage", "documentation": "Contribution To Group's Liabilities, Percentage" } } }, "auth_ref": [] }, "abvx_ContributionToGroupsNetProfitsLossesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ContributionToGroupsNetProfitsLossesPercentage", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contribution to Group's net profits (losses), percentage", "label": "Contribution To Group's Net Profits (Losses), Percentage", "documentation": "Contribution To Group's Net Profits (Losses), Percentage" } } }, "auth_ref": [] }, "abvx_ConversionPriceAdjustmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConversionPriceAdjustmentPeriod", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price, adjustment, period", "label": "Conversion Price, Adjustment, Period", "documentation": "Conversion Price, Adjustment, Period" } } }, "auth_ref": [] }, "abvx_ConversionPricePerShareMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConversionPricePerShareMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price per share (in euro per share)", "label": "Conversion Price Per Share, Measurement Input [Member]", "documentation": "Conversion Price Per Share, Measurement Input" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConvertibleLoansNotes", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loans notes", "label": "Convertible Loans Notes", "documentation": "Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotesCarryingAmountOfTheEquityComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConvertibleLoansNotesCarryingAmountOfTheEquityComponent", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount of the equity component", "label": "Convertible Loans Notes, Carrying Amount Of The Equity Component", "documentation": "Convertible Loans Notes, Carrying Amount Of The Equity Component" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConvertibleLoansNotesConversionOptionMaximumPeriodPriorToMaturityDate", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion option, maximum period prior to maturity date", "label": "Convertible Loans Notes, Conversion Option, Maximum Period Prior To Maturity Date", "documentation": "Convertible Loans Notes, Conversion Option, Maximum Period Prior To Maturity Date" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConvertibleLoansNotesEarlyRedemptionAmountPercentageOfOutstandongPrincipal", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Early redemption amount, percentage of outstandong principal", "label": "Convertible Loans Notes, Early Redemption Amount, Percentage Of Outstandong Principal", "documentation": "Convertible Loans Notes, Early Redemption Amount, Percentage Of Outstandong Principal" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConvertibleLoansNotesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loan notes", "label": "Convertible Loans Notes [Member]", "documentation": "Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotesNominalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConvertibleLoansNotesNominalValue", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loan notes, nominal value", "label": "Convertible Loans Notes, Nominal Value", "documentation": "Convertible Loans Notes, Nominal Value" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotesNumberOfSeparateClosings": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConvertibleLoansNotesNumberOfSeparateClosings", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loan notes, number of separate closings", "label": "Convertible Loans Notes, Number Of Separate Closings", "documentation": "Convertible Loans Notes, Number Of Separate Closings" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotesPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConvertibleLoansNotesPeriod", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loan notes, period", "label": "Convertible Loans Notes, Period", "documentation": "Convertible Loans Notes, Period" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConvertibleLoansNotesSettlementInSharesPercentageOfFairMarketValue", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement in shares, percentage of fair market value", "label": "Convertible Loans Notes, Settlement In Shares, Percentage Of Fair Market Value", "documentation": "Convertible Loans Notes, Settlement In Shares, Percentage Of Fair Market Value" } } }, "auth_ref": [] }, "abvx_ConvertibleLoansNotesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ConvertibleLoansNotesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loans notes, undiscounted cash flows", "label": "Convertible Loans Notes, Undiscounted Cash Flows", "documentation": "Convertible Loans Notes, Undiscounted Cash Flows" } } }, "auth_ref": [] }, "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PATENTS", "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r322" ] }, "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract", "lang": { "en-us": { "role": { "label": "Corporate information and statement of IFRS compliance [abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CreditRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CreditRiskMember", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit risk", "label": "Credit risk [member]" } }, "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r123", "r124", "r125", "r351" ] }, "ifrs-full_CreditSpreadMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CreditSpreadMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit spread", "label": "Credit spread, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for the credit spread used as a measurement input." } } }, "auth_ref": [ "r509" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency risk", "label": "Currency risk [member]" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r123", "r124", "r125", "r126", "r161" ] }, "abvx_CurrentAdvancesToCROContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CurrentAdvancesToCROContracts", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherCurrentFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advances related to CRO contracts", "label": "Current Advances To CRO Contracts", "documentation": "Current Advances To CRO Contracts" } } }, "auth_ref": [] }, "ifrs-full_CurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAdvancesToSuppliers", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current advances to suppliers", "label": "Current advances to suppliers" } }, "en": { "role": { "documentation": "The amount of current advances made to suppliers before goods or services are received." } } }, "auth_ref": [ "r519" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r91", "r300", "r335" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDeferredIncomeOtherThanCurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income", "label": "Current deferred income other than current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]" } } }, "auth_ref": [ "r522", "r525" ] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments", "label": "Current derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r522" ] }, "ifrs-full_CurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current financial liabilities", "label": "Current financial liabilities" } }, "en": { "role": { "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r141" ] }, "abvx_CurrentFinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CurrentFinancialLiabilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities-current portion", "label": "Current Financial Liabilities [Member]", "documentation": "Current Financial Liabilities" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r93", "r301", "r335" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "abvx_CurrentPayablesOnOtherTaxAndRelatedPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CurrentPayablesOnOtherTaxAndRelatedPayments", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": { "parentTag": "abvx_CurrentTaxAndEmployeeBenefitLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other tax and related payments", "label": "Current Payables On Other Tax And Related Payments", "documentation": "Current Payables On Other Tax And Related Payments" } } }, "auth_ref": [] }, "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": { "parentTag": "abvx_CurrentTaxAndEmployeeBenefitLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Social security and other", "label": "Current payables on social security and taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } } }, "auth_ref": [ "r525" ] }, "abvx_CurrentPortionOfNonCurrentConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CurrentPortionOfNonCurrentConvertibleLoansNotes", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loan notes", "label": "Current Portion Of Non-Current Convertible Loans Notes", "documentation": "Current Portion Of Non-Current Convertible Loans Notes" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Current prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r519" ] }, "abvx_CurrentPrepaidExpensesRelatedToCRO": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CurrentPrepaidExpensesRelatedToCRO", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current prepaid expenses related to CRO", "label": "Current Prepaid Expenses Related To CRO", "documentation": "Current Prepaid Expenses Related To CRO" } } }, "auth_ref": [] }, "abvx_CurrentReceivablesAndCurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CurrentReceivablesAndCurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "ifrs-full_OtherAssets", "weight": 1.0, "order": 1.0 }, "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables and assets", "totalLabel": "Total current other receivables and assets", "label": "Current Receivables And Current Prepaid Expenses", "documentation": "Current Receivables And Current Prepaid Expenses" } } }, "auth_ref": [] }, "abvx_CurrentReceivablesForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CurrentReceivablesForEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee-related receivables", "label": "Current Receivables for Employee Benefits", "documentation": "Current Receivables for Employee Benefits" } } }, "auth_ref": [] }, "abvx_CurrentReceivablesFromCreditNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CurrentReceivablesFromCreditNotes", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit notes", "label": "Current Receivables From Credit Notes", "documentation": "Current Receivables From Credit Notes" } } }, "auth_ref": [] }, "abvx_CurrentResearchTaxCreditReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CurrentResearchTaxCreditReceivables", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails", "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit (\"CIR\")", "label": "Current Research Tax Credit Receivables", "documentation": "Current Research Tax Credit Receivables" } } }, "auth_ref": [] }, "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Increase in net defined benefit liability (asset) resulting from current service cost" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r17", "r213" ] }, "abvx_CurrentTaxAndEmployeeBenefitLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "CurrentTaxAndEmployeeBenefitLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 }, "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax and employee-related payables", "totalLabel": "TAX AND EMPLOYEE-RELATED PAYABLES", "label": "Current Tax And Employee Benefit Liabilities", "documentation": "Current Tax And Employee Benefit Liabilities" } } }, "auth_ref": [] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "abvx_CurrentReceivablesAndCurrentPrepaidExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VAT receivables", "label": "Current value added tax receivables" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r523" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r390", "r479" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r390", "r479" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r392", "r481" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r392", "r481" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r394", "r483" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r392", "r481" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r385", "r474" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r386", "r475" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r386", "r475" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r384", "r473" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r384", "r473" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r384", "r473" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r387", "r476" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r389", "r478" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r389", "r478" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r390", "r479" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r393", "r482" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r391", "r480" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r388", "r477" ] }, "abvx_DecreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DecreaseInLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease", "label": "Decrease In Lease Liabilities", "documentation": "Decrease In Lease Liabilities" } } }, "auth_ref": [] }, "abvx_DecreaseInLeaseLiabilitiesThroughModificationOfTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DecreaseInLeaseLiabilitiesThroughModificationOfTerm", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in lease liabilities through modification of term", "label": "Decrease In Lease Liabilities Through Modification Of Term", "documentation": "Decrease In Lease Liabilities Through Modification Of Term" } } }, "auth_ref": [] }, "abvx_DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DecreaseThroughInterestPaidLiabilitiesArisingFromFinancingActivities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid", "label": "Decrease Through Interest Paid, Liabilities Arising From Financing Activities", "documentation": "Decrease Through Interest Paid, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "abvx_DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DecreaseThroughReassessmentOfLeaseTermRightOfUseAssets", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease through reassessment of lease term", "label": "Decrease Through Reassessment Of Lease Term, Right-Of-Use Assets", "documentation": "Decrease Through Reassessment Of Lease Term, Right-Of-Use Assets" } } }, "auth_ref": [] }, "abvx_DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DecreaseThroughRepaymentsLiabilitiesArisingFromFinancingActivities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments", "label": "Decrease Through Repayments, Liabilities Arising From Financing Activities", "documentation": "Decrease Through Repayments, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "abvx_DeferredFinancingCostsNettingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DeferredFinancingCostsNettingMember", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred financing costs", "label": "Deferred Financing Costs, Netting [Member]", "documentation": "Deferred Financing Costs, Netting" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails": { "parentTag": "ifrs-full_DeferredTaxLiabilityAsset", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails", "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "verboseLabel": "Deferred tax assets", "label": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r5", "r204", "r295", "r297" ] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails": { "parentTag": "ifrs-full_DeferredTaxLiabilityAsset", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails", "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax liabilities", "label": "Deferred tax liabilities" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r5", "r204", "r295", "r297" ] }, "abvx_DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DeferredTaxLiabilitiesAssetsNetOfUnrecognizedLiabilitiesAssets", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax liabilities", "label": "Deferred Tax Liabilities (Assets) Net of Unrecognized Liabilities (Assets)", "documentation": "Deferred Tax Liabilities (Assets) Net of Unrecognized Liabilities (Assets)" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxLiabilityAsset", "crdr": "credit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails": { "parentTag": "abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Deferred tax assets, net", "label": "Deferred tax liability (asset)" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r5", "r204" ] }, "abvx_DepreciationExpenseLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DepreciationExpenseLease", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense, lease", "label": "Depreciation Expense, Lease", "documentation": "Depreciation Expense, Lease" } } }, "auth_ref": [] }, "ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase", "label": "Depreciation, property, plant and equipment including right-of-use assets" } } }, "auth_ref": [ "r494" ] }, "ifrs-full_DerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Derivative financial liabilities at beginning of period", "periodEndLabel": "Derivative financial liabilities at end of period", "terseLabel": "Derivative financial liabilities", "label": "Derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r522" ] }, "ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativeFinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative financial liabilities, undiscounted cash flows", "label": "Derivative financial liabilities, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r151", "r268" ] }, "ifrs-full_DerivativesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments", "label": "Derivatives [member]" } }, "en": { "role": { "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r337", "r343", "r353", "r360" ] }, "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional advances and PGE", "label": "Description of accounting policy for borrowings [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Description of accounting policy for deferred income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits", "label": "Description of accounting policy for employee benefits [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets at amortized cost", "label": "Description of accounting policy for financial assets [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Description of accounting policy for financial liabilities [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Translation of transactions denominated in foreign currency", "label": "Description of accounting policy for foreign currency translation [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r520" ] }, "abvx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Going concern", "label": "Description Of Accounting Policy For Going Concern [Policy Text Block]", "documentation": "Description Of Accounting Policy For Going Concern" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForGoodwillExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Description of accounting policy for goodwill [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit and subsidies", "label": "Description of accounting policy for government grants [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r23", "r218" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of goodwill, intangible assets, property and plant and equipment", "label": "Description of accounting policy for impairment of non-financial assets [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Current taxes", "label": "Description of accounting policy for income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Description of accounting policy for intangible assets other than goodwill [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Description of accounting policy for issued capital [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Description of accounting policy for leases [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Description of accounting policy for property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Description of accounting policy for provisions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Description of accounting policy for share-based payment transactions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r520" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r83", "r197" ] }, "ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfDiscountRatesAppliedToCashFlowProjections", "presentation": [ "http://www.abivax.com/role/GoodwillandimpairmenttestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate (WACC)", "label": "Discount rate applied to cash flow projections" } }, "en": { "role": { "documentation": "The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Total for all cash-generating units [member]]" } } }, "auth_ref": [ "r49", "r50", "r231", "r232" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per share (in euro per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r40", "r41" ] }, "abvx_DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfAccountingPolicyForAccountingJudgementsAndEstimatesExplanatoryPolicyTextBlock", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of judgments and estimates", "label": "Disclosure Of Accounting Policy For Accounting Judgements And Estimates Explanatory [Policy Text Block]", "documentation": "Disclosure Of Accounting Policy For Accounting Judgements And Estimates Explanatory" } } }, "auth_ref": [] }, "abvx_DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfAccountingPolicyForAssetsAcquisitionsPolicyTextBlock", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting of Prosynergia acquisition", "label": "Disclosure Of Accounting Policy For Assets Acquisitions [Policy Text Block]", "documentation": "Disclosure Of Accounting Policy For Assets Acquisitions" } } }, "auth_ref": [] }, "abvx_DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfAccountingPolicyForNewRevisedOrAmendedStandardsAndInterpretationsPolicyTextBlock", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New, revised or amended Standards and Interpretations", "label": "Disclosure Of Accounting Policy For New, Revised Or Amended Standards And Interpretations [Policy Text Block]", "documentation": "Disclosure Of Accounting Policy For New, Revised Or Amended Standards And Interpretations" } } }, "auth_ref": [] }, "abvx_DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsIssuedByIASBButNotYetMandatoryPolicyTextBlock", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New standards, amendments and interpretations issued by IASB but not yet mandatory for financial years starting from January 1, 2023", "label": "Disclosure Of Accounting Policy For New Standards, Amendments And Interpretations Issued By IASB But Not Yet Mandatory [Policy Text Block]", "documentation": "Disclosure Of Accounting Policy For New Standards, Amendments And For Financial Years" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of attribution of expenses by nature to their function [line items]", "label": "Disclosure of attribution of expenses by nature to their function [line items]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of attribution of expenses by nature to their function [table]", "label": "Disclosure of attribution of expenses by nature to their function [table]" } } }, "auth_ref": [ "r516", "r519" ] }, "abvx_DisclosureOfAverageNumberOfEmployeesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfAverageNumberOfEmployeesTableTextBlock", "presentation": [ "http://www.abivax.com/role/EmployeesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of average workforce during the periods", "label": "Disclosure Of Average Number Of Employees [Table Text Block]", "documentation": "Disclosure Of Average Number Of Employees" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://www.abivax.com/role/Basisofpreparation" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of preparation", "label": "Disclosure of basis of preparation of financial statements [text block]" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of conditional advances", "label": "Disclosure of borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r515" ] }, "abvx_DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfBreakdownOfTradeAndOtherPayablesTableTextBlock", "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of breakdown of trade and other payables", "label": "Disclosure Of Breakdown Of Trade And Other Payables [Table Text Block]", "documentation": "Disclosure Of Breakdown Of Trade And Other Payables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.abivax.com/role/Cashandcashequivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Disclosure of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r515" ] }, "abvx_DisclosureOfCashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfCashAndCashEquivalentsLineItems", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Cash And Cash Equivalents [Line Items]", "label": "Disclosure Of Cash And Cash Equivalents [Line Items]", "documentation": "Disclosure Of Cash And Cash Equivalents [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfCashAndCashEquivalentsTable", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Cash And Cash Equivalents [Table]", "label": "Disclosure Of Cash And Cash Equivalents [Table]", "documentation": "Disclosure Of Cash And Cash Equivalents [Table]" } } }, "auth_ref": [] }, "abvx_DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfChangesInDerivativeFinancialInstrumentsTableTextBlock", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of changes in derivative instruments", "label": "Disclosure Of Changes In Derivative Financial Instruments [Table Text Block]", "documentation": "Disclosure Of Changes In Derivative Financial Instruments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [line items]", "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [table]", "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r189", "r274", "r306" ] }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsExplanatory", "presentation": [ "http://www.abivax.com/role/Offbalancesheetcommitmentsgiven" ], "lang": { "en-us": { "role": { "terseLabel": "Off-balance sheet commitments given", "label": "Disclosure of commitments [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments." } } }, "auth_ref": [ "r515" ] }, "abvx_DisclosureOfCommitmentsReceivedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfCommitmentsReceivedLineItems", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Commitments Received [Line Items]", "label": "Disclosure Of Commitments Received [Line Items]", "documentation": "Disclosure Of Commitments Received [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfCommitmentsReceivedTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfCommitmentsReceivedTable", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Commitments Received [Table]", "label": "Disclosure Of Commitments Received [Table]", "documentation": "Disclosure Of Commitments Received [Table]" } } }, "auth_ref": [] }, "abvx_DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfCompositionOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of composition of cash and cash equivalents", "label": "Disclosure Of Composition Of Cash And Cash Equivalents [Table Text Block]", "documentation": "Disclosure Of Composition Of Cash And Cash Equivalents" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCreditRiskExposureLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCreditRiskExposureLineItems", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of credit risk exposure [line items]", "label": "Disclosure of credit risk exposure [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCreditRiskExposureTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCreditRiskExposureTable", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of credit risk exposure [table]", "label": "Disclosure of credit risk exposure [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the credit risk exposure." } } }, "auth_ref": [ "r148", "r266" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [abstract]", "label": "Disclosure of defined benefit plans [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansExplanatory", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of main actuarial assumptions used to measure the retirement benefit obligations", "label": "Disclosure of defined benefit plans [text block]" } }, "en": { "role": { "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r14", "r210" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansLineItems", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails", "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [line items]", "label": "Disclosure of defined benefit plans [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails", "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of defined benefit plans [table]", "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r14", "r210" ] }, "abvx_DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfDetailedInformationAboutAssetsAcquisitionsExplanatoryTableTextBlock", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of allocation of acquisition cost", "label": "Disclosure Of Detailed Information About Assets Acquisitions Explanatory [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Assets Acquisitions Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails", "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreos2Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about borrowings [line items]", "label": "Disclosure of detailed information about borrowings [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails", "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreos2Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about borrowings [table]", "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r514" ] }, "abvx_DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeCostTableTextBlock", "presentation": [ "http://www.abivax.com/role/FinancialgainlossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of net financial income (loss)", "label": "Disclosure Of Detailed Information About Finance Income (Cost) [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Finance Income (Cost)" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/IntangibleassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of intangible assets", "label": "Disclosure of detailed information about intangible assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r62", "r243" ] }, "abvx_DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfDetailedInformationAboutOtherReceivablesAndOtherAssetsTableTextBlock", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of other receivables and other assets", "label": "Disclosure Of Detailed Information About Other Receivables And Other Assets [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Other Receivables And Other Assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of depreciation period of property, plant and equipment", "label": "Disclosure of detailed information about property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r11", "r209" ] }, "abvx_DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfDetailedInformationOfOperatingIncomeExplanatoryTableTextBlock", "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of breakdown of operating income", "label": "Disclosure Of Detailed Information Of Operating Income Explanatory [Table Text Block]", "documentation": "Disclosure Of Detailed Information Of Operating Income Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.abivax.com/role/Incomelosspershare" ], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) per share", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r44" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://www.abivax.com/role/Retirementbenefitobligations" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement benefit obligations", "label": "Disclosure of employee benefits [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r22" ] }, "abvx_DisclosureOfEmployeeWorkforceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfEmployeeWorkforceLineItems", "presentation": [ "http://www.abivax.com/role/EmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Employee Workforce [Line Items]", "label": "Disclosure Of Employee Workforce [Line Items]", "documentation": "Disclosure Of Employee Workforce [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfEmployeeWorkforceTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfEmployeeWorkforceTable", "presentation": [ "http://www.abivax.com/role/EmployeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Employee Workforce [Table]", "label": "Disclosure Of Employee Workforce [Table]", "documentation": "Disclosure Of Employee Workforce [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://www.abivax.com/role/Segmentinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment information", "label": "Disclosure of entity's operating segments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r171" ] }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesByNatureExplanatory", "presentation": [ "http://www.abivax.com/role/OperatingexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of expenses by nature", "label": "Disclosure of expenses by nature [text block]" } } }, "auth_ref": [ "r515" ] }, "abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]", "label": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]", "documentation": "Disclosure Of Fair Value Measurement Of Assets And Liabilities" } } }, "auth_ref": [] }, "abvx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesTable", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Table]", "label": "Disclosure Of Fair Value Measurement Of Assets And Liabilities [Table]", "documentation": "Disclosure Of Fair Value Measurement Of Assets And Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of carrying amounts and fair value of financial assets", "label": "Disclosure of fair value measurement of assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of assets." } } }, "auth_ref": [ "r108", "r272" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of carrying amounts and fair value of financial liabilities", "label": "Disclosure of fair value measurement of liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of liabilities." } } }, "auth_ref": [ "r108", "r272" ] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.abivax.com/role/Financialassetsandliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets and liabilities", "label": "Disclosure of fair value of financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://www.abivax.com/role/Financialgainloss" ], "lang": { "en-us": { "role": { "terseLabel": "Financial gain (loss)", "label": "Disclosure of finance income (cost) [text block]" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_DisclosureOfFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of other financial assets", "label": "Disclosure of financial assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r155", "r257" ] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [line items]", "label": "Disclosure of financial assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial assets [table]", "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r155", "r257" ] }, "abvx_DisclosureOfFinancialGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfFinancialGainLossLineItems", "presentation": [ "http://www.abivax.com/role/FinancialgainlossNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Gain (Loss) [Line Items]", "label": "Disclosure Of Financial Gain (Loss) [Line Items]", "documentation": "Disclosure Of Financial Gain (Loss) [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfFinancialGainLossTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfFinancialGainLossTable", "presentation": [ "http://www.abivax.com/role/FinancialgainlossNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Financial Gain (Loss) [Table]", "label": "Disclosure Of Financial Gain (Loss) [Table]", "documentation": "Disclosure Of Financial Gain (Loss) [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.abivax.com/role/Financialliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Disclosure of financial instruments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r162" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [line items]", "label": "Disclosure of detailed information about financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [table]", "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r142", "r147", "r155", "r257" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [abstract]", "label": "Disclosure of financial liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities breakdown", "label": "Disclosure of financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r155", "r257" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [line items]", "label": "Disclosure of financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of financial liabilities [table]", "label": "Disclosure of financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial liabilities." } } }, "auth_ref": [ "r155", "r257" ] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://www.abivax.com/role/Managementandassessmentoffinancialrisks" ], "lang": { "en-us": { "role": { "terseLabel": "Management and assessment of financial risks", "label": "Disclosure of financial risk management [text block]" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r515" ] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://www.abivax.com/role/TheGroup" ], "lang": { "en-us": { "role": { "terseLabel": "The Group", "label": "Disclosure of general information about financial statements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r186", "r289" ] }, "ifrs-full_DisclosureOfGeographicalAreasLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasLineItems", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of geographical areas [line items]", "label": "Disclosure of geographical areas [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeographicalAreasTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasTable", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of geographical areas [table]", "label": "Disclosure of geographical areas [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to geographical areas." } } }, "auth_ref": [ "r170" ] }, "ifrs-full_DisclosureOfGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGoodwillExplanatory", "presentation": [ "http://www.abivax.com/role/Goodwillandimpairmenttest" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and impairment test", "label": "Disclosure of goodwill [text block]" } }, "en": { "role": { "documentation": "The disclosure of goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r515" ] }, "abvx_DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfImpactOfTheUkraineRussiaHostilitiesOnTheGroupPolicyTextBlock", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of the Ukraine/Russia Hostilities on the Group", "label": "Disclosure Of Impact Of The Ukraine/Russia Hostilities On The Group [Policy Text Block]", "documentation": "Disclosure Of Impact Of The Ukraine/Russia Hostilities On The Group" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.abivax.com/role/Incometax" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r7" ] }, "abvx_DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfIndirectMeasurementOfConvertibleLoansInstrumentsTableTextBlock", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of main data and assumptions used for the measurement of convertible loan notes", "label": "Disclosure Of Indirect Measurement Of Convertible Loans Instruments [Table Text Block]", "documentation": "" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables", "http://www.abivax.com/role/SharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of main data and assumptions used for the measurement of other equity instruments", "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r133" ] }, "ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutEmployeesExplanatory", "presentation": [ "http://www.abivax.com/role/Employees" ], "lang": { "en-us": { "role": { "terseLabel": "Employees", "label": "Disclosure of information about employees [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about employees." } } }, "auth_ref": [ "r515" ] }, "ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesLineItems", "presentation": [ "http://www.abivax.com/role/GoodwillandimpairmenttestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of information for cash-generating units [line items]", "label": "Disclosure of information for cash-generating units [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationForIndividualAssetOrCashgeneratingUnitWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesTable", "presentation": [ "http://www.abivax.com/role/GoodwillandimpairmenttestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of information for cash-generating units [table]", "label": "Disclosure of information for cash-generating units [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to cash-generating units." } } }, "auth_ref": [ "r51", "r233" ] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/Intangibleassets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Disclosure of intangible assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r65" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails", "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [line items]", "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails", "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [table]", "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r62", "r243" ] }, "abvx_DisclosureOfLeaseLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfLeaseLiabilitiesLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Lease Liabilities [Line Items]", "label": "Disclosure Of Lease Liabilities [Line Items]", "documentation": "Disclosure Of Lease Liabilities [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfLeaseLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfLeaseLiabilitiesTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Lease Liabilities [Table]", "label": "Disclosure Of Lease Liabilities [Table]", "documentation": "Disclosure Of Lease Liabilities [Table]" } } }, "auth_ref": [] }, "abvx_DisclosureOfLeasesForLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfLeasesForLesseeTableTextBlock", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of variation in lease liabilities", "label": "Disclosure Of Leases For Lessee [Table Text Block]", "documentation": "Disclosure Of Leases For Lessee" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.abivax.com/role/Accountingprinciples" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting principles", "label": "Disclosure of material accounting policy information [text block]" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r198", "r276", "r286" ] }, "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [line items]", "label": "Disclosure of maturity analysis for derivative financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [table]", "label": "Disclosure of maturity analysis for derivative financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis for derivative financial liabilities." } } }, "auth_ref": [ "r151", "r268" ] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of changes in projected benefit obligation", "label": "Disclosure of net defined benefit liability (asset) [text block]" } }, "en": { "role": { "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r16", "r212" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]", "label": "Disclosure of non-adjusting events after reporting period [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-adjusting events after reporting period [table]", "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r0", "r199" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of other equity instruments", "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r512" ] }, "abvx_DisclosureOfOffBalanceSheetCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfOffBalanceSheetCommitmentsLineItems", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Off-Balance Sheet Commitments [Line Items]", "label": "Disclosure Of Off-Balance Sheet Commitments [Line Items]", "documentation": "Disclosure Of Off-Balance Sheet Commitments [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfOffBalanceSheetCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfOffBalanceSheetCommitmentsTable", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Off-Balance Sheet Commitments [Table]", "label": "Disclosure Of Off-Balance Sheet Commitments [Table]", "documentation": "Disclosure Of Off-Balance Sheet Commitments [Table]" } } }, "auth_ref": [] }, "abvx_DisclosureOfOperatingIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfOperatingIncomeLineItems", "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Income [Line Items]", "label": "Disclosure Of Operating Income [Line Items]", "documentation": "Disclosure Of Operating Income [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfOperatingIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfOperatingIncomeTable", "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Operating Income [Table]", "label": "Disclosure Of Operating Income [Table]", "documentation": "Disclosure Of Operating Income [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of operating segments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/Otherfinancialassets" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial assets", "label": "Disclosure of other assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of other assets. [Refer: Other assets]" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingExpenseExplanatory", "presentation": [ "http://www.abivax.com/role/Operatingexpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Disclosure of other operating expense [text block]" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExplanatory", "presentation": [ "http://www.abivax.com/role/Otheroperatingincome" ], "lang": { "en-us": { "role": { "terseLabel": "Other operating income", "label": "Disclosure of other operating income [text block]" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/Offbalancesheetcommitmentsreceivedandcontingentassets" ], "lang": { "en-us": { "role": { "terseLabel": "Off-balance sheet commitments received and contingent assets", "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets." } } }, "auth_ref": [ "r55" ] }, "abvx_DisclosureOfOtherReceivablesAndOtherAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfOtherReceivablesAndOtherAssetsLineItems", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Other Receivables And Other Assets [Line Items]", "label": "Disclosure Of Other Receivables And Other Assets [Line Items]", "documentation": "Disclosure Of Other Receivables And Other Assets [Line Items]" } } }, "auth_ref": [] }, "abvx_DisclosureOfOtherReceivablesAndOtherAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfOtherReceivablesAndOtherAssetsTable", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Other Receivables And Other Assets [Table]", "label": "Disclosure Of Other Receivables And Other Assets [Table]", "documentation": "Disclosure Of Other Receivables And Other Assets [Table]" } } }, "auth_ref": [] }, "abvx_DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfPrincipalAuditFeesAndServicesTableTextBlock", "presentation": [ "http://www.abivax.com/role/OperatingexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of principal audit fees and services", "label": "Disclosure Of Principal Audit Fees And Services [Table Text Block]", "documentation": "Disclosure Of Principal Audit Fees And Services" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.abivax.com/role/Propertyplantandequipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Disclosure of property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r13" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]", "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]", "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r11", "r209" ] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]", "label": "Disclosure of quantitative information about right-of-use assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]", "label": "Disclosure of quantitative information about right-of-use assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } } }, "auth_ref": [ "r116", "r178" ] }, "abvx_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock", "presentation": [ "http://www.abivax.com/role/IncometaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of effective income tax (loss)", "label": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate [Table Text Block]", "documentation": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of property, plant and equipment", "label": "Disclosure of reconciliation of changes in property, plant and equipment, including right-of-use assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in property, plant and equipment, including right-of-use assets." } } }, "auth_ref": [ "r494" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities", "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r194", "r331" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [line items]", "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [table]", "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } } }, "auth_ref": [ "r194", "r331" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.abivax.com/role/Relatedparties" ], "lang": { "en-us": { "role": { "terseLabel": "Related parties", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r35" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.abivax.com/role/Shareholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r190", "r275", "r307" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://www.abivax.com/role/Sharebasedpayments" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Disclosure of share-based payment arrangements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r129" ] }, "abvx_DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfSignificantEventsForThePeriodReportedAndEventsAfterReportingPeriodTextBlock", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequentevents" ], "lang": { "en-us": { "role": { "terseLabel": "Significant events for the years ended December 31, 2023, 2024 and 2025 and subsequent event", "label": "Disclosure Of Significant Events For The Period Reported And Events After Reporting Period [Text Block]", "documentation": "Disclosure Of Significant Events For The Period Reported And Events After Reporting Period" } } }, "auth_ref": [] }, "abvx_DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfTaxAndEmployeeRelatedPayablesExplanatoryTableTextBlock", "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of tax and employee-related payables", "label": "Disclosure Of Tax And Employee-Related Payables Explanatory [Table Text Block]", "documentation": "Disclosure Of Tax And Employee-Related Payables Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "presentation": [ "http://www.abivax.com/role/IncometaxTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of deferred tax assets and liabilities by nature", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]" } }, "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } } }, "auth_ref": [ "r6", "r205" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails", "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails", "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r6", "r205" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]", "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r131", "r253" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.abivax.com/role/Payablesandothercurrentliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Payables and other current liabilities", "label": "Disclosure of trade and other payables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.abivax.com/role/Otherreceivablesandotherassets" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables and other assets", "label": "Disclosure of trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r515" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://www.abivax.com/role/RelatedpartiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of aggregate compensation of the members of the Group\u2019s Board of Directors and CEO", "label": "Disclosure of transactions between related parties [text block]" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r32", "r223" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [line items]", "label": "Disclosure of transactions between related parties [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of transactions between related parties [table]", "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r34", "r225" ] }, "abvx_DisclosureOfWarrantsArrangementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfWarrantsArrangementsLineItems", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Warrants Arrangements [Line Items]", "label": "Disclosure Of Warrants Arrangements [Line Items]", "documentation": "Disclosure Of Warrants Arrangements" } } }, "auth_ref": [] }, "abvx_DisclosureOfWarrantsArrangementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DisclosureOfWarrantsArrangementsTable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Warrants Arrangements [Table]", "label": "Disclosure Of Warrants Arrangements [Table]", "documentation": "Disclosure Of Warrants Arrangements" } } }, "auth_ref": [] }, "abvx_DiscountRateAppliedToLongTermAdvances": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DiscountRateAppliedToLongTermAdvances", "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disount rate applied to long-term advances", "label": "Discount Rate Applied To Long-Term Advances", "documentation": "Discount Rate Applied To Long-Term Advances" } } }, "auth_ref": [] }, "ifrs-full_DiscountRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DiscountRateMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Discount rate, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation." } } }, "auth_ref": [ "r509" ] }, "ifrs-full_DiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DiscountedCashFlowMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discounted cash flow", "label": "Discounted cash flow [member]" } }, "en": { "role": { "documentation": "This member stands for a specific valuation technique consistent with the income approach that involves analysing future cash flow amounts through the application of present value techniques and inputs (for example, weighted average cost of capital, long-term revenue growth rate, long-term pre-tax operating margin, discount for lack of marketability, control premium). [Refer: Income approach [member]; Weighted average [member]]" } } }, "auth_ref": [ "r338", "r344" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposal", "label": "Disposals, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment including right-of-use assets resulting from disposals. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r494" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r382" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r381", "r382", "r405" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r381", "r382", "r405", "r448" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r377" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r382" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r426" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "abvx_DrawdownProbablityMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "DrawdownProbablityMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability of Drawdown of Tranche C credit facility", "label": "Drawdown Probablity, Measurement Input [Member]", "documentation": "Drawdown Probablity, Measurement Input" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r437" ] }, "abvx_EarlyRedemptionAmountMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EarlyRedemptionAmountMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Early redemption amount (put event)", "label": "Early Redemption Amount, Measurement Input [Member]", "documentation": "Early Redemption Amount, Measurement Input" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share (\u20ac/share)", "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.abivax.com/role/IncomelosspershareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of earnings per share", "label": "Earnings per share [text block]" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r40" ] }, "abvx_EbolaConditionalAdvanceBPIFranceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EbolaConditionalAdvanceBPIFranceMember", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ebola conditional advance, BPI France", "label": "Ebola Conditional Advance, BPI France [Member]", "documentation": "Ebola Conditional Advance, BPI France" } } }, "auth_ref": [] }, "abvx_EbolaConditionalAdvanceBPILanguedocRoussillonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EbolaConditionalAdvanceBPILanguedocRoussillonMember", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ebola conditional advance, BPI Languedoc-Roussillon", "label": "Ebola Conditional Advance, BPI Languedoc-Roussillon [Member]", "documentation": "Ebola Conditional Advance, BPI Languedoc-Roussillon" } } }, "auth_ref": [] }, "abvx_EbolaConditionalAdvanceBPIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EbolaConditionalAdvanceBPIMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ebola conditional advance", "verboseLabel": "EBOLA \u2013 Bpifrance", "label": "Ebola Conditional Advance, BPI [Member]", "documentation": "Ebola Conditional Advance, BPI" } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of movements in exchange rates on cash held", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r74", "r75" ] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Personnel costs", "label": "Employee benefits expense" } } }, "auth_ref": [ "r187", "r279", "r314", "r369" ] }, "abvx_EmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EmployeeMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee", "label": "Employee [Member]", "documentation": "Employee" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitiesTable", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r379" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r379" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r490" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r379" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInformationLineItems", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r488" ] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings, Exchange [Axis]", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r379" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r379" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r489" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r431" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r484" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r484" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r484" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/TheGroupDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Equity at beginning of period", "periodEndLabel": "Equity at end of period", "terseLabel": "Equity", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r86", "r88", "r103", "r104", "r106", "r226", "r251", "r270", "r271", "r278", "r296", "r304" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY", "label": "Equity and liabilities [abstract]" } } }, "auth_ref": [] }, "abvx_EquityInstrumentFairValueOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EquityInstrumentFairValueOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "FAIR VALUE OF THE BSA (in euro per share)", "terseLabel": "FAIR VALUE OF THE AGA (in euro per share)", "label": "Equity Instrument Fair Value, Other Equity Instruments Granted", "documentation": "Equity Instrument Fair Value, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_EquityInstrumentPriceOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EquityInstrumentPriceOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "BSA SUBSCRIPTION PRICE (in euro per share)", "terseLabel": "AGA PRICE (in euro per share)", "label": "Equity Instrument Price, Other Equity Instruments Granted", "documentation": "Equity Instrument Price, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_EquityInstrumentStrikePriceOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EquityInstrumentStrikePriceOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "STRIKE PRICE PER SHARE ( in euro per share)", "label": "Equity Instrument Strike Price, Other Equity Instruments Granted", "documentation": "Equity Instrument Strike Price, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_EquityIssuanceCashCarveOut": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EquityIssuanceCashCarveOut", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity issuance, cash carve-out", "label": "Equity Issuance, Cash Carve-Out", "documentation": "Equity Issuance, Cash Carve-Out" } } }, "auth_ref": [] }, "abvx_EquityIssuancePercentageOfCurrentShareCapital": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EquityIssuancePercentageOfCurrentShareCapital", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Equity issuance, percentage of current share capital", "label": "Equity Issuance, Percentage Of Current Share Capital", "documentation": "Equity Issuance, Percentage Of Current Share Capital" } } }, "auth_ref": [] }, "abvx_EquityIssuanceSubscriptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EquityIssuanceSubscriptionPricePerShare", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Equity issuance, subscripion price per share (in euro per share)", "label": "Equity Issuance, Subscription Price Per Share", "documentation": "Equity Issuance, Subscription Price Per Share" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r441" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r398", "r409", "r419", "r452" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r395", "r406", "r416", "r449" ] }, "abvx_EuropeanCentralBankBaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "EuropeanCentralBankBaseRateMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "European Central Bank base rate", "label": "European Central Bank Base Rate [Member]", "documentation": "European Central Bank Base Rate" } } }, "auth_ref": [] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ExchangeDomain", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange [Domain]", "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "abvx_ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExclusiveLicensingAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exclusive licensing agreement with CNRS, University of Montpellier and Institut Curie", "label": "Exclusive Licensing Agreement With CNRS, University Of Montpellier And Institut Curie [Member]", "documentation": "Exclusive Licensing Agreement With CNRS, University Of Montpellier And Institut Curie" } } }, "auth_ref": [] }, "abvx_ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExclusiveLicensingContractWithTheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exclusive licensing contract with the Scripps Research Institute, University of Chicago and Brigham Young University", "label": "Exclusive Licensing Contract With The Scripps Research Institute, University Of Chicago And Brigham Young University [Member]", "documentation": "Exclusive Licensing Contract With The Scripps Research Institute, University Of Chicago And Brigham Young University" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r447" ] }, "abvx_ExerciseOfDerivativeInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExerciseOfDerivativeInstruments", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercises", "label": "Exercise Of Derivative Instruments", "documentation": "Exercise Of Derivative Instruments" } } }, "auth_ref": [] }, "abvx_ExercisePriceOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExercisePriceOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price, other equity instruments granted (in euro per share)", "label": "Exercise Price, Other Equity Instruments Granted", "documentation": "Exercise Price, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_ExercisePricePerShareMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExercisePricePerShareMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per share (in euro per share)", "label": "Exercise Price Per Share, Measurement Input [Member]", "documentation": "Exercise Price Per Share, Measurement Input" } } }, "auth_ref": [] }, "abvx_ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExercisePricePercentageOf15DayWVAPOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price, percentage of 15-day WVAP", "label": "Exercise Price, Percentage Of 15-Day WVAP, Other Equity Instruments Granted", "documentation": "Exercise Price, Percentage Of 15-Day WVAP, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExercisePricePercentageOfPremiumOver15DayVWAPOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price, percentage of premium", "label": "Exercise Price, Percentage Of Premium Over 15-Day VWAP, Other Equity Instruments Granted", "documentation": "Exercise Price, Percentage Of Premium Over 15-Day VWAP, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price, share options granted (in euro per share)", "label": "Exercise price, share options granted" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r132" ] }, "abvx_ExpectedDividendMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExpectedDividendMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend", "label": "Expected Dividend, Measurement Input [Member]", "documentation": "Expected Dividend, Measurement Input" } } }, "auth_ref": [] }, "abvx_ExpectedMaturityOtherEquityInstrumentsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExpectedMaturityOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EXPECTED MATURITY", "label": "Expected Maturity, Other Equity Instruments Granted", "documentation": "Expected Maturity, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_ExpectedProceedsFromShareIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExpectedProceedsFromShareIssuance", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Expected proceeds from share issuance", "label": "Expected Proceeds From Share Issuance", "documentation": "Expected Proceeds From Share Issuance" } } }, "auth_ref": [] }, "abvx_ExpectedProceedsFromShareIssuanceShelfRegistration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExpectedProceedsFromShareIssuanceShelfRegistration", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Expected proceeds from share issuance, shelf registration", "label": "Expected Proceeds From Share Issuance, Shelf Registration", "documentation": "Expected Proceeds From Share Issuance, Shelf Registration" } } }, "auth_ref": [] }, "abvx_ExpectedVolatilityOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VOLATILITY", "label": "Expected Volatility, Other Equity Instruments Granted", "documentation": "Expected Volatility, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_ExpenseByNatureAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseByNatureAbstract", "lang": { "en-us": { "role": { "label": "Expenses by nature [abstract]" } } }, "auth_ref": [] }, "abvx_ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExpenseFromEquitySettledShareBasedPaymentTransactionsSocialTaxes", "crdr": "debit", "calculation": { "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails": { "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Social taxes related to AGAs", "label": "Expense From Equity-Settled Share-Based Payment Transactions, Social Taxes", "documentation": "Expense From Equity-Settled Share-Based Payment Transactions, Social Taxes" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails": { "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation expense", "label": "Expense from equity-settled share-based payment transactions" } } }, "auth_ref": [ "r135" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Expense from share-based payment transactions" } } }, "auth_ref": [ "r135", "r254" ] }, "abvx_ExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExpenseOnLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense on lease liabilities", "label": "Expense On Lease Liabilities", "documentation": "Expense On Lease Liabilities" } } }, "auth_ref": [] }, "abvx_ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense relating to short-term leases", "label": "Expense Relating To Short-Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used", "documentation": "Expense Relating To Short-Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used" } } }, "auth_ref": [] }, "abvx_ExpiryScenarioPeriodOtherEquityInstrumentsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExpiryScenarioPeriodOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiry scenario period, other equity instruments granted", "label": "Expiry Scenario Period, Other Equity Instruments Granted", "documentation": "Expiry Scenario Period, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_ExpiryScenarioProbablityMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ExpiryScenarioProbablityMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "7-year expiry scenario probability", "label": "Expiry Scenario Probablity, Measurement Input [Member]", "documentation": "Expiry Scenario Probablity, Measurement Input" } } }, "auth_ref": [] }, "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of breakdown of the compensation expenses", "label": "Explanation of effect of share-based payments on entity's profit or loss [text block]" } }, "en": { "role": { "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss)." } } }, "auth_ref": [ "r134" ] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "FR", "presentation": [ "http://www.abivax.com/role/EmployeesDetails", "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "France", "label": "FRANCE" } } }, "auth_ref": [] }, "abvx_FairValueMeasurementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FairValueMeasurementAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurement [Abstract]", "documentation": "Fair Value Measurement [Abstract]" } } }, "auth_ref": [] }, "abvx_FinalRedemptionFairValueOfMRIMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinalRedemptionFairValueOfMRIMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of MRI, final redemption", "label": "Final Redemption, Fair Value Of MRI , Measurement Input [Member]", "documentation": "Final Redemption, Fair Value Of MRI , Measurement Input" } } }, "auth_ref": [] }, "abvx_FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinalRedemptionProbabilityWeightedFairValueWithMRIMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Final redemption, probability-weighted fair value with MRI", "label": "Final Redemption, Probability-Weighted Fair Value With MRI , Measurement Input [Member]", "documentation": "Final Redemption, Probability-Weighted Fair Value With MRI , Measurement Input" } } }, "auth_ref": [] }, "abvx_FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinalRedemptionProbabilityWeightedFairValueWithoutMRIMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Final redemption, probability-weighted fair value without MRI", "label": "Final Redemption, Probability-Weighted Fair Value Without MRI , Measurement Input [Member]", "documentation": "Final Redemption, Probability-Weighted Fair Value Without MRI , Measurement Input" } } }, "auth_ref": [] }, "abvx_FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinalRedemptionProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability-weighted present value of shortfall payment, final redemption", "label": "Final Redemption, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input [Member]", "documentation": "Final Redemption,Probability-Weighted Present Value Of Shortfall Payment, Measurement Input" } } }, "auth_ref": [] }, "abvx_FinalRedemptionScenarioProbabilityMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinalRedemptionScenarioProbabilityMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Final redemption scenario probability", "label": "Final Redemption Scenario Probability, Measurement Input [Member]", "documentation": "Final Redemption Scenario Probability, Measurement Input" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 }, "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial expenses", "negatedTotalLabel": "Financial expenses", "label": "Finance costs" } } }, "auth_ref": [ "r311" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 }, "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial income", "totalLabel": "Financial income", "label": "Finance income" } } }, "auth_ref": [ "r527" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Financial gain (loss)", "label": "Finance income (cost)" } } }, "auth_ref": [ "r527" ] }, "abvx_FinancialAgreementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinancialAgreementAmount", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Financial agreement, amount", "label": "Financial Agreement, Amount", "documentation": "Financial Agreement, Amount" } } }, "auth_ref": [] }, "abvx_FinancialAgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinancialAgreementAxis", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Agreement [Axis]", "label": "Financial Agreement [Axis]", "documentation": "Financial Agreement" } } }, "auth_ref": [] }, "abvx_FinancialAgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinancialAgreementDomain", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Agreement [Domain]", "label": "Financial Agreement [Domain]", "documentation": "Financial Agreement [Domain]" } } }, "auth_ref": [] }, "abvx_FinancialAgreementNumberOfTransactions": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinancialAgreementNumberOfTransactions", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Financial agreement, number of transactions", "label": "Financial Agreement, Number Of Transactions", "documentation": "Financial Agreement, Number Of Transactions" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS AT AMORTIZED COST", "label": "Financial assets at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r158", "r260" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets, at fair value", "label": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r141" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS AT FAIR VALUE THROUGH PROFIT\u00a0AND LOSS", "label": "Financial assets at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r156", "r258" ] }, "abvx_FinancialIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinancialIncomeLossAbstract", "lang": { "en-us": { "role": { "label": "Financial Income (Loss) [Abstract]", "documentation": "Financial Income (Loss)" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial liabilities", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r141" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AT\u00a0AMORTIZED COST", "label": "Financial liabilities at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r159", "r261" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities, at fair value", "label": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r141" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AT FAIR VALUE THROUGH PROFIT\u00a0AND LOSS", "label": "Financial liabilities at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r157", "r259" ] }, "abvx_FinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Financial liabilities, undiscounted cash flows", "label": "Financial Liabilities, Undiscounted Cash Flows", "documentation": "Financial Liabilities, Undiscounted Cash Flows" } } }, "auth_ref": [] }, "abvx_FinancialRiskManagementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FinancialRiskManagementAbstract", "lang": { "en-us": { "role": { "label": "Financial Risk Management [Abstract]", "documentation": "Financial Risk Management [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_FixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FixturesAndFittingsMember", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office fixtures and fittings", "label": "Fixtures and fittings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r315" ] }, "ifrs-full_ForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange gains", "label": "Foreign exchange gain" } } }, "auth_ref": [ "r24", "r219", "r288" ] }, "abvx_ForeignExchangeGainsLossesOnTranslationOfForeignOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ForeignExchangeGainsLossesOnTranslationOfForeignOperations", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialgainlossNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation differences gains (loss)", "label": "Foreign Exchange Gains (Losses) On Translation Of Foreign Operations", "documentation": "Foreign Exchange Gains (Losses) On Translation Of Foreign Operations" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange losses", "terseLabel": "Foreign exchange loss", "label": "Foreign exchange loss" } } }, "auth_ref": [ "r24", "r219", "r288" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r402", "r413", "r423", "r456" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r402", "r413", "r423", "r456" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r402", "r413", "r423", "r456" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r402", "r413", "r423", "r456" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r402", "r413", "r423", "r456" ] }, "abvx_FormerChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FormerChiefExecutiveOfficerMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Former Chief Executive Officer", "label": "Former Chief Executive Officer [Member]", "documentation": "Former Chief Executive Officer" } } }, "auth_ref": [] }, "abvx_FoundersShareSubscriptionWarrantsBCEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FoundersShareSubscriptionWarrantsBCEMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total BCEs", "verboseLabel": "BCEs", "label": "Founders\u2019 Share Subscription Warrants (BCE) [Member]", "documentation": "Founders\u2019 Share Subscription Warrants (BCE)" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r436" ] }, "abvx_FreeSharesAGAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FreeSharesAGAMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total AGAs", "netLabel": "Free shares (AGA)", "verboseLabel": "AGAs", "label": "Free Shares (AGA) [Member]", "documentation": "Free Shares (AGA)" } } }, "auth_ref": [] }, "abvx_FurnitureAndComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FurnitureAndComputerEquipmentMember", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FURNITURE AND COMPUTER EQUIPMENT", "label": "Furniture And Computer Equipment [Member]", "documentation": "Furniture And Computer Equipment" } } }, "auth_ref": [] }, "abvx_FurnitureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "FurnitureMember", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture", "label": "Furniture [Member]", "documentation": "Furniture" } } }, "auth_ref": [] }, "ifrs-full_GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainLossArisingFromDifferenceBetweenCarryingAmountOfFinancialLiabilityExtinguishedAndConsiderationPaid", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss of extinguishment", "label": "Gain (loss) arising from difference between carrying amount of financial liability extinguished and consideration paid" } }, "en": { "role": { "documentation": "The gain (loss) arising from the difference between the carrying amount of the financial liability extinguished and the measurement of the consideration paid (equity instruments issued) to the creditor. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r85" ] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Actuarial gains and losses", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r19", "r215" ] }, "abvx_GainsArisingFromDerecognitionOfFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "GainsArisingFromDerecognitionOfFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on derecognition of financial liabilities", "label": "Gains Arising From Derecognition Of Financial Liabilities", "documentation": "Gains Arising From Derecognition Of Financial Liabilities" } } }, "auth_ref": [] }, "abvx_GainsArisingFromRecognitionOfFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "GainsArisingFromRecognitionOfFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Day-one gain on recognition of financial liabilities", "label": "Gains Arising From Recognition Of Financial Liabilities", "documentation": "Gains Arising From Recognition Of Financial Liabilities" } } }, "auth_ref": [] }, "ifrs-full_GainsOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in fair value", "terseLabel": "(Increase) / decrease in derivatives fair value", "verboseLabel": "Gains on change in fair value of derivatives", "label": "Gains on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r527" ] }, "abvx_GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "GainsOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss", "label": "Gains On Financial Liabilities At Fair Value Through Profit Or Loss", "documentation": "Gains On Financial Liabilities At Fair Value Through Profit Or Loss" } } }, "auth_ref": [] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "General and administrative", "label": "General and administrative expense" } } }, "auth_ref": [ "r519" ] }, "abvx_GeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "GeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expense", "label": "General And Administrative Expenses [Member]", "documentation": "General And Administrative Expenses" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.abivax.com/role/EmployeesDetails", "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [axis]", "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r170", "r317", "r345", "r350", "r363" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://www.abivax.com/role/EmployeesDetails", "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [domain]", "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r170", "r317", "r345", "r350", "r363" ] }, "ifrs-full_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/GoodwillandimpairmenttestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill" } }, "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r47", "r52", "r137", "r229", "r234", "r256", "r290" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GROSS VALUES", "label": "Gross carrying amount [member]" } } }, "auth_ref": [ "r9", "r57", "r68", "r71", "r137", "r146", "r148", "r207", "r238", "r247", "r250", "r265", "r266", "r352" ] }, "ifrs-full_GrossLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross lease liabilities", "label": "Gross lease liabilities" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r117", "r179", "r355" ] }, "abvx_GrossProceedsFromNonConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "GrossProceedsFromNonConvertibleLoansNotes", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the issuance of non-convertible bond loans", "label": "Gross Proceeds From Non-Convertible Loans Notes", "documentation": "Gross Proceeds From Non-Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_HeightsConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "HeightsConvertibleNotesMember", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Heights convertible notes", "label": "Heights Convertible Notes [Member]", "documentation": "Heights Convertible Notes" } } }, "auth_ref": [] }, "abvx_HeightsConvertibleNotesTrancheAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "HeightsConvertibleNotesTrancheAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Heights convertible notes, tranche A", "label": "Heights Convertible Notes, Tranche A [Member]", "documentation": "Heights Convertible Notes, Tranche A" } } }, "auth_ref": [] }, "abvx_HeightsConvertibleNotesTrancheBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "HeightsConvertibleNotesTrancheBMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Heights convertible notes, tranche B", "label": "Heights Convertible Notes, Tranche B [Member]", "documentation": "Heights Convertible Notes, Tranche B" } } }, "auth_ref": [] }, "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "HistoricalVolatilityForSharesMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility", "label": "Historical volatility for shares, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for the historical volatility for shares used as a measurement input." } } }, "auth_ref": [ "r341" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r381", "r382", "r405" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossGoodwill", "presentation": [ "http://www.abivax.com/role/GoodwillandimpairmenttestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss recognised in profit or loss, goodwill", "label": "Impairment loss recognised in profit or loss, goodwill" } } }, "auth_ref": [ "r136", "r255" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill", "presentation": [ "http://www.abivax.com/role/GoodwillandimpairmenttestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss recognised in profit or loss, intangible assets and goodwill", "label": "Impairment loss recognised in profit or loss, intangible assets and goodwill" } } }, "auth_ref": [ "r500" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.abivax.com/role/GoodwillandimpairmenttestDetails", "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Impairment loss recognised in profit or loss, intangible assets other than goodwill", "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill" } } }, "auth_ref": [ "r59", "r240" ] }, "abvx_IncomeFromDepositaryServiceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncomeFromDepositaryServiceFees", "crdr": "credit", "calculation": { "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depositary service fees", "label": "Income From Depositary Service Fees", "documentation": "Income From Depositary Service Fees" } } }, "auth_ref": [] }, "abvx_IncomeFromResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncomeFromResearchTaxCredit", "crdr": "credit", "calculation": { "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails", "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research tax credit (\"CIR\")", "label": "Income From Research Tax Credit", "documentation": "Income From Research Tax Credit" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax", "negatedTotalLabel": "Effective income tax (loss)", "label": "Tax expense (income)" } } }, "auth_ref": [ "r1", "r2", "r3", "r37", "r101", "r164", "r200", "r201", "r202", "r312" ] }, "ifrs-full_IncomeTaxesPaidRefundAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid (refund) [abstract]", "label": "Income taxes paid (refund) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income taxes paid", "label": "Income taxes paid (refund), classified as operating activities" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r77", "r323" ] }, "abvx_IncreaseDecreaseFromFreeSharesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseFromFreeSharesIssued", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of free shares", "label": "Increase (Decrease) From Free Shares Issued", "documentation": "Increase (Decrease) From Free Shares Issued" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseInCarryingValueDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in carrying value due to reasonably possible decrease in unobservable input liabilities", "label": "Increase (Decrease) In Carrying Value Due To Reasonably Possible Decrease In Unobservable Input Liabilities", "documentation": "Increase (Decrease) In Carrying Value Due To Reasonably Possible Decrease In Unobservable Input Liabilities" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseInCarryingValueDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in carrying value due to reasonably possible increase in unobservable input liabilities", "label": "Increase (Decrease) In Carrying Value Due To Reasonably Possible Increase In Unobservable Input Liabilities", "documentation": "Increase (Decrease) In Carrying Value Due To Reasonably Possible Increase In Unobservable Input Liabilities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (decrease) in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r82", "r196" ] }, "abvx_IncreaseDecreaseInCrohnsDiseaseResearchExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseInCrohnsDiseaseResearchExpenses", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in Crohn's Disease research expenses", "label": "Increase (Decrease) In Crohn's Disease Research Expenses", "documentation": "Increase (Decrease) In Crohn's Disease Research Expenses" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseInEmployerTaxAndSocialContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseInEmployerTaxAndSocialContributions", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in employer tax and social contributions", "label": "Increase (Decrease) In Employer Tax And Social Contributions", "documentation": "Increase (Decrease) In Employer Tax And Social Contributions" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleDecreaseInUnobservableInputLiabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in financial liabilities at fair value due to reasonably possible decrease in unobservable input", "label": "Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible decrease in an unobservable input." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputAssets", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in financial assets at fair value", "terseLabel": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets", "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of assets due to a reasonably possible increase in an unobservable input." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementDueToReasonablyPossibleIncreaseInUnobservableInputLiabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in financial liabilities at fair value", "verboseLabel": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities", "terseLabel": "Increase (decrease) in financial liabilities at fair value due to reasonably possible increase in unobservable input", "label": "Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities" } }, "en": { "role": { "documentation": "The amount of increase (decrease) in the fair value measurement of liabilities due to a reasonably possible increase in an unobservable input." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in number of ordinary shares issued (in shares)", "label": "Increase (decrease) in number of ordinary shares issued" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r519" ] }, "abvx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughCapitalIncrease", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Capital increase from issuance of ordinary shares (in shares)", "label": "Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase", "documentation": "Increase (Decrease) In Number Of Ordinary Shares Issued Through Capital Increase" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseInNumberOfSharesIssuedThroughConversionOfConvertibleInstruments", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of convertible instruments (in shares)", "label": "Increase (Decrease) In Number Of Shares Issued Through Conversion Of Convertible Instruments", "documentation": "Increase (Decrease) In Number Of Shares Issued Through Conversion Of Convertible Instruments" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseInNumberOfSharesIssuedThroughExerciseOfShareWarrants", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Exercises of share warrants (in shares)", "label": "Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants", "documentation": "Increase (Decrease) In Number Of Shares Issued Through Exercise Of Share Warrants" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseInTransversalActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseInTransversalActivities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in transversal activities", "label": "Increase (Decrease) In Transversal Activities", "documentation": "Increase (Decrease) In Transversal Activities" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseInTransversalActivitiesCombinationTherapy": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseInTransversalActivitiesCombinationTherapy", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in transversal activities, combination therapy", "label": "Increase (Decrease) In Transversal Activities, Combination Therapy", "documentation": "Increase (Decrease) In Transversal Activities, Combination Therapy" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseInUlcerativeColitisExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseInUlcerativeColitisExpenses", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in Ulcerative Colitis expenses", "label": "Increase (Decrease) In Ulcerative Colitis Expenses", "documentation": "Increase (Decrease) In Ulcerative Colitis Expenses" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Changes in working capital requirements", "label": "Increase (decrease) in working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r507" ] }, "abvx_IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseThroughAmortizationCostRemeasurementLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase (decrease) through amortization cost remeasurement", "terseLabel": "Non-cash changes: amortized cost remeasurement", "label": "Increase (Decrease) Through Amortization Cost Remeasurement, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Amortization Cost Remeasurement, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Appropriation of prior period net loss", "label": "Increase (decrease) through appropriation of retained earnings, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r517" ] }, "ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash changes: other fair value remeasurement", "label": "Increase (decrease) through changes in fair values, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r79", "r192" ] }, "abvx_IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseThroughClassificationOfEmbeddedDerivativesAsSeparateFinancialInstrumentsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash changes: classification of embedded derivatives as separate derivative financial instruments", "label": "Increase (Decrease) Through Classification of Embedded Derivatives as Separate Financial Instruments, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Classification of Embedded Derivatives as Separate Financial Instruments, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseThroughConversionIntoSharesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash changes: conversion into shares", "label": "Increase (Decrease) Through Conversion Into Shares, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Conversion Into Shares, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Conversion of Kreos Claret OCABSA and Heights notes", "terseLabel": "Increase (decrease) through conversion of convertible instruments, equity", "label": "Increase (decrease) through conversion of convertible instruments, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } } }, "auth_ref": [ "r517" ] }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non cash changes : Effect of the change in foreign currency exchange rates", "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r78", "r191" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercises of shares warrants", "terseLabel": "Exercises of the Kreos/Claret and other share warrants", "label": "Increase (decrease) through exercise of warrants, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r517" ] }, "abvx_IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseThroughGainLossOnRecognitionDerecognitionLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash changes: (gain)/loss on recognition or derecognition", "label": "Increase (Decrease) Through Gain (Loss) On Recognition/Derecognition, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Gain (Loss) On Recognition/Derecognition, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "abvx_IncreaseDecreaseThroughIssuanceOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseThroughIssuanceOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of share warrants", "label": "Increase (Decrease) Through Issuance of Warrants, Equity", "documentation": "Increase (Decrease) Through Issuance of Warrants, Equity" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of the change in foreign currency exchange rates", "label": "Increase (decrease) through net exchange differences, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment including right-of-use assets resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r494" ] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash changes: interest expense and other", "label": "Increase (decrease) through other changes, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r80", "r193" ] }, "abvx_IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseThroughRecognitionOfEarnOutLiabilityLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash changes: recognition of earn-out liability", "label": "Increase (Decrease) Through Recognition of Earn Out Liability, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Recognition of Earn Out Liability, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Shares based compensation expense", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r283" ] }, "abvx_IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseDecreaseThroughSubsidiesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash changes\u00a0: subsidies", "label": "Increase (Decrease) Through Subsidies, Liabilities Arising From Financing Activities", "documentation": "Increase (Decrease) Through Subsidies, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Transactions on treasury shares", "label": "Increase (decrease) through treasury share transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } } }, "auth_ref": [ "r284" ] }, "abvx_IncreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseInLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase", "label": "Increase In Lease Liabilities", "documentation": "Increase In Lease Liabilities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non cash changes: additional leases", "label": "Increase through new leases, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r329", "r333" ] }, "abvx_IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IncreaseThroughProceedsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds", "label": "Increase Through Proceeds, Liabilities Arising From Financing Activities", "documentation": "Increase Through Proceeds, Liabilities Arising From Financing Activities" } } }, "auth_ref": [] }, "ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis", "presentation": [ "http://www.abivax.com/role/GoodwillandimpairmenttestDetails", "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash-generating units [axis]", "label": "Cash-generating units [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r51", "r233" ] }, "ifrs-full_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesDomain", "presentation": [ "http://www.abivax.com/role/GoodwillandimpairmenttestDetails", "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash-generating units [domain]", "label": "Cash-generating units [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Cash-generating units' axis if no other member is used." } } }, "auth_ref": [ "r51", "r54", "r233", "r236" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r402", "r413", "r423", "r447", "r456", "r460", "r468" ] }, "abvx_IndustrialMaterialsAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IndustrialMaterialsAndEquipmentMember", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Industrial materials and equipment", "label": "Industrial Materials And Equipment [Member]", "documentation": "Industrial Materials And Equipment" } } }, "auth_ref": [] }, "abvx_InitialPriceLimitMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "InitialPriceLimitMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial price limit (in euro per share)", "label": "Initial Price Limit, Measurement Input [Member]", "documentation": "Initial Price Limit, Measurement Input" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r466" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r383", "r472" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r383", "r472" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r383", "r472" ] }, "ifrs-full_IntangibleAssetsAndGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsAndGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets and goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "periodStartLabel": "Intangible assets other than goodwill at beginning of period", "periodEndLabel": "Intangible assets other than goodwill at end of period", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r61", "r242", "r290" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsWithIndefiniteUsefulLife", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets with indefinite useful life", "label": "Intangible assets with indefinite useful life" } }, "en": { "role": { "documentation": "The amount of intangible assets assessed as having an indefinite useful life. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r48", "r53", "r63", "r230", "r235", "r244" ] }, "abvx_IntellectualPropertyFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IntellectualPropertyFees", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intellectual property fees", "label": "Intellectual Property Fees", "documentation": "Intellectual Property Fees" } } }, "auth_ref": [] }, "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)" } } }, "auth_ref": [ "r18", "r214" ] }, "ifrs-full_InterestExpenseOnBonds": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnBonds", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest on bond loans", "label": "Interest expense on bonds" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_InterestExpenseOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnBorrowings", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense on borrowings", "negatedTerseLabel": "Interest on conditional advances and PGE", "label": "Interest expense on borrowings" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_InterestExpenseOnDebtInstrumentsIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnDebtInstrumentsIssued", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest on convertible loan notes", "label": "Interest expense on debt instruments issued" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense on lease liabilities", "negatedTerseLabel": "Interest on lease liabilities", "label": "Interest expense on lease liabilities" } } }, "auth_ref": [ "r114", "r176" ] }, "abvx_InterestExpenseOnRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "InterestExpenseOnRoyaltyCertificates", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest on royalty certificates", "label": "Interest Expense On Royalty Certificates", "documentation": "Interest Expense On Royalty Certificates" } } }, "auth_ref": [] }, "abvx_InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "InterestExpenseOnRoyaltyCertificatesIncludingTheUnwindingOfDiscount", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense on royalty certificates, including the unwinding of discount", "label": "Interest Expense On Royalty Certificates, Including The Unwinding Of Discount", "documentation": "Interest Expense On Royalty Certificates, Including The Unwinding Of Discount" } } }, "auth_ref": [] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid", "label": "Interest paid, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r76" ] }, "abvx_InterestRateCollarRange": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "InterestRateCollarRange", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate collar range", "label": "Interest Rate Collar Range", "documentation": "Interest Rate Collar Range" } } }, "auth_ref": [] }, "ifrs-full_InterestRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestRateMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Interest rate, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for an interest rate used as a measurement input." } } }, "auth_ref": [ "r340" ] }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "label": "Interest received, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } } }, "auth_ref": [ "r76" ] }, "abvx_InvestmentsInMutualFundsAndStructuredNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "InvestmentsInMutualFundsAndStructuredNotes", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in mutual funds and structured notes", "label": "Investments In Mutual Funds And Structured Notes", "documentation": "Investments In Mutual Funds And Structured Notes" } } }, "auth_ref": [] }, "abvx_IssuanceOfDerivativeInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IssuanceOfDerivativeInstruments", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance", "label": "Issuance Of Derivative Instruments", "documentation": "Issuance Of Derivative Instruments" } } }, "auth_ref": [] }, "abvx_IssuanceOfOtherShareWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IssuanceOfOtherShareWarrants", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of other share warrants", "label": "Issuance Of Other Share Warrants", "documentation": "Issuance Of Other Share Warrants" } } }, "auth_ref": [] }, "abvx_IssuancePricePercentageOfDiscountTo15DayWVAP": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IssuancePricePercentageOfDiscountTo15DayWVAP", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance price, percentage of discount to 15-day WVAP", "label": "Issuance Price, Percentage Of Discount To 15-Day WVAP", "documentation": "Issuance Price, Percentage Of Discount To 15-Day WVAP" } } }, "auth_ref": [] }, "ifrs-full_IssueOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of convertible notes", "label": "Issue of convertible instruments" } }, "en": { "role": { "documentation": "The change in equity resulting from the issuing of convertible instruments." } } }, "auth_ref": [ "r517" ] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Capital increase from issuance of ordinary shares", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r283" ] }, "abvx_IssueOfEquityOfferingPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "IssueOfEquityOfferingPricePerShare", "presentation": [ "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of equity, offering price per share (in dollar/euro per share)", "label": "Issue Of Equity, Offering Price Per Share", "documentation": "Issue Of Equity, Offering Price Per Share" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r368", "r374" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "SHARE CAPITAL", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r285" ] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Key management personnel compensation" } } }, "auth_ref": [ "r31", "r222" ] }, "abvx_KeyManagementPersonnelCompensationAttendanceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KeyManagementPersonnelCompensationAttendanceFees", "crdr": "debit", "calculation": { "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attendance fees\u2014board of directors", "label": "Key Management Personnel Compensation, Attendance Fees", "documentation": "Key Management Personnel Compensation, Attendance Fees" } } }, "auth_ref": [] }, "abvx_KeyManagementPersonnelCompensationConsultingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KeyManagementPersonnelCompensationConsultingFees", "crdr": "debit", "calculation": { "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Consulting fees", "label": "Key Management Personnel Compensation, Consulting Fees", "documentation": "Key Management Personnel Compensation, Consulting Fees" } } }, "auth_ref": [] }, "abvx_KeyManagementPersonnelCompensationContractualSeveranceIndemnity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KeyManagementPersonnelCompensationContractualSeveranceIndemnity", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual severance indemnity", "label": "Key Management Personnel Compensation, Contractual Severance Indemnity", "documentation": "Key Management Personnel Compensation, Contractual Severance Indemnity" } } }, "auth_ref": [] }, "abvx_KeyManagementPersonnelCompensationFixedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KeyManagementPersonnelCompensationFixedCompensation", "crdr": "debit", "calculation": { "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed compensation owed", "label": "Key Management Personnel Compensation, Fixed Compensation", "documentation": "Key Management Personnel Compensation, Fixed Compensation" } } }, "auth_ref": [] }, "abvx_KeyManagementPersonnelCompensationInKindContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KeyManagementPersonnelCompensationInKindContributions", "crdr": "debit", "calculation": { "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions in-kind", "label": "Key Management Personnel Compensation, In-Kind Contributions", "documentation": "Key Management Personnel Compensation, In-Kind Contributions" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "crdr": "debit", "calculation": { "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contributions", "label": "Key management personnel compensation, post-employment benefits" } } }, "auth_ref": [ "r28" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Key management personnel compensation, share-based payment" } } }, "auth_ref": [ "r30" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total compensation", "label": "Key management personnel compensation, short-term employee benefits" } } }, "auth_ref": [ "r27" ] }, "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationTerminationBenefits", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination benefits", "label": "Key management personnel compensation, termination benefits" } } }, "auth_ref": [ "r29" ] }, "abvx_KeyManagementPersonnelCompensationVariableCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KeyManagementPersonnelCompensationVariableCompensation", "crdr": "debit", "calculation": { "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/RelatedpartiesDisclosureofaggregatecompensationofthemembersoftheGroupsBoardofDirectorsandCEODetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable compensation owed", "label": "Key Management Personnel Compensation, Variable Compensation", "documentation": "Key Management Personnel Compensation, Variable Compensation" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelOfEntityOrParentMember", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel", "label": "Key management personnel of entity or parent [member]" } }, "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } } }, "auth_ref": [ "r33", "r224" ] }, "abvx_Kreos12BondLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Kreos12BondLoansMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos 1 & 2 bond loans", "label": "Kreos 1 & 2 Bond Loans [Member]", "documentation": "Kreos 1 & 2 Bond Loans" } } }, "auth_ref": [] }, "abvx_Kreos1BondLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Kreos1BondLoansMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos 1 bond loans", "label": "Kreos 1 Bond Loans [Member]", "documentation": "Kreos 1 Bond Loans" } } }, "auth_ref": [] }, "abvx_Kreos1ClaretBondLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Kreos1ClaretBondLoansMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret bond loans", "label": "Kreos 1 & Claret Bond Loans [Member]", "documentation": "Kreos 1 & Claret Bond Loans" } } }, "auth_ref": [] }, "abvx_Kreos1ConvertibleBondLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Kreos1ConvertibleBondLoansMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos 1, convertible bond loans", "label": "Kreos 1, Convertible Bond Loans [Member]", "documentation": "Kreos 1, Convertible Bond Loans" } } }, "auth_ref": [] }, "abvx_Kreos1ConvertibleBondLoansTrancheAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Kreos1ConvertibleBondLoansTrancheAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos 1, convertible bond loans, tranche A", "label": "Kreos 1, Convertible Bond Loans, Tranche A [Member]", "documentation": "Kreos 1, Convertible Bond Loans, Tranche A" } } }, "auth_ref": [] }, "abvx_Kreos1ConvertibleBondLoansTrancheBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Kreos1ConvertibleBondLoansTrancheBMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreos2Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos 1, convertible bond loans, tranche B", "label": "Kreos 1, Convertible Bond Loans, Tranche B [Member]", "documentation": "Kreos 1, Convertible Bond Loans, Tranche B" } } }, "auth_ref": [] }, "abvx_Kreos1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Kreos1Member", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos A & B BSA", "label": "Kreos 1 [Member]", "documentation": "Kreos 1" } } }, "auth_ref": [] }, "abvx_Kreos1NonConvertibleBondLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Kreos1NonConvertibleBondLoansMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos 1, non-convertible bond loans", "label": "Kreos 1, Non-Convertible Bond Loans [Member]", "documentation": "Kreos 1, Non-Convertible Bond Loans" } } }, "auth_ref": [] }, "abvx_Kreos2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Kreos2Member", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos2Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos 2", "label": "Kreos 2 [Member]", "documentation": "Kreos 2" } } }, "auth_ref": [] }, "abvx_Kreos2TrancheAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Kreos2TrancheAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos2Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos 2, tranche A", "label": "Kreos 2, Tranche A [Member]", "documentation": "Kreos 2, Tranche A" } } }, "auth_ref": [] }, "abvx_Kreos2TrancheBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "Kreos2TrancheBMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos2Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos 2, tranche B", "label": "Kreos 2, Tranche B [Member]", "documentation": "Kreos 2, Tranche B" } } }, "auth_ref": [] }, "abvx_KreosABBSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosABBSAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos A & B BSA", "label": "Kreos A & B BSA [Member]", "documentation": "Kreos A & B BSA" } } }, "auth_ref": [] }, "abvx_KreosABCBSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosABCBSAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos A & B & C BSA", "label": "Kreos A & B & C BSA [Member]", "documentation": "Kreos A & B & C BSA" } } }, "auth_ref": [] }, "abvx_KreosABSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosABSAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos A BSA", "label": "Kreos A BSA [Member]", "documentation": "Kreos A BSA" } } }, "auth_ref": [] }, "abvx_KreosBBSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosBBSAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos B BSA", "label": "Kreos B BSA [Member]", "documentation": "Kreos B BSA" } } }, "auth_ref": [] }, "abvx_KreosCBSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosCBSAMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos C BSA", "label": "Kreos C BSA [Member]", "documentation": "Kreos C BSA" } } }, "auth_ref": [] }, "abvx_KreosClaretBondLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretBondLoansMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos/Claret bond loans", "label": "Kreos & Claret bond loans [Member]", "documentation": "Kreos & Claret bond loans" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingAndHeightsConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretFinancingAndHeightsConvertibleNotesMember", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret financing and Heights convertible notes", "label": "Kreos & Claret Financing And Heights Convertible Notes [Member]", "documentation": "Kreos & Claret Financing And Heights Convertible Notes" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingBAndCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretFinancingBAndCMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos/Claret financing B and C", "label": "Kreos/Claret Financing B And C [Member]", "documentation": "Kreos/Claret Financing B And C" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingBSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretFinancingBSAMember", "presentation": [ "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret BSA", "label": "Kreos & Claret Financing, BSA [Member]", "documentation": "Kreos & Claret Financing, BSA" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretFinancingMember", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret financing", "label": "Kreos & Claret Financing [Member]", "documentation": "Kreos & Claret Financing" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretFinancingSeniorSecuredNonConvertibleLoansMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret financing, tranche B and C", "label": "Kreos & Claret Financing, Senior Secured Non-Convertible Loans [Member]", "documentation": "Kreos & Claret Financing, Senior Secured Non-Convertible Loans" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheABAndCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretFinancingTrancheABAndCMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret Financing, Tranche A,B and C", "label": "Kreos & Claret Financing, Tranche A,B and C [Member]", "documentation": "Kreos & Claret Financing, Tranche A,B and C" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheABMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretFinancingTrancheABMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret financing, tranche A-B", "label": "Kreos & Claret Financing, Tranche A-B [Member]", "documentation": "Kreos & Claret Financing, Tranche A-B" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretFinancingTrancheAMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret convertible notes (OCABSA)", "netLabel": "Kreos/Claret BSA", "label": "Kreos & Claret Financing, Tranche A [Member]", "documentation": "Kreos & Claret Financing, Tranche A" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheBAndCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretFinancingTrancheBAndCMember", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret financing, tranche B and C", "label": "Kreos & Claret Financing, Tranche B and C [Member]", "documentation": "Kreos & Claret Financing, Tranche B and C" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretFinancingTrancheBMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret financing, tranche B", "label": "Kreos & Claret Financing, Tranche B [Member]", "documentation": "Kreos & Claret Financing, Tranche B" } } }, "auth_ref": [] }, "abvx_KreosClaretFinancingTrancheCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretFinancingTrancheCMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret financing, tranche C", "label": "Kreos & Claret Financing, Tranche C [Member]", "documentation": "Kreos & Claret Financing, Tranche C" } } }, "auth_ref": [] }, "abvx_KreosClaretMinimumReturnIndemnificationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosClaretMinimumReturnIndemnificationsMember", "presentation": [ "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos & Claret minimal return indemnifications", "verboseLabel": "Kreos/Claret Minimal Return Indemnifications", "label": "Kreos & Claret Minimum Return Indemnifications [Member]", "documentation": "Kreos & Claret Minimum Return Indemnifications" } } }, "auth_ref": [] }, "abvx_KreosOCABSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "KreosOCABSAMember", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Kreos OCABSA", "label": "Kreos OCABSA [Member]", "documentation": "Kreos OCABSA" } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LONGER THAN 5 YEARS", "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r118", "r119", "r128", "r181", "r184", "r354", "r357", "r359" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FROM 1 TO 2 YEARS", "label": "Later than one year and not later than two years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r118", "r119", "r128", "r354", "r359", "r519" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FROM 2 TO 5 YEARS", "label": "Later than two years and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than five years." } } }, "auth_ref": [ "r519" ] }, "abvx_LeaseBreakClausePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LeaseBreakClausePeriod", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, break clause period", "label": "Lease, Break Clause Period", "documentation": "Lease, Break Clause Period" } } }, "auth_ref": [] }, "abvx_LeaseDurationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LeaseDurationPeriod", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, duration period", "label": "Lease, Duration Period", "documentation": "Lease, Duration Period" } } }, "auth_ref": [] }, "abvx_LeaseExtensionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LeaseExtensionPeriod", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, extension period", "label": "Lease, Extension Period", "documentation": "Lease, Extension Period" } } }, "auth_ref": [] }, "abvx_LeaseFacilitiesBostonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LeaseFacilitiesBostonMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease facilities, Boston", "label": "Lease Facilities, Boston [Member]", "documentation": "Lease Facilities, Boston" } } }, "auth_ref": [] }, "abvx_LeaseFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LeaseFacilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease facilities", "label": "Lease Facilities [Member]", "documentation": "Lease Facilities" } } }, "auth_ref": [] }, "abvx_LeaseFacilitiesMontpellierMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LeaseFacilitiesMontpellierMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease facilities, Montpellier", "label": "Lease Facilities, Montpellier [Member]", "documentation": "Lease Facilities, Montpellier" } } }, "auth_ref": [] }, "abvx_LeaseFacilitiesParisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LeaseFacilitiesParisMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails", "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease facilities, Paris", "label": "Lease Facilities, Paris [Member]", "documentation": "Lease Facilities, Paris" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofvariationinleaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Lease liabilities at beginning of period", "periodEndLabel": "Lease liabilities at end of period", "terseLabel": "Lease liabilities", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r113" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Lease liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r330", "r334" ] }, "abvx_LeaseLiabilityPercentageOfTotal": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LeaseLiabilityPercentageOfTotal", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability, percentage of total", "label": "Lease Liability, Percentage Of Total", "documentation": "Lease Liability, Percentage Of Total" } } }, "auth_ref": [] }, "abvx_LeaseTacitRenewalPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LeaseTacitRenewalPeriod", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, tacit renewal period", "label": "Lease, Tacit Renewal Period", "documentation": "Lease, Tacit Renewal Period" } } }, "auth_ref": [] }, "abvx_LeasesRelatedTemporaryDifferencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LeasesRelatedTemporaryDifferencesMember", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Leases Related Temporary Differences [Member]", "documentation": "Leases Related Temporary Differences" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "verboseLabel": "Liabilities", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r103", "r104", "r106", "r165", "r168", "r270", "r271", "r296" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Liabilities arising from financing activities at beginning of period", "periodEndLabel": "Liabilities arising from financing activities at end of period", "label": "Liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } } }, "auth_ref": [ "r194", "r331" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [axis]", "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r194", "r331" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [domain]", "label": "Liabilities arising from financing activities [domain]" } }, "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r194", "r331" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Net defined benefit liability (asset) at beginning of period", "periodEndLabel": "Net defined benefit liability (asset) at end of period", "label": "Net defined benefit liability (asset)" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r16", "r212" ] }, "ifrs-full_LicencesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LicencesMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LICENSES", "label": "Licences [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r501" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentFinancialAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits", "label": "Long-term deposits" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r522" ] }, "abvx_LossesArisingFromDerecognitionOfFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LossesArisingFromDerecognitionOfFinancialLiabilities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on derecognition of financial liabilities", "label": "Losses Arising From Derecognition Of Financial Liabilities", "documentation": "Losses Arising From Derecognition Of Financial Liabilities" } } }, "auth_ref": [] }, "ifrs-full_LossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LossesOnChangeInFairValueOfDerivatives", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase in fair value", "negatedTerseLabel": "(Increase) / decrease in derivatives fair value", "netLabel": "Losses on change in fair value of derivatives", "label": "Losses on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r527" ] }, "abvx_LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "LossesOnFinancialLiabilitiesAssetsAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Losses on financial liabilities", "negatedTerseLabel": "(Increase) / decrease in other liabilities / (assets) at fair value through profit and loss", "label": "Losses On Financial Liabilities (Assets) At Fair Value Through Profit Or Loss", "documentation": "Losses On Financial Liabilities (Assets) At Fair Value Through Profit Or Loss" } } }, "auth_ref": [] }, "abvx_MajorShareBasedTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "MajorShareBasedTransactionsMember", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major share-based transactions", "label": "Major Share-Based Transactions [Member]", "documentation": "Major Share-Based Transactions" } } }, "auth_ref": [] }, "srt_ManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ManagementMember", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key magement", "label": "Management [Member]" } } }, "auth_ref": [] }, "abvx_MarketRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "MarketRateMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Market rate", "label": "Market Rate, Measurement Input [Member]", "documentation": "Market Rate, Measurement Input" } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAnalysisForDerivativeFinancialLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of remaining contractual maturities of derivative financial liabilities", "label": "Disclosure of maturity analysis for derivative financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for derivative financial liabilities, including the remaining contractual maturities for those derivative financial liabilities for which contractual maturities are essential for an understanding of the timing of the cash flows. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r151", "r268" ] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of remaining contractual maturities of non-derivative financial liabilities", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r150", "r267" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [axis]", "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r110", "r118", "r119", "r120", "r121", "r122", "r128", "r140", "r152", "r174", "r175", "r182", "r185", "r263", "r299", "r318", "r354" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [domain]", "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r110", "r118", "r119", "r120", "r121", "r122", "r128", "r140", "r174", "r175", "r182", "r185", "r263", "r299", "r318", "r354", "r358" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [] }, "abvx_MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "MaximumNumberOfOtherEquityInstrumentsToBeIssuedInShareBasedPaymentArrangementIfAllConditionsAreMet", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares to be issued if all conditions are met (in shares)", "label": "Maximum Number Of Other Equity Instruments To Be Issued In Share-Based Payment Arrangement If All Conditions Are Met", "documentation": "Maximum Number Of Other Equity Instruments To Be Issued In Share-Based Payment Arrangement If All Conditions Are Met" } } }, "auth_ref": [] }, "abvx_MaximumNumberOfSharesToBeIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "MaximumNumberOfSharesToBeIssued", "presentation": [ "http://www.abivax.com/role/IncomelosspershareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares to be issued (in shares)", "label": "Maximum Number Of Shares To Be Issued", "documentation": "Maximum Number Of Shares To Be Issued" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r439" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r439" ] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement [axis]", "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r66", "r70", "r103", "r249", "r270" ] }, "ifrs-full_MeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement [domain]", "label": "Measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r66", "r70", "r103", "r249", "r270" ] }, "abvx_MinimalReturnMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "MinimalReturnMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimal return", "label": "Minimal Return, Measurement Input [Member]", "documentation": "Minimal Return, Measurement Input" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" ], "lang": { "en-us": { "role": { "netLabel": "Other sales and marketing expenses", "terseLabel": "Other research and development expenses", "verboseLabel": "Other general and administrative expenses", "label": "Miscellaneous other operating expense" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails", "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Miscellaneous other operating income" } } }, "auth_ref": [ "r519" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r459" ] }, "abvx_MonteCarloModel1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "MonteCarloModel1Member", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monte Carlo Model", "label": "Monte Carlo Model1 [Member]", "documentation": "Monte Carlo Model" } } }, "auth_ref": [] }, "abvx_MonteCarloModelIFRSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "MonteCarloModelIFRSMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monte Carlo model", "label": "Monte Carlo Model IFRS [Member]", "documentation": "Monte Carlo Model IFRS" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r467" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r440" ] }, "abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition", "crdr": "debit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails", "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred taxes, net recognized in the statement of financial position", "negatedTerseLabel": "Net deferred tax liabilities", "label": "Net Deferred Tax Assets (Liabilities) Recognised In Financial Position", "documentation": "Net Deferred Tax Assets (Liabilities) Recognised In Financial Position" } } }, "auth_ref": [] }, "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetAxis", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net defined benefit liability (asset) [axis]", "label": "Net defined benefit liability (asset) [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r16", "r212" ] }, "ifrs-full_NetDefinedBenefitLiabilityAssetDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetDomain", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net defined benefit liability (asset) [domain]", "label": "Net defined benefit liability (asset) [domain]" } }, "en": { "role": { "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r16", "r212" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)" } } }, "auth_ref": [] }, "abvx_NetProceedsFromConvertibleLoanNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NetProceedsFromConvertibleLoanNotes", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from convertible loan notes", "label": "Net Proceeds From Convertible Loan Notes", "documentation": "Net Proceeds From Convertible Loan Notes" } } }, "auth_ref": [] }, "abvx_NetProceedsFromConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NetProceedsFromConvertibleLoansNotes", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from convertible loan notes", "label": "Net Proceeds From Convertible Loans Notes", "documentation": "Net Proceeds From Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_NetProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NetProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issue of ordinary shares", "label": "Net Proceeds From Issue Of Ordinary Shares", "documentation": "Net Proceeds From Issue Of Ordinary Shares" } } }, "auth_ref": [] }, "abvx_NetProceedsFromNonConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NetProceedsFromNonConvertibleLoansNotes", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from non-convertible bond loans", "label": "Net Proceeds From Non-Convertible Loans Notes", "documentation": "Net Proceeds From Non-Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_NetProceedsFromSaleOfRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NetProceedsFromSaleOfRoyaltyCertificates", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from sale of royalty certificates", "label": "Net Proceeds From Sale Of Royalty Certificates", "documentation": "Net Proceeds From Sale Of Royalty Certificates" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "No Trading Symbol Flag", "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "abvx_NonCurrentAdvancesToCROContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NonCurrentAdvancesToCROContractsMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term advances made to CROs", "label": "Non-Current Advances To CRO Contracts [Member]", "documentation": "Non-Current Advances To CRO Contracts" } } }, "auth_ref": [] }, "abvx_NonCurrentAdvancesToCROContractsUndiscountedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NonCurrentAdvancesToCROContractsUndiscountedAmount", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails", "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advances related to CRO contracts", "label": "Non-Current Advances To CRO Contracts, Undiscounted Amount", "documentation": "Non-Current Advances To CRO Contracts, Undiscounted Amount" } } }, "auth_ref": [] }, "abvx_NonCurrentConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NonCurrentConvertibleLoansNotes", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible loan notes", "label": "Non-Current Convertible Loans Notes", "documentation": "Non-Current Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_NonCurrentFinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NonCurrentFinancialLiabilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities-non current portion", "label": "Non-Current Financial Liabilities [Member]", "documentation": "Non-Current Financial Liabilities" } } }, "auth_ref": [] }, "abvx_NonCurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NonCurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentNonfinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses - non current", "label": "Non-Current Prepaid Expenses", "documentation": "Non-Current Prepaid Expenses" } } }, "auth_ref": [] }, "abvx_NonCurrentRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NonCurrentRoyaltyCertificates", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 4.0 }, "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificates", "label": "Non-Current Royalty Certificates", "documentation": "Non-Current Royalty Certificates" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r439" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r402", "r413", "r423", "r447", "r456" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r430" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r429" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r447" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r467" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r467" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [axis]", "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r199" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [domain]", "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r199" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r92", "r300", "r335" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments", "label": "Non-current derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r522" ] }, "ifrs-full_NoncurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-current financial liabilities", "label": "Non-current financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r141" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r94", "r301", "r335" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPortionOfOtherNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Non-current portion of other non-current borrowings" } }, "en": { "role": { "documentation": "The non-current portion of non-current other borrowings. [Refer: Other borrowings]" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement benefit obligations", "label": "Non-current provisions for employee benefits" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r277", "r303" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LESS THAN 1 YEAR", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r118", "r119", "r128", "r180", "r183", "r298", "r354", "r359" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreos2Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "verboseLabel": "Original principal amount", "label": "Notional amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r519" ] }, "ifrs-full_NumberAndAverageNumberOfEmployeesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberAndAverageNumberOfEmployeesAbstract", "lang": { "en-us": { "role": { "label": "Number and average number of employees [abstract]" } } }, "auth_ref": [] }, "abvx_NumberOfADSPerOrdinaryShares": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfADSPerOrdinaryShares", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Number of ADS per ordinary shares (in shares)", "label": "Number of ADS per Ordinary Shares", "documentation": "Number of ADS per Ordinary Shares" } } }, "auth_ref": [] }, "abvx_NumberOfAcademicInstitutions": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfAcademicInstitutions", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of academic institutions", "label": "Number Of Academic Institutions", "documentation": "Number Of Academic Institutions" } } }, "auth_ref": [] }, "abvx_NumberOfConvertibleNotesConverted": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfConvertibleNotesConverted", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Number of convertible notes converted", "label": "Number Of Convertible Notes Converted", "documentation": "Number Of Convertible Notes Converted" } } }, "auth_ref": [] }, "abvx_NumberOfConvertibleNotesIssued": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfConvertibleNotesIssued", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of convertible notes issued (in shares)", "label": "Number Of Convertible Notes Issued", "documentation": "Number Of Convertible Notes Issued" } } }, "auth_ref": [] }, "abvx_NumberOfConvertibleNotesOutstanding": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfConvertibleNotesOutstanding", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of outstanding notes (in shares)", "label": "Number Of Convertible Notes Outstanding", "documentation": "Number Of Convertible Notes Outstanding" } } }, "auth_ref": [] }, "abvx_NumberOfExclusiveLicenses": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfExclusiveLicenses", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of exclusive licenses", "label": "Number Of Exclusive Licenses", "documentation": "Number Of Exclusive Licenses" } } }, "auth_ref": [] }, "abvx_NumberOfFinancialInstitutionsToMaintainCash": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfFinancialInstitutionsToMaintainCash", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of financial institutions to maintain cash", "label": "Number Of Financial Institutions To Maintain Cash", "documentation": "Number Of Financial Institutions To Maintain Cash" } } }, "auth_ref": [] }, "abvx_NumberOfFreeSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfFreeSharesIssued", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of free shares (in shares)", "label": "Number Of Free Shares Issued", "documentation": "Number Of Free Shares Issued" } } }, "auth_ref": [] }, "abvx_NumberOfFreeSharesPlansIssued": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfFreeSharesPlansIssued", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Number of free shares plans issued", "label": "Number Of Free Shares Plans Issued", "documentation": "Number Of Free Shares Plans Issued" } } }, "auth_ref": [] }, "abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfInstrumentsGrantedOtherEquityInstrumentsPercentageExercisableImmediately", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments granted, percentage exercisable immediately", "label": "Number Of Instruments Granted, Other Equity Instruments, Percentage Exercisable Immediately", "documentation": "Number Of Instruments Granted, Other Equity Instruments, Percentage Exercisable Immediately" } } }, "auth_ref": [] }, "abvx_NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfInstrumentsGrantedOtherEquityInstrumentsRemainingPercentageExercisable", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments granted, remaining percentage exercisable", "label": "Number Of Instruments Granted, Other Equity Instruments, Remaining Percentage Exercisable", "documentation": "Number Of Instruments Granted, Other Equity Instruments, Remaining Percentage Exercisable" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments issued (in shares)", "verboseLabel": "NUMBE OF BSAs ( in shares)", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r133", "r512" ] }, "ifrs-full_NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsThatAreAntidilutiveInPeriodPresented", "presentation": [ "http://www.abivax.com/role/IncomelosspershareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments that are antidilutive in period presented (in shares)", "label": "Number of instruments that are antidilutive in period presented" } }, "en": { "role": { "documentation": "Number of (units of) instruments that are antidilutive in the period presented." } } }, "auth_ref": [ "r43" ] }, "abvx_NumberOfOperatingSegment": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfOperatingSegment", "presentation": [ "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segment", "documentation": "Number of Operating Segment" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments exercisable (in shares)", "label": "Number of other equity instruments exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r512" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of instruments exercised (in shares)", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r512" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of instruments lapsed (in shares)", "label": "Number of other equity instruments expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement." } } }, "auth_ref": [ "r512" ] }, "abvx_NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfOtherEquityInstrumentsGrantedSubjectToNonMarketPerformanceCondition", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments issued subject to non-market performance condition (in shares)", "label": "Number Of Other Equity Instruments Granted Subject To Non-Market Performance Condition", "documentation": "Number Of Other Equity Instruments Granted Subject To Non-Market Performance Condition" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of instruments outstanding, beginning balance (in shares)", "periodEndLabel": "Number of instruments outstanding, ending balance (in shares)", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r512" ] }, "abvx_NumberOfOtherShareWarrantsConverted": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfOtherShareWarrantsConverted", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other share warrants converted (in shares)", "label": "Number Of Other Share Warrants Converted", "documentation": "Number Of Other Share Warrants Converted" } } }, "auth_ref": [] }, "abvx_NumberOfOtherShareWarrantsRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfOtherShareWarrantsRepurchased", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Number of other share warrants repurchased (in shares)", "label": "Number Of Other Share Warrants Repurchased", "documentation": "Number Of Other Share Warrants Repurchased" } } }, "auth_ref": [] }, "abvx_NumberOfProbabilityWeightedScenarios": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfProbabilityWeightedScenarios", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of probability-weighted scenarios", "label": "Number Of Probability-Weighted Scenarios", "documentation": "Number Of Probability-Weighted Scenarios" } } }, "auth_ref": [] }, "abvx_NumberOfProjectsTerminated": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfProjectsTerminated", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of projects terminated", "label": "Number Of Projects Terminated", "documentation": "Number Of Projects Terminated" } } }, "auth_ref": [] }, "abvx_NumberOfShareBasedCompensationPlansIssued": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfShareBasedCompensationPlansIssued", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Number of share-based compensation plans issued", "label": "Number Of Share-Based Compensation Plans Issued", "documentation": "Number Of Share-Based Compensation Plans Issued" } } }, "auth_ref": [] }, "abvx_NumberOfShareWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfShareWarrantsIssued", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued (in shares)", "label": "Number Of Share Warrants Issued", "documentation": "Number Of Share Warrants Issued" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares issued at beginning of period (in shares)", "periodEndLabel": "Number of shares issued at end of period (in shares)", "terseLabel": "Number of shares issued (in shares)", "label": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r517" ] }, "abvx_NumberOfSharesLapsed": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfSharesLapsed", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares lapsed (in shares)", "label": "Number Of Shares Lapsed", "documentation": "Number Of Shares Lapsed" } } }, "auth_ref": [] }, "abvx_NumberOfSharesPerShareWarrant": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfSharesPerShareWarrant", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares (in shares)", "label": "Number Of Shares per Share Warrant", "documentation": "Number Of Shares per Share Warrant" } } }, "auth_ref": [] }, "abvx_NumberOfSharesReceivedPerADS": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfSharesReceivedPerADS", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares received per ADS (in shares)", "label": "Number Of Shares Received Per ADS", "documentation": "Number Of Shares Received Per ADS" } } }, "auth_ref": [] }, "abvx_NumberOfSharesWaived": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfSharesWaived", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares waived (in shares)", "label": "Number Of Shares Waived", "documentation": "Number Of Shares Waived" } } }, "auth_ref": [] }, "abvx_NumberOfSharesWithPerformanceConditionsWaived": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfSharesWithPerformanceConditionsWaived", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares with performance conditions waived (in shares)", "label": "Number Of Shares With Performance Conditions Waived", "documentation": "Number Of Shares With Performance Conditions Waived" } } }, "auth_ref": [] }, "abvx_NumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfTranches", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of tranches", "label": "Number Of Tranches", "documentation": "Number Of Tranches" } } }, "auth_ref": [] }, "abvx_NumberOfTreasurySharesHeld": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfTreasurySharesHeld", "presentation": [ "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of treasury shares held (in shares)", "label": "Number Of Treasury Shares Held", "documentation": "Number Of Treasury Shares Held" } } }, "auth_ref": [] }, "abvx_NumberOfWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfWarrantsExercised", "presentation": [ "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants exercised (in shares)", "label": "Number Of Warrants Exercised", "documentation": "Number Of Warrants Exercised" } } }, "auth_ref": [] }, "abvx_NumberOfWarrantsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfWarrantsGranted", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants granted (in shares)", "label": "Number Of Warrants Granted", "documentation": "Number Of Warrants Granted" } } }, "auth_ref": [] }, "abvx_NumberOfWarrantsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfWarrantsOutstanding", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of outstanding warrants (in shares)", "label": "Number Of Warrants Outstanding", "documentation": "Number Of Warrants Outstanding" } } }, "auth_ref": [] }, "abvx_NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfWarrantsOutstandingSubjectToNonMarketPerformanceCondition", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of outstanding warrants subject to non-market performance condition (in shares)", "label": "Number Of Warrants Outstanding Subject To Non-Market Performance Condition", "documentation": "Number Of Warrants Outstanding Subject To Non-Market Performance Condition" } } }, "auth_ref": [] }, "abvx_NumberOfWarrantsRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "NumberOfWarrantsRepurchased", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants repurchased (in shares)", "label": "Number Of Warrants Repurchased", "documentation": "Number Of Warrants Repurchased" } } }, "auth_ref": [] }, "abvx_OCEANEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OCEANEMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "OCEANE", "label": "OCEANE [Member]", "documentation": "OCEANE" } } }, "auth_ref": [] }, "abvx_OceaneConversionOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OceaneConversionOptionMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oceane conversion option", "verboseLabel": "OCEANE conversion option", "label": "Oceane Conversion Option [Member]", "documentation": "Oceane Conversion Option" } } }, "auth_ref": [] }, "abvx_OffBalanceSheetCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OffBalanceSheetCommitmentsAbstract", "lang": { "en-us": { "role": { "label": "Off-Balance Sheet Commitments [Abstract]", "documentation": "Off-Balance Sheet Commitments" } } }, "auth_ref": [] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment", "verboseLabel": "EQUIPMENT", "label": "Office equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r316" ] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total operating expenses", "totalLabel": "Operating expenses", "label": "Operating expense" } } }, "auth_ref": [ "r527" ] }, "ifrs-full_OptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OptionPricingModelMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option pricing model", "label": "Option pricing model [member]" } }, "en": { "role": { "documentation": "This member stands for a specific valuation technique consistent with the income approach that involves analysing future amounts with option pricing models, such as the Black-Scholes-Merton formula or a binominal model (ie a lattice model), that incorporate present value techniques and reflect both the time value and intrinsic value of an option. [Refer: Income approach [member]]" } } }, "auth_ref": [ "r339", "r344" ] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r526" ] }, "abvx_OrdinarySharesNASDAQGlobalMarketMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OrdinarySharesNASDAQGlobalMarketMember", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, nominal value \u20ac0.01 per share", "label": "Ordinary Shares, NASDAQ Global Market [Member]", "documentation": "Ordinary Shares, NASDAQ Global Market [Member]" } } }, "auth_ref": [] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other adjustments for non-cash items" } } }, "auth_ref": [ "r506" ] }, "ifrs-full_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other receivables and assets", "label": "Other assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r522" ] }, "ifrs-full_OtherCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notice accounts", "label": "Other cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r508" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "terseLabel": "Other comprehensive income (loss)", "label": "Other comprehensive income" } } }, "auth_ref": [ "r96", "r282", "r309", "r313" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation differences", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r302", "r313" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gains and losses on retirement benefit obligations", "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r302", "r313", "r495" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Items that are or may be reclassified subsequently to profit or loss", "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r375", "r376" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Items that will not be reclassified to profit or loss", "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r375", "r376" ] }, "ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Other current borrowings and current portion of other non-current borrowings" } }, "en": { "role": { "documentation": "The amount of current other borrowings and the current portion of non-current other borrowings. [Refer: Other borrowings]" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_OtherCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial assets", "totalLabel": "Total other current financial assets", "label": "Other current financial assets" } }, "en": { "role": { "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]" } } }, "auth_ref": [ "r291" ] }, "ifrs-full_OtherCurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial liabilities", "label": "Other current financial liabilities" } }, "en": { "role": { "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]" } } }, "auth_ref": [ "r98", "r294" ] }, "abvx_OtherCurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherCurrentInvestments", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherCurrentFinancialAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments", "label": "Other Current Investments", "documentation": "Other Current Investments" } } }, "auth_ref": [] }, "abvx_OtherCurrentPayablesIncludingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherCurrentPayablesIncludingAdjustments", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Current Payables, Including Adjustments", "documentation": "Other Current Payables, Including Adjustments" } } }, "auth_ref": [] }, "abvx_OtherEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherEmployeesMember", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other employees", "label": "Other Employees [Member]", "documentation": "Other Employees" } } }, "auth_ref": [] }, "abvx_OtherEquityAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherEquityAgreementsMember", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other equity agreement", "label": "Other Equity Agreements [Member]", "documentation": "Other Equity Agreements" } } }, "auth_ref": [] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other financial expense", "label": "Other finance cost" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_OtherFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherFinanceIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial income", "label": "Other finance income" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_OtherFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherFinancialAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other financial assets", "label": "Other financial assets" } }, "en": { "role": { "documentation": "The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r291" ] }, "abvx_OtherFinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherFinancialAssetsMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial assets", "label": "Other Financial Assets [Member]", "documentation": "Other Financial Assets" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherFinancialLiabilitiesAnnualPercentageOfProceedsFromSaleOfIntellectualPropertyRight", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual percentage of proceeds from sale of intellectual property right", "label": "Other Financial Liabilities, Annual Percentage Of Proceeds From Sale Of Intellectual Property Right", "documentation": "Other Financial Liabilities, Annual Percentage Of Proceeds From Sale Of Intellectual Property Right" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherFinancialLiabilitiesAnnualRevenueFromSaleOfProductsDevelopedPeriod", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual revenue from sale of products developed, period", "label": "Other Financial Liabilities, Annual Revenue From Sale Of Products Developed, Period", "documentation": "Other Financial Liabilities, Annual Revenue From Sale Of Products Developed, Period" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherFinancialLiabilitiesMaximumDrawdownCapacity", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum drawdown capacity", "label": "Other Financial Liabilities, Maximum Drawdown Capacity", "documentation": "Other Financial Liabilities, Maximum Drawdown Capacity" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherFinancialLiabilitiesMaximumDrawdownCapacityIncludingInterest", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum drawdown capacity including interest", "label": "Other Financial Liabilities, Maximum Drawdown Capacity Including Interest", "documentation": "Other Financial Liabilities, Maximum Drawdown Capacity Including Interest" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherFinancialLiabilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Other Financial Liabilities [Member]", "documentation": "Other Financial Liabilities" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherFinancialLiabilitiesPayableAnnualRevenueFromSaleOfProductsDeveloped", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual revenue from sale of products developed", "label": "Other Financial Liabilities, Payable, Annual Revenue From Sale Of Products Developed", "documentation": "Other Financial Liabilities, Payable, Annual Revenue From Sale Of Products Developed" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDeveloped", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of annual revenue from sale of products developed", "label": "Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed", "documentation": "Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherFinancialLiabilitiesPercentageOfAnnualRevenueFromSaleOfProductsDevelopedPreTaxRevenueThreshold", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax revenue threshold", "label": "Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed, Pre-Tax Revenue Threshold", "documentation": "Other Financial Liabilities, Percentage Of Annual Revenue From Sale Of Products Developed, Pre-Tax Revenue Threshold" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherFinancialLiabilitiesRelatedTemporaryDifferencesMember", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial liabilities", "label": "Other Financial Liabilities Related Temporary Differences [Member]", "documentation": "Other Financial Liabilities Related Temporary Differences" } } }, "auth_ref": [] }, "abvx_OtherFinancialLiabilitiesRepaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherFinancialLiabilitiesRepaymentPeriod", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment period", "label": "Other Financial Liabilities, Repayment Period", "documentation": "Other Financial Liabilities, Repayment Period" } } }, "auth_ref": [] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 1.0 }, "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other operating income", "totalLabel": "Total operating income", "label": "Other income" } } }, "auth_ref": [ "r36", "r369", "r370" ] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other inflows (outflows) of cash, classified as financing activities" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r73" ] }, "ifrs-full_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other intangible assets", "label": "Other intangible assets [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r501" ] }, "abvx_OtherLiabilitiesNumberOfTransactions": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherLiabilitiesNumberOfTransactions", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities, number of transactions", "label": "Other Liabilities, Number Of Transactions", "documentation": "Other Liabilities, Number Of Transactions" } } }, "auth_ref": [] }, "ifrs-full_OtherLongtermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherLongtermProvisions", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "verboseLabel": "Other non-current provisions", "label": "Other non-current provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]" } } }, "auth_ref": [ "r277", "r303" ] }, "abvx_OtherNonCurrentMiscellaneousFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherNonCurrentMiscellaneousFinancialAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentFinancialAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Non-Current Miscellaneous Financial Assets", "documentation": "Other Non-Current Miscellaneous Financial Assets" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0, "order": 2.0 }, "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial assets", "totalLabel": "Total other non-current financial assets", "label": "Other non-current financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]" } } }, "auth_ref": [ "r291" ] }, "ifrs-full_OtherNoncurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial liabilities", "label": "Other non-current financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]" } } }, "auth_ref": [ "r99", "r294" ] }, "ifrs-full_OtherNoncurrentNonfinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentNonfinancialAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails": { "parentTag": "ifrs-full_OtherAssets", "weight": 1.0, "order": 2.0 }, "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/OtherreceivablesandotherassetsDisclosureofotherreceivablesandotherassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "totalLabel": "Total other non-current assets", "label": "Other non-current non-financial assets" } }, "en": { "role": { "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r522" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r439" ] }, "abvx_OtherReceivablesAndAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherReceivablesAndAssetsMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables and assets", "label": "Other Receivables And Assets [Member]", "documentation": "Other Receivables And Assets" } } }, "auth_ref": [] }, "abvx_OtherShareWarrantsExercisePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherShareWarrantsExercisePeriod", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other share warrants, exercise period", "label": "Other Share Warrants, Exercise Period", "documentation": "Other Share Warrants, Exercise Period" } } }, "auth_ref": [] }, "abvx_OtherShareWarrantsSubscriptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "OtherShareWarrantsSubscriptionPricePerShare", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other share warrants, subscripion price per share (in euro per share)", "label": "Other Share Warrants, Subscription Price Per Share", "documentation": "Other Share Warrants, Subscription Price Per Share" } } }, "auth_ref": [] }, "ifrs-full_OtherShorttermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherShorttermProvisions", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Other current provisions" } }, "en": { "role": { "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r277", "r303" ] }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r2", "r201" ] }, "ifrs-full_OtherTemporaryDifferencesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherTemporaryDifferencesMember", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other items", "label": "Other temporary differences [member]" } }, "en": { "role": { "documentation": "This member stands for temporary differences that the entity does not separately disclose in the same statement or note. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r491" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r400", "r411", "r421", "r454" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r403", "r414", "r424", "r457" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r403", "r414", "r424", "r457" ] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/ShareholdersequitySharecapitalissuedDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Par value per share (in euro per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r188", "r273", "r305" ] }, "ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PastServiceCostNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Past services cost", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from past service cost" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [domain]]" } } }, "auth_ref": [ "r20", "r216" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r428" ] }, "abvx_PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "PaymentsForAdvancesMadeToContractResearchOrganizationsUndiscountedAmount", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash advances and loans made to CRO", "label": "Payments For Advances Made to Contract Research Organizations, Undiscounted Amount", "documentation": "Payments For Advances Made to Contract Research Organizations, Undiscounted Amount" } } }, "auth_ref": [] }, "abvx_PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "PaymentsForAdvancesReimbursedMadeToContractResearchOrganizations", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Advances reimbursed by / (made to) CROs", "label": "Payments For Advances Reimbursed (Made to) Contract Research Organizations", "documentation": "Payments For Advances Reimbursed (Made to) Contract Research Organizations" } } }, "auth_ref": [] }, "ifrs-full_PaymentsForDebtIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForDebtIssueCosts", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for debt issue costs", "label": "Payments for debt issue costs" } }, "en": { "role": { "documentation": "The cash outflow for debt issue costs." } } }, "auth_ref": [ "r504" ] }, "abvx_PaymentsForProceedsFromShareIssueRelatedCostsCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "PaymentsForProceedsFromShareIssueRelatedCostsCredit", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transaction costs related to capital increase", "label": "Payments For (Proceeds From) Share Issue Related Costs (Credit)", "documentation": "Payments For (Proceeds From) Share Issue Related Costs (Credit)" } } }, "auth_ref": [] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for share issue costs", "label": "Payments for share issue costs" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r504" ] }, "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefits paid", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan" } }, "en": { "role": { "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r21", "r217" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of the lease liabilities", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r328" ] }, "abvx_PeakPenetrationMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "PeakPenetrationMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Peak penetration", "label": "Peak Penetration, Measurement Input [Member]", "documentation": "Peak Penetration, Measurement Input" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r438" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r438" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r430" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r447" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r440" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r429" ] }, "abvx_PercentageOfConditionalAdvancesWaived": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "PercentageOfConditionalAdvancesWaived", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of conditional advances waived", "label": "Percentage Of Conditional Advances Waived", "documentation": "Percentage Of Conditional Advances Waived" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Percentage of reasonably possible decrease in unobservable input, liabilities", "label": "Percentage of reasonably possible decrease in unobservable input, liabilities" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities." } } }, "auth_ref": [ "r510" ] }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputAssets", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of reasonably possible increase in unobservable input, assets", "label": "Percentage of reasonably possible increase in unobservable input, assets" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of assets." } } }, "auth_ref": [ "r510" ] }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of reasonably possible increase in unobservable input, liabilities", "label": "Percentage of reasonably possible increase in unobservable input, liabilities" } }, "en": { "role": { "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities." } } }, "auth_ref": [ "r510" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r431" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r487" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r430" ] }, "ifrs-full_PresentValueOfDefinedBenefitObligationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PresentValueOfDefinedBenefitObligationMember", "presentation": [ "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofchangesinprojectedbenefitobligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RETIREMENT BENEFIT OBLIGATIONS", "label": "Present value of defined benefit obligation [member]" } }, "en": { "role": { "documentation": "This member stands for the present value of a defined benefit obligation. The present value of a defined benefit obligation is the present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods." } } }, "auth_ref": [ "r15", "r211" ] }, "abvx_PretGarantiParLEtatPGEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "PretGarantiParLEtatPGEMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PGE", "label": "Pr\u00eat Garanti Par l'Etat (PGE) [Member]", "documentation": "Pr\u00eat Garanti Par l'Etat (PGE)" } } }, "auth_ref": [] }, "abvx_PrincipalAgreementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "PrincipalAgreementsAxis", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Agreements [Axis]", "label": "Principal Agreements [Axis]", "documentation": "Principal Agreements" } } }, "auth_ref": [] }, "abvx_PrincipalAgreementsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "PrincipalAgreementsDomain", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Agreements [Domain]", "label": "Principal Agreements [Domain]", "documentation": "Principal Agreements [Domain]" } } }, "auth_ref": [] }, "abvx_ProbabilityOfSuccessMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ProbabilityOfSuccessMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "POS", "label": "Probability Of Success, Measurement Input [Member]", "documentation": "Probability Of Success, Measurement Input" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowings", "label": "Proceeds from borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r326" ] }, "abvx_ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ProceedsFromBorrowingsNetOfRefinancingOfExistingIndebteness", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowings, net of refinancing of existing indebteness", "label": "Proceeds From Borrowings, Net Of Refinancing Of Existing Indebteness", "documentation": "Proceeds From Borrowings, Net Of Refinancing Of Existing Indebteness" } } }, "auth_ref": [] }, "abvx_ProceedsFromConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ProceedsFromConditionalAdvances", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from conditional advances", "label": "Proceeds From Conditional Advances", "documentation": "Proceeds From Conditional Advances" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants", "label": "Proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r504" ] }, "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from government grants", "label": "Proceeds from government grants, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r497" ] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issue of ordinary shares", "label": "Proceeds from issue of ordinary shares" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r504" ] }, "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingOtherEquityInstruments", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuing other equity instruments", "label": "Proceeds from issuing other equity instruments" } }, "en": { "role": { "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r325" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Capital increases", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r325" ] }, "abvx_ProceedsFromIssuingSharesAndConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ProceedsFromIssuingSharesAndConvertibleLoansNotes", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuing shares and convertible loan notes", "label": "Proceeds From Issuing Shares And Convertible Loans Notes", "documentation": "Proceeds From Issuing Shares And Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ProceedsFromIssuingSharesOtherThanThroughExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Capital increases", "label": "Proceeds From Issuing Shares Other Than Through Exercise Of Warrants", "documentation": "Proceeds From Issuing Shares Other Than Through Exercise Of Warrants" } } }, "auth_ref": [] }, "abvx_ProceedsFromReimbursementsOfDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ProceedsFromReimbursementsOfDeposits", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in deposits", "label": "Proceeds From Reimbursements Of Deposits", "documentation": "Proceeds From Reimbursements Of Deposits" } } }, "auth_ref": [] }, "abvx_ProceedsFromResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ProceedsFromResearchTaxCredit", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from research tax credit", "label": "Proceeds From Research Tax Credit", "documentation": "Proceeds From Research Tax Credit" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromSaleOrIssueOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSaleOrIssueOfTreasuryShares", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from sale of treasury shares", "label": "Proceeds from sale or issue of treasury shares" } }, "en": { "role": { "documentation": "The cash inflow from the sale or issuing of treasury shares. [Refer: Sale or issue of treasury shares; Treasury shares]" } } }, "auth_ref": [ "r504" ] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofgeneralandadministrativeexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consulting and professional fees", "label": "Professional fees expense" } } }, "auth_ref": [ "r519" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 }, "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss for the period", "terseLabel": "Net loss for the period", "negatedLabel": "Net loss", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r87", "r89", "r165", "r166", "r227", "r252", "r281", "r308", "r335", "r348" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before tax", "label": "Profit (loss) before tax" } } }, "auth_ref": [ "r138", "r361", "r362", "r369", "r370" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Profit (loss) from operating activities" } } }, "auth_ref": [ "r319", "r527" ] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "periodStartLabel": "Property, plant and equipment including right-of-use assets at beginning of period", "periodEndLabel": "Property, plant and equipment including right-of-use assets at end of period", "label": "Property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]" } } }, "auth_ref": [ "r112", "r494", "r521" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment including right-of-use assets [axis]", "label": "Property, plant and equipment including right-of-use assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r494" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment including right-of-use assets [domain]", "label": "Property, plant and equipment including right-of-use assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a class of asset representing property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r494" ] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r11", "r209", "r320", "r347", "r365", "r366" ] }, "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proportion of ownership interests held by non-controlling interests", "label": "Proportion of ownership interests held by non-controlling interests" } }, "en": { "role": { "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Total for all subsidiaries [member]; Non-controlling interests]" } } }, "auth_ref": [ "r90" ] }, "abvx_ProsynergiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ProsynergiaMember", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prosynergia", "label": "Prosynergia [Member]", "documentation": "Prosynergia" } } }, "auth_ref": [] }, "abvx_ProvisionsForAGATaxesRelatedTemporaryDifferencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ProvisionsForAGATaxesRelatedTemporaryDifferencesMember", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions for AGA taxes", "label": "Provisions For AGA Taxes Related Temporary Differences [Member]", "documentation": "Provisions For AGA Taxes Related Temporary Differences" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisitions of intangible assets", "label": "Purchase of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r324" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions of property, plant and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r324" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r428" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r428" ] }, "abvx_RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RNPVIRConditionalAdvanceBPIAndCARENAConditionalAdvanceBPIMember", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "RNP-VIR conditional advance and CARENA conditional advance", "label": "RNP-VIR Conditional Advance, BPI And CARENA Conditional Advance, BPI [Member]", "documentation": "RNP-VIR Conditional Advance, BPI And CARENA Conditional Advance, BPI" } } }, "auth_ref": [] }, "abvx_RNPVIRConditionalAdvanceBPIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RNPVIRConditionalAdvanceBPIMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofconditionaladvancesDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails", "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "RNP-VIR conditional advance", "verboseLabel": "RNP VIR \u2013 Bpifrance", "label": "RNP-VIR Conditional Advance, BPI [Member]", "documentation": "RNP-VIR Conditional Advance, BPI" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails", "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails", "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails", "http://www.abivax.com/role/SegmentinformationDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [axis]", "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r81", "r109", "r122", "r130", "r195", "r342", "r344", "r514" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails", "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails", "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails", "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails", "http://www.abivax.com/role/SegmentinformationDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [domain]", "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r81", "r109", "r122", "r130", "r195", "r342", "r344", "r514" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails", "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "abvx_ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ReclassificationOfPrepaidExpensesToCarryingValueOfDebtComponent", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/OtherreceivablesandotherassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of prepaid expenses to carrying value of debt component", "label": "Reclassification of Prepaid Expenses to Carrying Value of Debt Component", "documentation": "Reclassification of Prepaid Expenses to Carrying Value of Debt Component" } } }, "auth_ref": [] }, "ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RecognisedLiabilitiesDefinedBenefitPlan", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net defined benefit liability", "label": "Net defined benefit liability" } }, "en": { "role": { "documentation": "The amount of deficit in a defined benefit plan. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r522" ] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://www.abivax.com/role/IntangibleassetsDisclosureofreconciliationofintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in intangible assets other than goodwill [abstract]", "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]", "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of number of shares outstanding [abstract]", "label": "Reconciliation of number of shares outstanding [abstract]" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r395", "r406", "r416", "r449" ] }, "ifrs-full_RecurringFairValueMeasurementMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RecurringFairValueMeasurementMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring fair value measurement", "label": "Recurring fair value measurement [member]" } } }, "auth_ref": [ "r103", "r270" ] }, "abvx_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RegisteredDirectOfferingMember", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Registered direct offering", "label": "Registered Direct Offering [Member]", "documentation": "Registered Direct Offering" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related party transactions [abstract]", "label": "Related party transactions [abstract]" } } }, "auth_ref": [] }, "abvx_RemeasurementPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RemeasurementPeriodAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasurement Period [Axis]", "label": "Remeasurement Period [Axis]", "documentation": "Remeasurement Period" } } }, "auth_ref": [] }, "abvx_RemeasurementPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RemeasurementPeriodDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasurement Period [Domain]", "label": "Remeasurement Period [Domain]", "documentation": "Remeasurement Period [Domain]" } } }, "auth_ref": [] }, "abvx_RepaymentOfExcessConditionalAdvancesClaimed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RepaymentOfExcessConditionalAdvancesClaimed", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess conditional advances claimed", "label": "Repayment Of Excess Conditional Advances Claimed", "documentation": "Repayment Of Excess Conditional Advances Claimed" } } }, "auth_ref": [] }, "abvx_RepaymentsOfBondLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RepaymentsOfBondLoans", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of bond loans", "label": "Repayments Of Bond Loans", "documentation": "Repayments Of Bond Loans" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of borrowings, classified as financing activities", "label": "Repayments of borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r327" ] }, "abvx_RepaymentsOfConditionalAdvances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RepaymentsOfConditionalAdvances", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of conditional advances", "terseLabel": "Repayments of conditional advances", "label": "Repayments Of Conditional Advances", "documentation": "Repayments Of Conditional Advances" } } }, "auth_ref": [] }, "abvx_RepaymentsOfConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RepaymentsOfConvertibleLoansNotes", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreos2Details", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of convertible loan notes", "terseLabel": "Repayments of convertible loan notes", "label": "Repayments Of Convertible Loans Notes", "documentation": "Repayments Of Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_RepaymentsOfNonConvertibleLoansNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RepaymentsOfNonConvertibleLoansNotes", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of non-convertible bond loans", "label": "Repayments Of Non-Convertible Loans Notes", "documentation": "Repayments Of Non-Convertible Loans Notes" } } }, "auth_ref": [] }, "abvx_RepaymentsOfPGE": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RepaymentsOfPGE", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of PGE", "label": "Repayments Of PGE", "documentation": "Repayments Of PGE" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [] }, "abvx_RepurchaseOfDerivativeInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RepurchaseOfDerivativeInstruments", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesChangeinfinancialliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofchangesinderivativeinstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchases", "negatedLabel": "Repurchases", "label": "Repurchase Of Derivative Instruments", "documentation": "Repurchase Of Derivative Instruments" } } }, "auth_ref": [] }, "abvx_ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ResearchAndCollaborationAgreementWithCNRSUniversityOfMontpellierAndInstitutCurieMember", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and collaboration agreement with CNRS, University of Montpellier and Institut Curie", "label": "Research And Collaboration Agreement With CNRS, University Of Montpellier And Institut Curie [Member]", "documentation": "Research And Collaboration Agreement With CNRS, University Of Montpellier And Institut Curie" } } }, "auth_ref": [] }, "abvx_ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias": { "xbrltype": "integerItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ResearchAndDevelopmentCostsRecognitionInitialMeasurementNumberOfCriterias", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development costs recognition, initial measurement, number of criterias", "label": "Research And Development Costs Recognition, Initial Measurement, Number Of Criterias", "documentation": "Research And Development Costs Recognition, Initial Measurement, Number Of Criterias" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research and development", "label": "Research and development expense" } } }, "auth_ref": [ "r64", "r245" ] }, "abvx_ResearchAndDevelopmentExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ResearchAndDevelopmentExpensesMember", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails", "http://www.abivax.com/role/OperatingexpensesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research And Development Expenses [Member]", "documentation": "Research And Development Expenses" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Translation reserve", "label": "Reserve of exchange differences on translation" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r25", "r220" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "TRANSLATION RESERVE", "label": "Reserve of exchange differences on translation [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r25", "r220", "r371" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r396", "r407", "r417", "r450" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r397", "r408", "r418", "r451" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r404", "r415", "r425", "r458" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained earnings, excluding profit (loss) for reporting period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]" } } }, "auth_ref": [ "r524" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodMember", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "RETAINED EARNINGS", "label": "Retained earnings, excluding profit (loss) for reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit, excluding profit or loss for the reporting period. [Refer: Retained earnings [member]]" } } }, "auth_ref": [ "r518" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss for the period", "label": "Retained earnings, profit (loss) for reporting period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r524" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "NET LOSS FOR THE YEAR", "label": "Retained earnings, profit (loss) for reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r518" ] }, "abvx_RetirementBenefitObligationsRelatedTemporaryDifferencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RetirementBenefitObligationsRelatedTemporaryDifferencesMember", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement benefit obligation", "label": "Retirement Benefit Obligations Related Temporary Differences [Member]", "documentation": "Retirement Benefit Obligations Related Temporary Differences" } } }, "auth_ref": [] }, "abvx_RevaluationOfCashEquivalentsMeasuredAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RevaluationOfCashEquivalentsMeasuredAtFairValue", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Revaluation of cash equivalents measured at fair value", "label": "Revaluation Of Cash Equivalents Measured At Fair Value", "documentation": "Revaluation Of Cash Equivalents Measured At Fair Value" } } }, "auth_ref": [] }, "ifrs-full_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueAbstract", "lang": { "en-us": { "role": { "label": "Revenue [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RevenueAndOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueAndOperatingIncome", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating income", "label": "Revenue and other operating income" } } }, "auth_ref": [ "r527" ] }, "ifrs-full_RevenueFromGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromGovernmentGrants", "crdr": "credit", "calculation": { "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesConditionaladvancesDetails", "http://www.abivax.com/role/FinancialliabilitiesStateguaranteedloanPGEDetails", "http://www.abivax.com/role/OtheroperatingincomeDisclosureofbreakdownofoperatingincomeDetails", "http://www.abivax.com/role/OtheroperatingincomeNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "verboseLabel": "Income from government grants", "terseLabel": "Subsidies", "label": "Income from government grants" } } }, "auth_ref": [ "r498" ] }, "ifrs-full_RevenueFromInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromInterest", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest income" } }, "en": { "role": { "documentation": "The amount of income arising from interest." } } }, "auth_ref": [ "r100", "r163", "r169", "r519" ] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r112", "r115", "r177" ] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://www.abivax.com/role/PropertyplantandequipmentDisclosureofreconciliationofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU", "label": "Right-of-use assets [member]" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r111" ] }, "abvx_RiskFreeInterestRateMeasurementInputExpiryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RiskFreeInterestRateMeasurementInputExpiryMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate, expiry", "label": "Risk-Free Interest Rate, Measurement Input, Expiry [Member]", "documentation": "Risk-Free Interest Rate, Measurement Input, Expiry" } } }, "auth_ref": [] }, "abvx_RiskFreeInterestRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RiskFreeInterestRateMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate", "label": "Risk-Free Interest Rate, Measurement Input [Member]", "documentation": "Risk-Free Interest Rate, Measurement Input" } } }, "auth_ref": [] }, "abvx_RiskFreeInterestRateMeasurementInputTenderOfferMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RiskFreeInterestRateMeasurementInputTenderOfferMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate, tender offer", "label": "Risk-Free Interest Rate, Measurement Input, Tender Offer [Member]", "documentation": "Risk-Free Interest Rate, Measurement Input, Tender Offer" } } }, "auth_ref": [] }, "abvx_RiskFreeInterestRateOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RISK\u00a0FREE\u00a0RATE", "label": "Risk Free Interest Rate, Other Equity Instruments Granted", "documentation": "Risk Free Interest Rate, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificateExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RoyaltyCertificateExpirationPeriod", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificate, expiration period", "label": "Royalty Certificate, Expiration Period", "documentation": "Royalty Certificate, Expiration Period" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificateMaximumAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RoyaltyCertificateMaximumAmount", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificate, maximum amount", "label": "Royalty Certificate, Maximum Amount", "documentation": "Royalty Certificate, Maximum Amount" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificatePercentageOfFutureSales": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RoyaltyCertificatePercentageOfFutureSales", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificate, percentage of future sales", "label": "Royalty Certificate, Percentage Of Future Sales", "documentation": "Royalty Certificate, Percentage Of Future Sales" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificatesEIR": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RoyaltyCertificatesEIR", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificates, EIR", "label": "Royalty Certificates, EIR", "documentation": "Royalty Certificates, EIR" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RoyaltyCertificatesMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesBreakdownoffinancialliabilitiesbymaturityDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiesbreakdownDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofreconciliationofliabilitiesarisingfromfinancingactivitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificates", "label": "Royalty Certificates [Member]", "documentation": "Royalty Certificates" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificatesRelatedTemporaryDifferencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RoyaltyCertificatesRelatedTemporaryDifferencesMember", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails", "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificates", "label": "Royalty Certificates Related Temporary Differences [Member]", "documentation": "Royalty Certificates Related Temporary Differences" } } }, "auth_ref": [] }, "abvx_RoyaltyCertificatesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "RoyaltyCertificatesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "abvx_FinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofremainingcontractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty certificates, undiscounted cash flows", "label": "Royalty Certificates, Undiscounted Cash Flows", "documentation": "Royalty Certificates, Undiscounted Cash Flows" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r467" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r467" ] }, "abvx_SaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "SaleOfStockAxis", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Sale Of Stock [Axis]", "label": "Sale Of Stock [Axis]", "documentation": "Sale Of Stock" } } }, "auth_ref": [] }, "abvx_SaleOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "SaleOfStockDomain", "presentation": [ "http://www.abivax.com/role/BasisofpreparationDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details" ], "lang": { "en-us": { "role": { "terseLabel": "Sale Of Stock [Domain]", "label": "Sale Of Stock [Domain]", "documentation": "Sale Of Stock [Domain]" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Sales and marketing", "label": "Sales and marketing expense" } } }, "auth_ref": [ "r527" ] }, "abvx_SalesAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "SalesAndMarketingExpenseMember", "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofsalesandmarketingexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing expenses", "label": "Sales And Marketing Expense [Member]", "documentation": "Sales And Marketing Expense" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r378" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r380" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "abvx_SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRisk10AdverseChangeInExchangeRateImpactOnForeignExchangeGainLoss", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Adverse change in exchange rate, impact on foreign exchange loss", "label": "Sensitivity Analysis For Types Of Market Risk, 10% Adverse Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)", "documentation": "Sensitivity Analysis For Types Of Market Risk, 10% Adverse Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)" } } }, "auth_ref": [] }, "abvx_SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRisk10FavorableChangeInExchangeRateImpactOnForeignExchangeGainLoss", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Favorable change in exchange rate, impact on foreign exchange gain", "label": "Sensitivity Analysis For Types Of Market Risk, 10% Favorable Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)", "documentation": "Sensitivity Analysis For Types Of Market Risk, 10% Favorable Change in Exchange Rate, Impact On Foreign Exchange Gain (Loss)" } } }, "auth_ref": [] }, "abvx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reasonably possible change in risk variable, percent", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "abvx_ShareBasedPaymentArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ShareBasedPaymentArrangementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangements [Abstract]", "label": "Share-Based Payment Arrangements [Abstract]", "documentation": "Share-Based Payment Arrangements [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Share issue related cost", "label": "Share issue related cost" } } }, "auth_ref": [ "r517" ] }, "abvx_ShareIssueRelatedCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ShareIssueRelatedCostCredit", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transaction costs related to capital increase", "label": "Share Issue Related Cost (Credit)", "documentation": "Share Issue Related Cost (Credit)" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" ], "lang": { "en-us": { "role": { "terseLabel": "Premiums related to share capital", "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r368", "r374" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "PREMIUMS RELATED TO SHARE CAPITAL", "verboseLabel": "Share premium", "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r285" ] }, "abvx_SharePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "SharePrice1", "presentation": [ "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (euro per share)", "label": "Share Price1", "documentation": "Share Price1" } } }, "auth_ref": [] }, "abvx_SharePriceMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "SharePriceMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary share price (in euro per share)", "label": "Share Price, Measurement Input [Member]", "documentation": "Share Price, Measurement Input" } } }, "auth_ref": [] }, "abvx_ShareSubscriptionWarrantsBSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ShareSubscriptionWarrantsBSAMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total BSAs", "verboseLabel": "BSAs", "label": "Share Subscription Warrants (BSA) [Member]", "documentation": "Share Subscription Warrants (BSA)" } } }, "auth_ref": [] }, "abvx_ShareWarrantsSubscriptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "ShareWarrantsSubscriptionPricePerShare", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share warrants, subscription price (in euro per share)", "label": "Share Warrants, Subscription Price Per Share", "documentation": "Share Warrants, Subscription Price Per Share" } } }, "auth_ref": [] }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails": { "parentTag": "ifrs-full_OtherCurrentFinancialAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/OtherfinancialassetsDisclosureofotherfinancialassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits", "label": "Short-term deposits, not classified as cash equivalents" } }, "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r522" ] }, "ifrs-full_ShorttermEmployeeBenefitsAccruals": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermEmployeeBenefitsAccruals", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails": { "parentTag": "abvx_CurrentTaxAndEmployeeBenefitLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureoftaxandemployeerelatedpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee-related payables", "label": "Short-term employee benefits accruals" } }, "en": { "role": { "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]" } } }, "auth_ref": [ "r525" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiaries [axis]", "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r38", "r39", "r102", "r269" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesDomain", "presentation": [ "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiaries [domain]", "label": "Subsidiaries [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r38", "r39", "r102", "r269" ] }, "ifrs-full_SignificantUnobservableInputAssets": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantUnobservableInputAssets", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable input, assets", "label": "Significant unobservable input, assets" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of assets." } } }, "auth_ref": [ "r105" ] }, "ifrs-full_SignificantUnobservableInputLiabilities": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantUnobservableInputLiabilities", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable input, liabilities", "label": "Significant unobservable input, liabilities" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } } }, "auth_ref": [ "r105" ] }, "abvx_SplicosSASABX464Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "SplicosSASABX464Member", "presentation": [ "http://www.abivax.com/role/GoodwillandimpairmenttestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Splicos SAS", "label": "Splicos SAS - ABX464 [Member]", "documentation": "Splicos SAS - ABX464" } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [line items]", "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r285" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfIFRSCompliance": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfIFRSCompliance", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of compliance", "label": "Statement of IFRS compliance [text block]" } } }, "auth_ref": [ "r287" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r399", "r410", "r420", "r453" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "abvx_SubContractingStudiesAndResearchExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "SubContractingStudiesAndResearchExpenses", "crdr": "debit", "calculation": { "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/OperatingexpensesDisclosureofresearchanddevelopmentexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sub-contracting, studies and research", "label": "Sub-Contracting, Studies And Research Expenses", "documentation": "Sub-Contracting, Studies And Research Expenses" } } }, "auth_ref": [] }, "abvx_SubsidiesRelatedTemporaryDifferencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "SubsidiesRelatedTemporaryDifferencesMember", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidies", "label": "Subsidies Related Temporary Differences [Member]", "documentation": "Subsidies Related Temporary Differences" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r446" ] }, "abvx_TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TaxEffectOfChangesInDerivativeFairValueAndOtherLiabilitiesMeasuredAtFVTPL", "crdr": "debit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease / (increase) in derivatives and other liabilities measured at FVTPL", "label": "Tax Effect Of Changes In Derivative Fair Value And Other Liabilities Measured At FVTPL", "documentation": "Tax Effect Of Changes In Derivative Fair Value And Other Liabilities Measured At FVTPL" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfForeignTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectOfForeignTaxRates", "crdr": "debit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax rates in foreign jurisdictions", "label": "Tax effect of foreign tax rates" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } } }, "auth_ref": [ "r2", "r201" ] }, "abvx_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferences", "crdr": "credit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-recognition of deferred tax assets related to tax losses and temporary differences", "label": "Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Tax Losses And Temporary Differences", "documentation": "Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Tax Losses And Temporary Differences" } } }, "auth_ref": [] }, "abvx_TaxEffectOfResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TaxEffectOfResearchTaxCredit", "crdr": "debit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CIR", "label": "Tax Effect Of Research Tax Credit", "documentation": "Tax Effect Of Research Tax Credit" } } }, "auth_ref": [] }, "abvx_TaxEffectOfShareBasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TaxEffectOfShareBasedPayment", "crdr": "debit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment", "label": "Tax Effect Of Share-Based Payment", "documentation": "Tax Effect Of Share-Based Payment" } } }, "auth_ref": [] }, "abvx_TaxEffectOfTransactionCostsRelatedToCapitalIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TaxEffectOfTransactionCostsRelatedToCapitalIncrease", "crdr": "debit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs related to capital increase", "label": "Tax Effect Of Transaction Costs Related To Capital Increase", "documentation": "Tax Effect Of Transaction Costs Related To Capital Increase" } } }, "auth_ref": [] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofreconciliationofeffectiveincometaxlossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nominal income tax using statutory French tax rate", "label": "Tax expense (income) at applicable tax rate" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r2", "r201" ] }, "abvx_TechnicalFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TechnicalFacilitiesMember", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technical facilities", "label": "Technical Facilities [Member]", "documentation": "Technical Facilities" } } }, "auth_ref": [] }, "abvx_TechnologyBasedIntangibleAssetsAssetsAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TechnologyBasedIntangibleAssetsAssetsAcquisitions", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Technology-Based Intangible Assets, Assets Acquisitions", "documentation": "Technology-Based Intangible Assets, Assets Acquisitions" } } }, "auth_ref": [] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails", "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]", "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6", "r205" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails", "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [domain]", "label": "Temporary difference, unused tax losses and unused tax credits [domain]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r6", "r205" ] }, "abvx_TenderOfferFairValueOfMRIMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TenderOfferFairValueOfMRIMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of MRI, tender offer", "label": "Tender Offer, Fair Value Of MRI , Measurement Input [Member]", "documentation": "Tender Offer, Fair Value Of MRI , Measurement Input" } } }, "auth_ref": [] }, "abvx_TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TenderOfferProbabilityWeightedPresentValueOfShortfallPaymentMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability-weighted present value of shortfall payment, tender offer", "label": "Tender Offer, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input [Member]", "documentation": "Tender Offer, Probability-Weighted Present Value Of Shortfall Payment, Measurement Input" } } }, "auth_ref": [] }, "abvx_TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TheScrippsResearchInstituteUniversityOfChicagoAndBrighamYoungUniversityMember", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsgivenDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The Scripps Research Institute, University of Chicago and Brigham Young University", "label": "The Scripps Research Institute, University Of Chicago And Brigham Young University [Member]", "documentation": "The Scripps Research Institute, University Of Chicago And Brigham Young University" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails", "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title and Position [Axis]", "label": "Title and Position [Axis]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.abivax.com/role/RelatedpartiesNarrativeDetails", "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title and Position [Domain]", "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails", "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails", "http://www.abivax.com/role/OtherfinancialassetsNarrativeDetails", "http://www.abivax.com/role/RetirementbenefitobligationsDisclosureofmainactuarialassumptionsusedtomeasuretheretirementbenefitobligationsDetails", "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of range", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r81", "r109", "r122", "r130", "r195", "r342", "r344", "r514" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r438" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r445" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 }, "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION", "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and other current liabilities", "totalLabel": "Trade payables and other current liabilities", "label": "Trade and other current payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r293" ] }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other current payables [abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/PayablesandothercurrentliabilitiesDisclosureofbreakdownoftradeandotherpayablesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade payables", "label": "Current trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r372", "r525" ] }, "ifrs-full_TradeAndOtherPayablesToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayablesToRelatedParties", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payables to related parties", "label": "Payables to related parties" } }, "en": { "role": { "documentation": "The amount of payables due to related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r525" ] }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other receivables [abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherReceivablesDueFromRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherReceivablesDueFromRelatedParties", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables due from related parties", "label": "Receivables due from related parties" } }, "en": { "role": { "documentation": "The amount of receivables due from related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r367", "r373" ] }, "abvx_TradePayablesAndOtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TradePayablesAndOtherCurrentLiabilitiesMember", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables and other current liabilities", "label": "Trade Payables And Other Current Liabilities [Member]", "documentation": "Trade Payables And Other Current Liabilities" } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r466" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r468" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.abivax.com/role/Coverpage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "abvx_TrancheBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TrancheBMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche B", "label": "Tranche B [Member]", "documentation": "Tranche B" } } }, "auth_ref": [] }, "abvx_TrancheCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TrancheCMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche C", "label": "Tranche C [Member]", "documentation": "Tranche C" } } }, "auth_ref": [] }, "abvx_TrancheFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TrancheFiveMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 5", "label": "Tranche Five [Member]", "documentation": "Tranche Five" } } }, "auth_ref": [] }, "abvx_TrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TrancheFourMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 4", "label": "Tranche Four [Member]", "documentation": "Tranche Four" } } }, "auth_ref": [] }, "abvx_TrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TrancheOneMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 1", "label": "Tranche One [Member]", "documentation": "Tranche One" } } }, "auth_ref": [] }, "abvx_TrancheSixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TrancheSixMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 6", "label": "Tranche Six [Member]", "documentation": "Tranche Six" } } }, "auth_ref": [] }, "abvx_TrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TrancheThreeMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 3", "label": "Tranche Three [Member]", "documentation": "Tranche Three" } } }, "auth_ref": [] }, "abvx_TrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TrancheTwoMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 2", "label": "Tranche Two [Member]", "documentation": "Tranche Two" } } }, "auth_ref": [] }, "abvx_TranchesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TranchesAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranches [Axis]", "label": "Tranches [Axis]", "documentation": "Tranches" } } }, "auth_ref": [] }, "abvx_TranchesDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TranchesDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranches [Domain]", "label": "Tranches [Domain]", "documentation": "Tranches [Domain]" } } }, "auth_ref": [] }, "abvx_TranchesOneToFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TranchesOneToFourMember", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranches 1-4", "label": "Tranches One To Four [Member]", "documentation": "Tranches One To Four" } } }, "auth_ref": [] }, "abvx_TransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "TransactionCosts", "crdr": "debit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Transaction costs", "label": "Transaction Costs", "documentation": "Transaction Costs" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r469" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r470" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r470" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r468" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r468" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r471" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r469" ] }, "ifrs-full_TypesOfContractsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails", "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts [axis]", "label": "Types of contracts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r346", "r349", "r364" ] }, "ifrs-full_TypesOfContractsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesLeaseliabilitiesDetails", "http://www.abivax.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts [domain]", "label": "Types of contracts [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } } }, "auth_ref": [ "r346", "r349", "r364" ] }, "ifrs-full_TypesOfInterestRatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInterestRatesAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of interest rates [axis]", "label": "Types of interest rates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r513" ] }, "ifrs-full_TypesOfInterestRatesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInterestRatesDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of interest rates [domain]", "label": "Types of interest rates [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r513" ] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [axis]", "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r26", "r123", "r124", "r125", "r127", "r139", "r143", "r144", "r221" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [domain]", "label": "Types of risks [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r26", "r123", "r124", "r125", "r127", "r139", "r143", "r144", "r221" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [axis]", "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r131", "r253" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofbreakdownofthecompensationexpensesDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBCEsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofreconciliationofBSAsDetails", "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/ShareholdersequityChangeinsharecapitalDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [domain]", "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r131", "r253" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://www.abivax.com/role/EmployeesDetails", "http://www.abivax.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "USD", "presentation": [ "http://www.abivax.com/role/CashandcashequivalentsNarrativeDetails", "http://www.abivax.com/role/FinancialgainlossNarrativeDetails", "http://www.abivax.com/role/ManagementandassessmentoffinancialrisksDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States of America, Dollars", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "abvx_UnderlyingShareFairValueOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "UnderlyingShareFairValueOtherEquityInstrumentsGranted", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofAGAsDetails", "http://www.abivax.com/role/SharebasedpaymentsDisclosureofassumptionsusedforthemeasurementofBSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE OF THE UNDERLYING SHARE (in euro per share)", "label": "Underlying Share Fair Value, Other Equity Instruments Granted", "documentation": "Underlying Share Fair Value, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_UndrawnBorrowingFacilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UndrawnBorrowingFacilities", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/OffbalancesheetcommitmentsreceivedandcontingentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undrawn borrowing facilities", "label": "Undrawn borrowing facilities" } }, "en": { "role": { "documentation": "The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]" } } }, "auth_ref": [ "r332" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r465" ] }, "abvx_UnobservableInputLiabilitiesDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "UnobservableInputLiabilitiesDiscountRate", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unobservable input, liabilities, discount rate", "label": "Unobservable Input, Liabilities, Discount Rate", "documentation": "Unobservable Input, Liabilities, Discount Rate" } } }, "auth_ref": [] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unobservable inputs [axis]", "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r105", "r511" ] }, "ifrs-full_UnobservableInputsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails", "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unobservable inputs [domain]", "label": "Unobservable inputs [domain]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r105", "r511" ] }, "abvx_UnrecognitionDayOneGainOfFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "UnrecognitionDayOneGainOfFinancialLiabilities", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognition day-one gain of financial liabilities", "label": "Unrecognition Day-One Gain Of Financial Liabilities", "documentation": "Unrecognition Day-One Gain Of Financial Liabilities" } } }, "auth_ref": [] }, "abvx_UnrecognizedDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "UnrecognizedDeferredTaxAssets", "crdr": "credit", "calculation": { "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails": { "parentTag": "abvx_NetDeferredTaxAssetsLiabilitiesRecognisedInFinancialPosition", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrecognized deferred tax assets", "label": "Unrecognized Deferred Tax Assets", "documentation": "Unrecognized Deferred Tax Assets" } } }, "auth_ref": [] }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "presentation": [ "http://www.abivax.com/role/IncometaxNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused tax losses for which no deferred tax asset recognised", "label": "Unused tax losses for which no deferred tax asset recognised" } }, "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } } }, "auth_ref": [ "r4", "r203" ] }, "ifrs-full_UnusedTaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnusedTaxLossesMember", "presentation": [ "http://www.abivax.com/role/IncometaxDisclosureofdeferredtaxassetsandliabilitiesbynatureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax losses carryforward", "label": "Unused tax losses [member]" } }, "en": { "role": { "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r6", "r205" ] }, "abvx_UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "UnwindingEffectOfDiscountRelatedToAdvancesMadeToCROs", "crdr": "credit", "calculation": { "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abivax.com/role/FinancialgainlossDisclosureofnetfinancialincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of unwinding the discount related to advances made to CROs", "label": "Unwinding Effect Of Discount Related To Advances Made To CROs", "documentation": "Unwinding Effect Of Discount Related To Advances Made To CROs" } } }, "auth_ref": [] }, "abvx_UnwindingOfDiscountOnRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "UnwindingOfDiscountOnRoyalties", "crdr": "debit", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unwinding of discount on royalties", "label": "Unwinding Of Discount On Royalties", "documentation": "Unwinding Of Discount On Royalties" } } }, "auth_ref": [] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesIntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life measured as period of time, intangible assets other than goodwill", "label": "Useful life measured as period of time, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r56", "r237" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://www.abivax.com/role/AccountingprinciplesDisclosureofdepreciationperiodofpropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Useful life measured as period of time, property, plant and equipment", "label": "Useful life measured as period of time, property, plant and equipment" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r8", "r206" ] }, "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ValuationTechniquesUsedInFairValueMeasurementAxis", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation techniques used in fair value measurement [axis]", "label": "Valuation techniques used in fair value measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r105" ] }, "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ValuationTechniquesUsedInFairValueMeasurementDomain", "presentation": [ "http://www.abivax.com/role/FinancialassetsandliabilitiesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretminimumreturnindemnificationsDetails", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/FinancialliabilitiesOCEANEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation techniques used in fair value measurement [domain]", "label": "Valuation techniques used in fair value measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for valuation techniques used by the entity to measure fair value. It also represents the standard value for the 'Valuation techniques used in fair value measurement' axis if no other member is used. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r105" ] }, "abvx_VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementChangeOfControlMinimumThreshold", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change of control, minimum percentage", "label": "Vesting Requirements For Share-Based Payment Arrangement, Change Of Control, Minimum Threshold", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Change Of Control, Minimum Threshold" } } }, "auth_ref": [] }, "abvx_VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementPerformanceConditionsMinimumFinancing", "crdr": "credit", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance conditions, minimum financing", "label": "Vesting Requirements For Share-Based Payment Arrangement, Performance Conditions, Minimum Financing", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Performance Conditions, Minimum Financing" } } }, "auth_ref": [] }, "abvx_VestingRequirementsForShareBasedPaymentArrangementServicePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementServicePeriod", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service period", "label": "Vesting Requirements For Share-Based Payment Arrangement, Service Period", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Service Period" } } }, "auth_ref": [] }, "abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPercentage", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage", "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage" } } }, "auth_ref": [] }, "abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth": { "xbrltype": "percentItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPercentagePerMonth", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage per month", "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage Per Month", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage Per Month" } } }, "auth_ref": [] }, "abvx_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPeriod", "presentation": [ "http://www.abivax.com/role/SharebasedpaymentsNarrativeDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2024Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2025Details", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsSubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period" } } }, "auth_ref": [] }, "abvx_VolatilityForSharesMeasurementInputExpiryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "VolatilityForSharesMeasurementInputExpiryMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility, expiry", "label": "Volatility For Shares Measurement Input, Expiry [Member]", "documentation": "Volatility For Shares Measurement Input, Expiry" } } }, "auth_ref": [] }, "abvx_VolatilityForSharesMeasurementInputTenderOfferMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "VolatilityForSharesMeasurementInputTenderOfferMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility, tender offer", "label": "Volatility For Shares Measurement Input, Tender Offer [Member]", "documentation": "Volatility For Shares Measurement Input, Tender Offer" } } }, "auth_ref": [] }, "abvx_VoluntaryConversionScenarioProbabilityMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "VoluntaryConversionScenarioProbabilityMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsHeightsconvertibleloannotesDetails", "http://www.abivax.com/role/FinancialliabilitiesHeightsconvertiblenotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held to maturity / voluntary conversion scenario probability", "label": "Voluntary Conversion Scenario Probability, Measurement Input [Member]", "documentation": "Voluntary Conversion Scenario Probability, Measurement Input" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r434" ] }, "abvx_WarrantsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "WarrantsAxis", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [Axis]", "label": "Warrants [Axis]", "documentation": "Warrants" } } }, "auth_ref": [] }, "abvx_WarrantsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "WarrantsDomain", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosBSADetails", "http://www.abivax.com/role/FinancialliabilitiesDisclosureofthemaindataandassumptionsKreosClaretBSADetails", "http://www.abivax.com/role/FinancialliabilitiesKreos1Details", "http://www.abivax.com/role/FinancialliabilitiesKreosClaretFinancingDetails", "http://www.abivax.com/role/SignificanteventsfortheyearsendedDecember3120232024and2025andsubsequenteventsFortheyearended2023Details" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [Domain]", "label": "Warrants [Domain]", "documentation": "Warrants" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageCostOfCapitalMeasurementInputMember", "presentation": [ "http://www.abivax.com/role/FinancialliabilitiesRoyaltycertificatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WACC", "label": "Weighted average cost of capital, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for the weighted average cost of capital used as a measurement input." } } }, "auth_ref": [ "r336", "r344" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.abivax.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.abivax.com/role/IncomelosspershareScheduleofearningspershareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average number of outstanding shares used for computing basic loss per share (in shares)", "terseLabel": "Weighted average number of outstanding shares, basic loss per share (in shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r42" ] }, "abvx_WittycelSASABX196Member": { "xbrltype": "domainItemType", "nsuri": "http://www.abivax.com/20251231", "localname": "WittycelSASABX196Member", "presentation": [ "http://www.abivax.com/role/GoodwillandimpairmenttestDetails", "http://www.abivax.com/role/IntangibleassetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wittycel SAS", "label": "Wittycel SAS - ABX196 [Member]", "documentation": "Wittycel SAS - ABX196" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r432" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_a&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_b&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_d&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_g&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_b&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "d", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_d_v&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_v&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "135", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_135&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS37_g84-92_TI", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_d&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_e&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_46&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRIC", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&num=19&code=ifrs-tx-2025-en-r&anchor=para_11&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_c&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "58", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_58&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "128", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_c&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_d&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_e&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "170", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_170&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_e&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_c&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "204", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_a&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_b&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_c&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_d&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_f&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "216", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_216_a&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231_f&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "250", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_250&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_a&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_b&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "f", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_f_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "255", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_255_a&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "255", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_255_b&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "255", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_255&doctype=Standard", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_a&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "264", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_264_a&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "274", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "34", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37_c&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "43", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_a&doctype=Standard", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_b&doctype=Standard", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_c&doctype=Standard", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "72", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_a&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "72", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_b&doctype=Standard", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard", "URIDate": "2025-03-27" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_d&doctype=Standard", "URIDate": "2025-03-27" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "m", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_m&doctype=Standard", "URIDate": "2025-03-27" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard", "URIDate": "2025-03-27" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard", "URIDate": "2025-03-27" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard", "URIDate": "2025-03-27" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r315": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2025-03-27" }, "r316": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2025-03-27" }, "r317": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r318": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r319": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r320": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r321": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2025-03-27" }, "r322": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_e&doctype=Standard", "URIDate": "2025-03-27" }, "r323": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2025-03-27" }, "r324": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r325": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r326": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r327": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r328": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r329": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B&doctype=Standard", "URIDate": "2025-03-27" }, "r330": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2025-03-27" }, "r331": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2025-03-27" }, "r332": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_a&doctype=Standard", "URIDate": "2025-03-27" }, "r333": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r334": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2025-03-27" }, "r335": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r336": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r337": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r338": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B11", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r339": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B11", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B11_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r340": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r341": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r342": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r343": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r344": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r345": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r346": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r347": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r348": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r349": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2025-03-27" }, "r350": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r351": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r352": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r353": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r354": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r355": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r356": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r357": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r358": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r359": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r360": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG40B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r361": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r362": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r363": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r364": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_d&doctype=Standard", "URIDate": "2025-03-27" }, "r365": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r366": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "251", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_251&doctype=Standard", "URIDate": "2025-03-27" }, "r367": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r368": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r369": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r370": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r371": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r372": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r373": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r374": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r375": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard", "URIDate": "2025-03-27" }, "r376": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r377": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r378": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r379": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r382": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r383": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r384": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r385": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r386": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r387": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r388": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r389": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r390": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r391": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r392": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r393": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r394": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r395": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r396": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r397": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r398": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r399": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r400": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r401": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r402": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r403": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r404": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r405": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r406": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r407": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r408": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r409": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r410": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r411": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r412": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r413": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r414": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r415": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r416": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r417": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r418": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r419": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r420": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r421": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r422": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r423": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r424": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r425": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r432": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r444": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r445": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r446": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r447": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r448": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r449": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r450": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r451": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r452": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_144&doctype=Standard", "URIDate": "2025-03-27" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2025-03-27" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard", "URIDate": "2025-03-27" }, "r502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2025-03-27" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard", "URIDate": "2025-03-27" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }